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ABSTRACT
The C(3)-quaternary substituted pyrroloindoline is a motif that is found in many 
natural products; therefore, a suitable methodology that can construct such a motif and 
has broad range and versatility is highly valuable. Discussed herein is the development of 
a novel method of the construction of C(3)-quaternary substituted pyrroloindolines and 
the application of the methodology to natural product synthesis.
A ring contraction o f C(3)-bromo pyrroloindolines to form a highly strained 
cyclopropane intermediate allows for the direct addition of a wide range of nucleophiles 
to form valuable C(3)-quaternary substituted pyrroloindolines including C(3)-N(1') 
heterodimeric indolines. The heterodimeric indolines synthesized using this method were 
then used in the total syntheses of Kapakahines E and F and toward a total synthesis of 
chetomin.
To Sharon Kirk 
"That's How Strong My Love Is" - Otis Redding
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CHAPTER 1
AN EXPEDIENT CONSTRUCTION OF C(3)-QUATERNARY 
SUBSTITUTED PYRROLOINDOLINES
Introduction
Pyrroloindolines with various atom substituents at the C(3)-position, including carbon, 
nitrogen, oxygen, etc., represent an incredibly diverse class of compounds that are 
ubiquitous in nature. The field of the isolation and synthesis of C(3)-substituted 
pyrroloindolines is quite remarkable as it has been an ongoing pursuit, both intellectual 
and practical, since before the 1930s. It has been a battleground for the testing of 
imaginative chemical transformations as well as bringing to the forefront of knowledge 
the inconceivable and breaking the consensus of what is thought impossible.
While a comprehensive review of C(3)-substituted pyrroloindolines is outside the 
scope of this dissertation, a representative field of examples of the stereoselective 
synthesis of natural products pertaining to C(3)-carbon, -oxygen, and -nitrogen 
substituted pyrroloindolines have been concisely documented in order to give the reader 
an inside view of the broad range of chemistry associated with this class of alkaloids. It is 
the wish of the author that the reader comes away with an appreciation of the beauty of 
pyrroloindoline alkaloid chemistry.
C(3)-Carbon Substituted Pyrroloindolines
Pyrroloindolines that are C(3)-carbon substituted are replete in nature and many 
synthetic methods have been developed in order to construct this bond. A representative 
array of this class of compounds is given in Figure 1.1 and includes dimeric and non- 
dimeric indolines.1 A number of notable methods have been developed to address the 
issue of constructing C(3)-carbon substituted pyrroloindolines in the course of natural
2 3product synthesis. ’
While brilliant methods had been devised toward the synthesis of C(3)-carbon 
substituted pyrroloindolines prior to the 1990s, there was a marked lack of 
enantioselectivity in these methods. Several total syntheses that display powerful 
stereoselective methods are deserving of mention and these include Danishefsky’s 
syntheses of amauromine and ardeemin, Overman’s syntheses of (+)- and (-)- 
chimonanthine, and Movassaghi’s syntheses of (+)-chimonanthine and (+)-naseseazine 
A.4,5,6
Danishefsky’s syntheses of amauromine and ardeemin showcase an oxidative 
cyclization of tryptophan derivatives with N-phenylselenophthalimide (N-PSP) and 
reverse prenylation of an activated C(3)-phenylseleno pyrroloindoline (Schemes 1.1- 
1.2).4 The syntheses begin with a highly diastereoselective phenylselenocyclization of 
tryptophan 1.11 by reaction of the electrophilic selenium with the indole-[2,3]-n-bond to 
give pyrroloindoline 1.12 as essentially a single isomer in the syn-cis configuration.
2
3General C(3)-Carbon Substituted Pyrroloindolines
































Scheme 1.1. Danishefsky’s Total Synthesis of Amauromine
51.15
1 . cyanuric trifluoride, 
pyridine, CH2CI2 (93%)
---------------------------- »
2. D-Ala-OMe HCI, 
NaHC03, H20 , CH2CI2
(71%)
1.18
1. TMSI, CH3CN (86%)
2. NH3, sat. in MeOH, 
cat. DMAP (86%)
1. KHMDS, o-azidobenzoyl 
chloride, THF (80%)
----------------------------- ►
2. P(nBu)3, benzene (72%)
Scheme 1.2. Danishefsky’s Total Synthesis of Ardeemin
The C(3)-phenylselenyl group was then activated with MeOTf to form a cationic 
selenium species that behaved as an excellent leaving group. This provided a transiently 
formed tertiary benzylic carbocation that was trapped by the prenyl nucleophile to give 
pyrroloindoline 1.13. The pyrroloindoline 1.13 was then either hydrolyzed to give acid 
1.15 or deprotected to give bis-amine 1.14 providing not only the starting material for the 
synthesis of ardeemin, but also the two subunits for the synthesis of amauromine. After 
peptide coupling between 1.14 and 1.15, protecting group removal and subsequent 
diketopiperazine formation provides the natural product amauromine.
For ardeemin, the acid 1.15 undergoes a peptide coupling with alanine followed by 
deprotection and diketopiperazine formation to provide 1.19. The synthesis was 
completed by benzoylation of the diketopiperazine followed by a Staudinger reaction to 
provide the natural product ardeemin. The syntheses required 6 and 10 steps overall from 
L-tryptophan methyl ester hydrochloride to amauromine and ardeemin, respectively.
The Overman group provided the first enantioselective synthesis of (+)-chimonanthine 
through the dialkylation of a metal dienolate with a tartrate derived electrophile that used 
the chirality of the tartrate moiety to control absolute stereochemistry (Scheme 1.3).5b 
The Overman group also developed a powerful intramolecular Heck reaction that allowed 
them to synthesize a number of natural products including (-)-chimonanthine and 
asperazine (Schemes 1.4-1.6).5c,d
Beginning with isoindigo 1.20, Zn-mediated reduction gave oxindole dimer 1.21. 
Alkylation of a di-metal enolate generated from 1.21 with bis-triflate 1.22 provided bis- 
spirooxindole 1.23 as the major isomer. Deprotection of the ketal with CSA and 
methanol followed by diol cleavage with lead tetraacetate and reduction of the bis- 
aldehyde with sodium borohydride provided diol 1.24. Amide reduction with Red-Al 
gave 1.25. Substitution of the diols with azide and reduction to a bis-amine cyclizes to a 
pyrroloindoline dimer after subjection to hot MeOH. Reductive methylation with 
formaldehyde then provided 1.26, and finally benzyl group removal with sodium and 











1. CSA, MeOH/CH2CI2 
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1. (Ph0)2P(0)N3, Ph3P, 
Et02CN=NC02Et, THF
2. H2, 10% Pd/C, EtOH 
 >
3. MeOH, 110 °C
4. CH20 , NaBH(OAc)3, 
MeOH (69% from 1.24)
Bn
1.26 (+)-chimonanthine (1.27)
Scheme 1.3. Overman’s Total Synthesis of (+)-Chimonanthine
Overman’s synthesis of (-)-chimonanthine employed a significantly different route.5c 
Starting with the coupling between the dimethyl succinate 1.28 and bis-triflate 1.29, 
followed by iodination and elimination gave unsaturated diester 1.30. Reaction with the 
aluminum amide of o-iodoaniline afforded the corresponding bis-amide. Benzyl 
protection of the amides followed by exchange of the benzyl ethers for an acetonide 
protecting group gave 1.31 that was ready for the intramolecular Heck cascade reaction. 
The palladium-catalyzed Heck reaction performed well with a single isomer being 
obtained as 1.32.
Acetonide deprotection afforded a keto-alcohol that was reduced with sodium 
borohydride; the diol was cleaved to the corresponding dialdehyde and reduced to diol 
1.33. The same protocol that was used to transform diol 1.24 to (+)-chimonanthine 
(Scheme 1.3) was then used to transform diol 1.33 to (-)-chimonanthine (Scheme 1.4). 
The overall synthesis from 1.28 required 17 steps.
The power of the Heck reaction was clearly shown in the adaptation of this technology 
by the Overman group in their total synthesis of asperazine (Schemes 1.5-1.6).5d They 
rapidly constructed ynoate 1.38 from D-serine and perform Pd-catalyzed 
hydrostannylation to provide vinyl stannane 1.39 to be used in a Stille coupling. The 
coupling partner was synthesized from L-tryptophan methyl ester hydrochloride by way 
of reduction to the indoline, Boc-protection, reduction of the ester to the corresponding 
primary alcohol, and then protection with 2,2-dimethoxypropane to give indoline 1.41. 
Ortho-directed metalation with sec-BuLi followed by quenching with iodine and 
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1. AIMe3, o-iodoaniline (92%)
2. NaH, BnBr, DMF (87%) 
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4. CSA, 2,2-DMP (80%)
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2. H2, 10% Pd/C, EtOH
3. MeOH, 110°C
4. CH20, NaBH(OAc)3, 
MeOH (69% from 1.34)
1.35 (-)-chimonanthine (1.36)
Scheme 1.4. Overman’s Total Synthesis of (-)-Chimonanthine
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Scheme 1.5. Overman’s Synthesis of Asperazine Precursor 1.44
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1.49 asperazine (1 .6)
Scheme 1.6. Overman’s Total Synthesis of Asperazine
After the Stille coupling between stannane 1.39 and iodide 1.42, thermal deprotection 
of the indole-Boc protecting group gave indole 1.43. Amide formation with o-iodoaniline 
and protection with SEMCl provided 1.44. Finally, the crucial Heck reaction was 
performed followed by SEM removal and a substrate-controlled hydrogenation to 
provide advanced tryptophan dimer 1.46.
Protecting group manipulation, diastereomer separation, and then reduction with 
lithium triethylborohydride followed by methanolysis gave pyrroloindoline 1.48 (Scheme 
1.6). The primary alcohols were oxidized to the corresponding acids and coupled with D- 
phenylalanine to provide peptide 1.49. After protecting group removal, diketopiperazine 
formation completed the synthesis of the natural product asperazine in 22 steps from D- 
serine.
Movassaghi’s synthesis of (+)-chimonanthine involved the direct dimerization of 
C(3)-bromo pyrroloindoline 1.52 via the corresponding tertiary benzylic radical using a 
Co(I) reagent (Scheme 1.7).6a Barton radical bis-decarboxylation of 1.53 gave 1.54, 
followed by reduction of the sulfonamide protecting groups and reduction of the 
carbomethoxy protecting groups giving the natural product in 10 steps from L-tryptophan 
methyl ester hydrochloride.
In addition to the synthesis of symmetrical pyrroloindoline dimers, the Movassaghi 
group has also developed a novel diazene fragmentation of pyrroloindoline heterodimers 
that readily accesses not only asymmetrical pyrroloindoline dimers but also a variety of 
C(3)-carbon substituted pyrroloindolines (Scheme 1.8). Substitution of the bromide in 
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Scheme 1.7. Movassaghi’s Total Synthesis of (+)-Chimonanthine
After synthesis of the sulfamoyl chloride, addition of an appropriate amine provided 
sulfamide 1.57. Subsequent oxidation with NCS initiated a sequence that involves SO2 
expulsion to form diazene 1.59 which may be isolated. The diazene was irradiated to 
expulse dinitrogen to form solvent caged radicals that then combine giving C(3)-carbon 
pyrroloindoline 1.60 (Scheme 1.8).
The Movassaghi group also developed Friedel-Crafts based technology starting from 
C(3)-bromo pyrroloindolines using halophile Ag(I) and a broad range of n-nucleophiles
(Scheme 1.9). This reaction was then utilized to complete a total synthesis of (+)- 
naseseazine A (Scheme 1.10).
The synthesis of (+)-naseseazine A begins with Cbz protection and Horner- 
Wadsworth-Emmons olefination of indole 1.73. Enantioselective hydrogenation followed 
by diketopiperazine synthesis provided indole 1.77. Next, a Miyaura boration converted 
the aryl bromide to a boronate with subsequent conversion to the tetrafluoroborate salt 
1.79. Nucleophilic substitution of 1.79 on bromide 1.65 in the presence of Ag(I) and 
deprotection provided the natural product (+)-naseseazine A in 11 steps from indole 1.73 
(Scheme 1.10).
C(3)-Hydroxy Substituted Pyrroloindolines
Pyrroloindolines that are C(3)-hydroxy substituted are also found in nature and many 
synthetic methods have been developed in order to construct this bond.7 A representative 
array of this class of compounds is given in Figure 1.2. Worthwhile mentions in total 
synthesis include Corey’s synthesis of okaramine N and Danishefsky’s synthesis of 
himastatin.9,10
First, Corey developed interesting methodology for the synthesis of okaramine N that 
involved a palladium catalyzed indolocyclization, the development of a novel protecting 
group for the indole-[2,3]-n bond, and selective photooxygenation (Scheme 1.11).9 The 
synthesis began with the reductive alkylation of amine 1.86 with aldehyde 1.87 to give 
tryptophan 1.88. Boc protected tryptophan was then reduced to a mixture of indolines 
1.89 and 1.90 and this mixture underwent nucleophilic substitution with propargyl 
acetate 1.91. Dehydrogenation of the indoline and hydrogenation of the alkyne to the
14
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,C02Me 1 TMSn3, SnCI4 
2 . dithiothreitol
HoN
\  'C 0 2Me (71%overaN)
,C02Me -i. c iS03H, Na2C 03
2. (COCI)2, DMF 





\  xC 02Me 
N H t
C 02Me




(1.57) R = aryl, tertiary alkyl 
^C02Me
hv




















^ s ^ S n B u g
OTMS
M e '^ W
c b r
1.68 1.69 1.70 1.71 1.72
Scheme 1.9. Movassaghi’s Friedel-Crafts Based Technology
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1. AgSbF6, 18-crown-6, 
1.65, EtNOz (56%)
2. H2, Pd/C, AcOH 
 »
1. CbzCI, Et3N, DMAP, 
CH2CI2 (100%)
------------------------ 1





1.TFA, CH2CI2; EDC HCI,
HOBt, Et3N, Boc-L-Pro 
--------------------------- 1


















2. KHF2 (aq.), MeOH (88%)
1.79
Scheme 1.10. Movassaghi’s Total Synthesis of (+)-Naseseazine A
alkene provided tryptophan 1.92. Hydrolysis o f the ester followed by replacement of the 
Boc group with Fmoc then gave tryptophan 1.93 and coupling with 1.88 gave bis- 
tryptophan 1.94.
Palladium promoted indolocyclization and Fmoc removal generated octacyclic 
diketopiperazine 1.95. Corey next introduced a novel indole-[2,3]-n bond protecting 
group, MTAD, through a reversible ene reaction. Photooxygenation then cyclized the 
unprotected indole and thermolysis of the protecting group provided the natural product 
okaramine N in 13 steps overall.
Danishefsky’s synthesis of himastatin was also a landmark synthesis of a C(3)- 
hydroxy pyrroloindoline natural product.10a-c The synthesis included electrophilic 
oxygenation of the indole-[2,3]-n bond and complex cyclic peptide synthesis (Schemes 
1.12-1.15).
The synthesis began with the conversion of commercially available tosylate 1.98 to 
bromide 1.99 through methanolysis and epoxide formation followed by opening the 
epoxide with LiBr and TBS protection afforded bromide 1.99. Formation of the enolate 
and trapping with DBAD and cyclization gave a mixture of piperazic esters 1.100 and 
1.101. The desired isomer was Boc deprotected and protection with Teoc followed by 
hydrolysis gave piperazic acid 1.103. The undesired isomer 1.100 can also be converted 
to 1.103 by using an epimerization strategy (Scheme 1.12).
With the piperazic acid in hand, they then focused on the synthesis of 
pentadepsipeptide 1.109 (Scheme 1.13). The allyl ester of D-threonine was prepared and 
the hydroxy group protected as a silyl ether. Peptide coupling with Fmoc protected 
leucine and removal of the Fmoc group gave dipetide 1.106. Subsequent coupling with
18
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Various C(3)-Hydroxy Substituted Natural Products
..M eMe
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next step
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2. 0 2, sunlamp, MeOH, 
methylene blue; Me2S
okaramlne N (1.84) 





2. LiBr, THF, HOAc Me02C.
 ^ 3. TBSOTf, 2,6-lutidine,
j S0 —■* CH2CI2 (60% overall)
1.98 1.99
1. NaHMDS, DBAD, THF Me0 2C ^ N ° C Me02C _ N ° C
2. NaH, DMF 2 'NBoc NBoc
(35% of 1.100; 
29% of 1.101





Me02C% .N !°  2. TeocCI, /Pr2NEt,
* " 'S  NBoc CH2CI2 (92% overall)^ 2 NTeoc




2. TeocCI, pyridine, CH2CI2
3. TBSOTf, 2,6-lutidine, CH2CI2
4. LiOH, THF (82% overall)
Me02C . .N°C 1 ■ TBAF, THF (80%) ^oc
z V  NBoc 2. DBU, PhMe (69%) 'NBocV  --------- ►
OTBS
1.100 1.102
Scheme 1.12. Danishefsky’s Synthesis of Piperazic Acid 1.103
piperazic acid 1.103 afforded tripeptide 1.107. Coupling with a hydroxy valeric acid 
derivative, deprotection, another coupling with a D-valine derivative and deprotection 
yielded the desired acid 1.109 (Scheme 1.13).
The Danishefsky group then completed the total synthesis by performing an 
oxycyclization on tryptophan 1.111 using DMDO to provide the C(3)-hydroxy 






1. allyl alcohol, pTsOH, 
PhH, Dean-Stark
2. TBSCI, imid., CH2CI2 
 *
3. Fmoc-L-leucine, EDCI, 
DMAP, CH2CI2

















1. Troc-D-valine, IPCF, 
Et3N, DMAP, CH2CI2
2. ZnCI2, CH3N02 
 1
3. TBSOTf, 2,6-lutidine, 
CH2CI2




Scheme 1.13. Danishefsky’s Synthesis of Pentadepsipeptide 1.109
nucleus was halogenated with ICl and half of the resulting aryl iodide was converted into 
the stannane 1.115 under Pd catalysis. A Stille coupling between aryl iodide 1.114 and 
stannane 1.115 gave the pyrroloindoline dimer 1.116. Protecting group manipulation 
followed by introduction of depsipeptide 1.109 and macrolactamization of the resulting 





1. TrtCI, Et3N, THF











2. TBSCI, DBU, DMF 
(61% overall)
















Scheme 1.14. Danishefsky’s Synthesis of Dimer 1.116
24
1. TBAF, THF TESO
1 116  2. TESCI, DBU, DMF ^ '
' 3. H2, Pd/C, EtOAc " '
4. FmocOSu, pyridine,
CH2CI2 (91% overall)




.COzAllyl 1 . HATU, HOAt, collidine, 
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3. piperidine, CH3CN (74%)
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Scheme 1.15. Danishefsky’s Total Synthesis of Himastatin
C(3)-Nitrogen Substituted Pyrroloindolines 
Heterodimeric indolines that contain a C(3)-N(1') bond represent a class of 
structurally unique molecules with interesting biological properties (Figure 1.3).11 Our 
laboratory began research on the construction of the C(3)-N(1') bond to fill a relatively 
large gap in the literature to construct such a bond. At the onset of our research only one
synthetically useful method was known and had been developed by the Takayama group
12in their total synthesis of (±)-psychotrimine (Scheme 1.17). This method has the
drawback in that the pyrroloindoline motif is synthesized over many steps.
Shortly thereafter, the Baran group published their technology for the formation of the 
C(3)-N(1') bond which relied on the oxidative cyclization of tryptamine derivatives with 
electrophilic nitrogen and also focuses on the synthesis of (±)-psychotrimine (Scheme
131.16). This cyclization is believed to be mechanistically similar to that of the 
cyclization of tryptamine derivatives with electrophilic selenium as displayed in 
Danishefsky’s syntheses of amauromine and ardeemin. It involved in situ activation of 
aniline 1.125 to form N-iodoaniline 1.127 that acts as a source of electrophilic nitrogen 
and interacts with the indole-[2,3]-n double bond as in 1.128.
The Takayama synthesis of psychotrimine began with a Strecker reaction between 
indoline and 2-bromobenzaldehyde to give 1.131 (Scheme 1.17). Alkylation of 1.131 
with nitroethylene and dehydrogenation with DDQ provides indole 1.133 and the 
requisite C(3)-N(1') bond. Reduction with Fe powder and Boc protection generated 
amidine 1.134, followed by a Cu-catalyzed intramolecular Buchwald-Hartwig coupling 
and reduction gave pyrroloindoline 1.136 as a racemic mixture in the cis configuration. 
The aniline nitrogen was Boc protected and ortho-metalation followed by quenching with 
iodine provides indole 1.137. Tryptamine synthesis by reacting the indole with 
nitroethylene, reduction of the nitro group to a free amine with Fe powder followed by 
protection of the amine with p-nitrobenzenesulfonyl chloride gave a sulfonamide. 
Methylation of the sulfonamide with dimethylsulfate and base, and deprotection of the 
Boc group gave 1.139. Cu-catalyzed Buchwald-Hartwig amination of aryl iodide 1.139 
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Scheme 1.16. Baran’s C(3)-N(1') Bond Forming Technology
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Scheme 1.17. Takayama’s Total Synthesis of (±)-Psychotrimine
Our Approach Toward C(3)-N(D Heterodimeric Indolines
Our laboratory initially focused on utilizing C(3)-halogen substituted pyrroloindolines 
as precursors to C(3)-N(1') heterodimeric indolines by the direct nucleophilic substitution 
of the halogen with indole.14 The primary inspiration for this approach came from the 
pioneering work by Danishefsky and coworkers on the substitution of C(3)-phenylseleno 
pyrroloindolines (Scheme 1.18).4 They reported that the activation of phenylseleno 
pyrroloindoline 1.12 with MeOTf presumably forms the cationic selenium intermediate 
1.142 that acts as a leaving group to generate a stabilized carbocation (1.143 and 1.144) 
that is then trapped by prenyl tributylstannane to give pyrroloindoline 1.13 (Scheme 
1.18).
Our laboratory wished to use this process as a template to form the proposed benzylic 
carbocationic intermediate 1.143 and trap this intermediate with an N-metalated-indole 
nucleophile. It was hypothesized that a C(3)-halogen or C(3)-triflate substituent would 
serve as alternative sources of carbocation 1.143 due to their perceived similar ability to 
readily ionize (Scheme 1.19).
It was established by de Lera and coworkers that C(3)-bromo pyrroloindolines could 
be synthesized from (D)-tryptophan in high diastereoselectivity analogous to the 
methodology developed by Danishefsky and coworkers in their synthesis of C(3)- 
phenylseleno pyrroloindoline 1.12 (Scheme 1.20).15 Given the ready availability of 
bromopyrroloindoline 1.147 as essentially a single diastereomer from bis-Boc tryptophan 
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Scheme 1.18. Danishefsky’s Substitution of C(3)-Phenylseleno Pyrroloindolines
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Scheme 1.19. Alternative Sources of Carbocation 1.143
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Scheme 1.20. De Lera’s Synthesis of C(3)-Bromo Pyrroloindoline 1.147
A model reaction was designed that utilized bromopyrroloindoline 1.148 and the 
sodium salt of indole (Scheme 1.21). Silver nitrate was added to the reaction mixture due 
to the well known ability of Ag(I) salts to activate organic halides in substitution 
reactions with nucleophiles. In the event, the reaction proceeded upon addition of 1.148 
to a mixture of N-sodio-indole and AgNO3 to give heterodimer 1.149 in 28% yield as a 
single diastereomer (Scheme 1.21). Interestingly, the methyl ester had epimerized from 
the exo isomer (syn-cis) to the thermodynamically more stable endo isomer (anti-cis) 
under the strong base conditions used in the substitution reaction.2a
We initially proposed that the mechanism for the heterodimerization involved 
production of carbocation 1.143 followed by trapping with N-metalated-indole in an SN1 
fashion (Scheme 1.22). The reaction was optimized using indole as the standard 
nucleophile and it was found that superior yields were achieved when a solution of 
potassium tert-butoxide in THF was added slowly to a mixture of indole and an excess of 
1.148 in acetonitrile (Table 1.1). Under these conditions, a mixture of endo:exo isomers 
were generally obtained due to thermodynamic equilibration with potassium tert- 
butoxide with a preference of the endo isomer over the exo isomer.
An initial investigation of the scope of the reaction was also performed and it was 
found that a variety o f substituted indoles were valid substrates for the reaction (Table 
1.1). Protected tryptamine analogues could be used, but low yields were observed when 
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Scheme 1.22. Initial Mechanistic Proposal for the Production of 1.149
33






entry indole (eq) base(eq) solvent dimer (ando:exo)3 yield (%)
1 1.151 (1.2) NaH (1.1)1 THF:DMF (2:1) 1.149 (>95:5) 28
2 1.151 (2.0) NaH (1.75) HMPA2 1.149(3:1) 63
3 1.151 (1.5) KOfBu (1.2) c h 3cn 1.149(13:1) 43
4 1.151(1.5) KO/Bu(1.2) CH3CN2 1.149(5:1) 47
5 1.152(1.5) NaH (1.4) DMF:HMPA(5:1)2 1.157 (4:1) 59
6 1.152(1.5) KOfBu (1.2) ch3cn 1.157(11:1) 43
7 1.153 (13) KOfBu (2.0) c h 3cn 1.158 (>95:5) 26
B 1.151 (0.7) KOfBu (2.0) CHgCN 1.149(7:1) 82
9 1.151 (0.7) KOfBu (2 0) CH3CN 1.149 (5:1) 79
10 1.151 (0.7) KOfBu (1.5) ch3cn 1.149(10:1) 64
11 1.152(0.7) KOfBu (2 0) c h 3cn 1.157(3:1) 81
12 1.153(0.7) KOfBu (2.0) ch3cn 1.158 (>95:5) 48
13 1.154(0.7) KOfBu (2.0) CHjCN 1.159 (>95:5) 38
14 1.155(0.7) KOfBu (2.0) ch3cn 1.160 (>95:5) 78
15 1.156(0 7) KOfBu (2.0) c h 3cn 1.161 (5:1) 76
AgNQ3 (2.5 mol%)was used as an additive 
2: Reaction mixture was allowed to warm to room temperature 
3: Ratio determined using fH NMR
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Scheme 1.23. Attempted Synthesis of Heterodimer 1.164










Scheme 1.24. Attempted Coupling of 1.148 with Strong Nucleophiles
We were forced to reevaluate the proposed mechanism upon the attempted coupling 
between bromopyrroloindoline 1.163 and indole (Scheme 1.23). It became apparent that 
the ester was intimately involved in the mechanism and was necessary for the success of 
the reaction. Interestingly, we did not observe any coupled products from the reaction 
between bromopyrroloindoline 1.148 and NaN3 or PhSK (Scheme 1.24).
This result led us to propose that since the coupling of 1.148 with nucleophiles only 
seemed to take place under conditions that affected the epimerization of the methyl ester, 
it was probable that the reactive isomer o f 1.148 was the endo isomer rather than the exo 
isomer. It was believed that the endo methyl ester was set up to provide anchimeric 
assistance by way of the lone pair on the carbonyl oxygen in order to facilitate ionization 
of the bromide (Scheme 1.25).16
35
Native Puckered Conformation 
of Pyrroloindolines
Boc-V-N* 
M e O ^ V  N­O i 
Boc
1.148-endo
Br© 0  P Me
Boc
1.167
Proposed Lone Pair/Anti-Bonding 


















Scheme 1.25. Proposed Anchimeric Assistance Mechanism
During this time, another appealing mechanism was devised that also explained the 
nonreactivity of 1.148 toward nucleophiles under conditions that were insufficiently 
basic enough to cause deprotonation of the methyl ester. This alternative mechanistic 
proposal involved the generation of the strained transient cyclopropane 1.170 from the 
enolate 1.169 (Scheme 1.26). In addition, precedent for the synthesis of cyclopropanes 
using an anionic ring closure has been documented.14 The ring strain inherent in the 









Scheme 1.26. Proposed Strained Cyclopropane Mechanism
give the enolate of the methyl ester. Kinetic protonation of the enolate would then lead 
to the endo isomer and equilibration under the reaction conditions would lead to the exo 
isomer.
A defining experiment was performed in order to differentiate between the two 
mechanisms. We hypothesized that the use of a bromopyrroloindoline that contained a 
non-enolizable ester that was fixed in the endo position, would supply valuable 
information. In this case, a successful reaction would disprove the cyclopropane 
mechanism while providing excellent support for the anchimeric assistance mechanism. 
Failure o f the reaction would provide strong evidence against the anchimeric assistance 
mechanism (Scheme 1.27). To test this hypothesis, bromopyrroloindoline 1.174 was 





Scheme 1.27. Mechanistic Analysis of 1.171 to 1.172
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Scheme 1.28. Synthesis of 1.174 and Attempted Heterodimerization
The known pyrroloindoline 1.50 was methylated using LHMDS and Mel to give
1.173 followed by radical bromination with NBS to provide 1.174. Subjection of 1.174 to 
standard heterodimerization conditions only resulted in recovered starting material along 
with some decomposition. Given this result, we were led to believe that the cyclopropane 
mechanism was operative barring further experiments to the contrary.
Cyclopropylazetoindoline
We proposed that the bromopyrroloindoline 1.148 was decomposing during the 
heterodimerization reaction due to the fact that 1.148 was completely consumed during 
the reaction but that an excess of 1.148 was necessary for high yields (Table 1.1). In an 
effort to try to understand the decomposition pathway of 1.148 during the 
heterodimerization reaction, we performed a control reaction in the absence of a 
nucleophile. To our delight, when 1.148 was subjected to KO/Bu in CH3CN we isolated 
cyclopropane 1.170 (cyclopropylazetoindoline) along with acetonitrile adduct 1.176 and 
starting material (Table 1.2).
During the optimization process for the generation of 1.170, we found that as the 
amount of KO/Bu was increased the amount of adduct 1.176 was also increased at the 
expense of 1.170 (entries 2-4, Table 1.2). By switching the solvent to THF we were able 
to eliminate the formation of 1.176 while cleanly converting 1.148 to 1.170 in high yield 
in gram quantities (entry 5, Table 1.2). Also to our surprise was the stability of 1.170 in 
that it could be subjected to silica gel column chromatography, could be refluxed in THF 
for several hours, and could be stored at 0 °C for several weeks without noticeable 
decomposition. Additionally, we were hopeful that 1.170 could be used as an electrophile
38
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Table 1.2. Isolation of Cyclopropylazetoindoline 1.170 and Optimization
1.148 1.170 1.176
entry KOfBu (eq) solvent yield o fl.1701 1.170:1.176:1.1482
1 1.0 c h 3c n 44% 1:0:1
2 1.2 c h 3c n 55% 11:3:5
3 1.5 c h 3c n 20% 1:2:1
4 2.0 c h 3c n 0% 0:1:03
5 1.2 THF 89-95 % 1:0:0
1: Isolated Yield
2: Ratio determined using 1H NMR 
3: 1.176 was isolated in 42% yield
due to the apparent addition of the anion of CH3CN to 1.170 to form 1.176. The 
geometry of cyclopropane 1.170 was optimized using density functional theory (DFT) 
calculations (Figure 1.4, coordinates given in Table 1.4).
The calculated carbon-carbon bond lengths about the cyclopropane in 1.170 for C(11)- 
C(17), C(15)-C(17), and C(11)-C(15) are 1.48 A, 1.51 A, and 1.57 A, respectively 
(carbon numbering used is in Figure 1.4), and the carbon-carbon bond length for parent 
cyclopropane is 1.51 A . 17 Given that the C(11)-C(15) bond is calculated to be an 
abnormally long 1.57 A, in addition to the “push-pull” nature of the cyclopropane (refer 
to 1.182), we can predict that the C(11)-C(15) bond would be the weakest bond and 
would undergo fragmentation when exposed to nucleophiles. While we have postulated 
that the reaction likely proceeds through an SN2 addition of nucleophile, SN2 additions of
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nucleophiles to form quaternary substituted carbon centers is not a well known process
due to the significant amount of steric crowding around the carbon nucleus. However,
18there are some unique examples of SN2 reactions occurring at tertiary carbon centers.
The structural assignment of compound 1.170 was determined by spectroscopic 
analysis due to the inability to obtain a crystal suitable for X-ray crystallographic 
analysis. The 1H NMR displayed nonconventional chemical shifts for the methylene 
protons in the cyclopropane ring. Typically, the chemical shifts of methylene protons 
directly attached to a cyclopropane ring fall between the range of 0 -1  ppm, whereas the 
typical chemical shifts for methylene protons in an alkyl chain containing electronegative 
substituents (e.g. the methylene protons in 1.177) fall between the range of 2-3 ppm 
(Figure 1.5). The chemical shifts of H(18) and H(19) for compound 1.170 (numbering 
given in Figure 1.4) are 2.80 and 2.22 ppm, respectively.
This unusually large chemical shift can be explained by examining the amount of 
carbocation character on C(11) of compound 1.170 (numbering given in Figure 1.4). 
Given the push-pull nature of this cyclopropane (refer to 1.182) combined with a 
calculated C(11)-C(15) bond length of 1.57 A (numbering given in Figure 1.4), it is 
predicted that C(11) should exhibit a high degree of carbocationic character. This 
property is significant because it would explain the large chemical shift of the methylene 
protons in 1.170; the strong carbocationic character of C(11) would serve to deshield the 
methylene protons on C(17) (Figure 1.5) . 19
We also examined the one bond proton-carbon coupling constants ( J c H) of the 
methylene protons on 1.170 and found that they were 170.9 Hz and 168.7 Hz. This is 
significant because the 1J CH can be highly diagnostic for assigning protons attached to a
41
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-(2-3 ppm) (2.22 ppm, 2.28 ppm)
1.180 1.181
Figure 1.5. Chemical Shifts of Selected Methylene Protons
cyclopropyl ring; typical 1J CH values for cyclopropyl protons are about 170 Hz whereas 
typical 1J CH values for alkyl protons are about 125 Hz. These data, combined with the 
products arising from the addition of nucleophiles to the isolated compound, support the 
cyclopropane structure given in 1.170.
Reactivity of the Cyclopropylazetoindoline 
With ready access to gram quantities of cyclopropylazetoindoline 1.170 we next 
surveyed its reactivity with nucleophiles and its decomposition pathway. We found that 
1.170 could be converted to 1.184 through a proposed pathway that reflects the donor- 
acceptor nature of the cyclopropane (Scheme 1.29). Next, we attempted the direct 
introduction of a nucleophile to 1.170 and were pleased to find that 1.170 could be made 
to react quite readily with a variety of nucleophiles under very mild conditions and all 
products were obtained as the endo isomer (Table 1.3).
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Scheme 1.29. Proposed Decomposition Pathway of 1.170 to 1.184
Table 1.3. Reaction of Cyclopropylazetoindoline 1.170 with Nucleophiles
Boc Boc
1.170 1.185
entry nucleophile (eq) conditions R (product) yield (%)
1 indole (1.5) THF:DMF (2:1) N-indolyl (1.149) 70
2 NaBH4 (10) THF, rt, 2 h H (1.186) 75
3 NaN3 (10) PPTS, DMF, rt, 2 h N3(1.187) 72
4 C6H5OH (5) DBU, THF, rt, 6 h C6H50(1.188) 70
5 p-MeOC6H4OH (5) DBU.THF, rt, 6 h p-Me0C6H40(1.189) 76
6 p-N02C6H40H (5) DBU, THF, rt, 6 h p-N02C6H40  (1.190) 70
7 C6H5SH (5) DBU, THF, rt, 6 h C6H5S (1.191) 84
8 p-N02C6H4SH (5) DBU, THF, rt, 6 h p-N02C6H4S (1.192) 80
9 AIMe3 (2) CH2CI2, “40 to 0°C, 0.5 h Me (1.193) 76
10 KCN (10) PPTS, 18-crown-6, THF, rt, 4 h CN (1.194) 70
11 c h 3n o 2 DBU, THF:CH3N 02 (4:1), rt, 2 h CH2N 02(1.195) 50
12 NCCH2CN (10) DBU, THF, rt, 6 h NCCHCN (1.196) 60
13 methyl acetoacetate (5) DBU, THF, rt, 6 h
CH3C(0)CHC02Me
(1.197) 75
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Scheme 1.30. Enantioselective Formal Synthesis of (-)-Physostigmine
Gratifyingly, we were able to obtain a wide range of C(3)-carbon substituted products 
(entries 9-14, Table 1.3). The importance of the ability to obtain C(3)-carbon substituted 
pyrroloindolines was discussed above (Figure 1.1).
Enantioselective Formal Synthesis of (-)-Physostigmine 
In order to show the utility of the cyclopropylazetoindoline methodology, we 
completed a formal total synthesis of reversible cholinesterase inhibitor (-)- 
physostigmine (Scheme 1.30).3x To this end, methyl adduct 1.193 underwent a Barton 
decarboxylation to afford 1.199, and ^N'-dimethyl-pyrrolodindoline 1.200 was obtained 
after protecting group removal and reductive amination of the bis-amine. Synthesis of
1.200 intercepts Kulkarni and coworkers' intermediate.
Conclusions
We have demonstrated a new synthesis of C(3)-quaternary substituted indolines that 
employs a novel reaction of bromopyrroloindolines. This unique reaction is very useful 
in terms of the substrates generated and the types of nucleophiles that may be added to 
the generated cyclopropylazetoindoline. Additionally, we have shown the utility of this 
technology in performing an enantioselective formal synthesis of (-)-physostigmine. 
Further work will be done in the pursuit of establishing the exact reaction mechanism that 
the cyclopropylazetoindoline undergoes upon addition of nucleophiles.
Experimental Section
Chemicals were either used as received or purified according to Purification o f
20Common Laboratory Chemicals. Glassware was dried in an oven at 130 °C or flame 
dried and cooled under a dry atmosphere prior to use. All reactions were performed using 
common dry, inert atmosphere techniques. Reactions were monitored by TLC and 
visualized by a dual short wave/long wave UV lamp and stained with an ethanolic 
solution of potassium permanganate or p-anisaldehyde. Column flash chromatography 
was performed using 230-400 mesh silica gel. NMR spectra were recorded on Varian 
Unity-300, Varian VXR-500, or Varian Inova-500 spectrometers. Chemical shifts for 1H 
NMR were reported as 8 , parts per million, relative to the signal of tetramethylsilane at 0
13ppm. Chemical shifts for C NMR were reported as 8 , parts per million, relative to the 
center line signal of the CDCl3 triplet at 77 ppm. Proton and carbon assignments were
1 13established using spectral data of similar compounds, H nOe analysis, and C DEPT 
NMR. The abbreviations s, bs, d, dd, bd, ddd, t, q, bq, and m stand for the resonance
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multiplicity singlet, broad singlet, doublet, doublet of doublets, broad doublet, doublet of 
doublet of doublets, triplet, quartet, broad quartet, and multiplet, respectively. IR spectra 
were recorded on a Bruker Tensor 27 FT-IR spectrometer. Optical rotations were 
obtained on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell with a 1 
decimeter path length. Mass spectra were recorded at the Mass Spectrometry Facility at 
the Department of Chemistry of the University of Utah at Salt Lake City on a Finnigan 
MAT 95 double focusing high resolution mass spectrometer. Concentration refers to 
removal of solvent under reduced pressure (house vacuum at ca. 20 mmHg).
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1.201 1.148
Preparation of (25',3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-bromo-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1.148). To a solution of 
bis-Boc protected tryptophan 1.201 (0.169 g, 0.40 mmol) in methylene chloride (4 mL) at 
rt was added PPTS (0.102 g, 0.40 mmol) and NBS (0.073 g, 0.40 mmol). After stirring 
for 8 h the solution was diluted with CH2Cl2 (20 mL) and washed with brine (20 mL). 
The organic phase was dried (MgSO4) and concentrated. Flash chromatography (5-10% 
EtOAc:hexanes) afforded 0.186 g (92%) of 1.148 as a white foam. 1.148: Rf 0.30 (20% 
EtOAc:hexanes); [a]25D = -157.3 (c = 0.635, CHCfe); 1H NMR (300 MHz, CDClj) 8 7.57 
(broad s, 1H), 7.37-7.30 (m, 2H), 7.13 (dd, J  = 7.5 Hz, 7.5 Hz, 1H), 6.40 (s, 1H), 3.89 
(dd, J  = 10.2 Hz, 6.0 Hz, 1H), 3.75 (s, 3H), 3.21 (dd, J  = 12.6, 6.3 Hz, 1H), 2.82 (dd, J  =
12.6 Hz, 10.2 Hz, 1H), 1.60 (s, 9H), 1.40 (bs, 9H); 13C NMR (125 MHz, CDCU) 8 171.5 
(broad), 152.2, 152.2, 141.5, 132.9 (broad), 130.6, 124.4 (broad), 123.2, 118.5 (broad),
83.8, 82.2, 81.5 (broad), 59.7 (broad), 59.4, 52.3, 41.9 (broad), 28.2, 28.2; IR (neat) 2980, 
1754, 1720, 1604, 1478, 1396, 1367, 1335, 1258, 1204, 1163 cm-1; LRMS (ESI) calcd 





Preparation of (25',3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(1#-indol-1-yl)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1. 149-exo) and 
(2.R,3aR,8aR)-1,8-di-fert-butyl 2-methyl 3a-(1#-indol-1-yl)-3,3a-dihydropyrrolo[2,3- 
#]indole-1,2,8(2#,8aff)-tricarboxylate (1.149-en^o). To a solution of 1.148 (0.196 g, 
0.39 mmol) and 1.151 (0.031 g, 0.26 mmol) in CH3CN (8  mL) at 0 °C was added KOtBu 
(0.52 mL, 1M in THF) dropwise and the mixture stirred for 20 min. The mixture was 
quenched with sat. NaHCO3 (1 mL) and diluted with CH2Cl2 (60 mL). The organic phase 
was washed with brine (20 mL), dried (MgSO4), and concentrated. Flash chromatography 
(10% EtOAc:hexanes) afforded 0.019 g (14%) of 1.149-exo and 0.091 g (65%) of 1.149- 
endo. 1.149-exo: white foam; R/ 0.28 (10% EtOAc:hexanes); [a]D = +60.4 (c = 0.605); 1H 
NMR (300 MHz, CDCb) 8 7.78-7.58 (partially obscured m, 1 H), 7.65 (d, J  = 8.7 Hz, 
1H), 7.60 (d, J  = 7.8 Hz, 1H), 7.50-7.42 (m, 2H), 7.31-7.12 (m, 3H), 6.81 (s, 1H), 6.70 
(broad d, J  = 3.3 Hz, 1H), 6.35 (d, J  = 3.6 Hz, 1H), 4.12 (dd, J  = 9.9, 7.2 Hz, 1H), 3.80 (s,
3H), 3.34 (dd, J  = 12.9, 10.5 Hz, 1H), 2.94 (dd, J  = 12.9, 7.2 Hz, 1H), 1.44 (s, 9H), 1.40 
(broad s, 9H); 13C NMR (75 MHz, CDQ3) 8 172.4, 152.1, 152.1, 142.8, 134.4, 131.0,
130.5, 130.2 (broad), 126.5, 125.1, 124.1, 122.2, 121.5, 120.2, 119.2 (broad), 111.7,
101.8, 82.2, 81.4 (broad), 78.9, 71.4 (broad), 59.2, 52.4, 36.3 (broad), 28.2, 28.0; IR 
(neat) 2978, 1604, 1481, 1396, 1336, 1160, 1018 cm-1; LRMS (ESI) calcd for 
C30H36N3O6 m/z (M+H+) 534.3, found 534.1. 1.149-endo: R /0.20 (10% EtOAc:hexanes); 
white foam; [ci]d = +82.8 (c = 0.115); 1H NMR (300 MHz, CDQ3) 8 7.69 (broad s, 1H), 
7.63-7.60 (m, 1H), 7.40-7.28 (m, 3H), 7.22-7.06 (m, 3H), 6.96 (broad d, J  = 3.3 Hz, 1H), 
6.81 (s, 1H), 6.41 (dd, J  = 3.3, 0.6 Hz, 1H), 4.91 (broad d, J  = 8.1 Hz, 1H), 3.55 (dd, J  = 
12.9, 9.3 Hz, 1H), 3.23 (s, 3H), 3.04 (d, J  = 13.2 Hz, 1H), 1.52 (s, 9H), 1.50 (s, 9H); 13C 
NMR (125 MHz, CDQ3) 8 171.0, 153.3 (broad), 152.0, 143.6, 134.5, 130.9, 130.5, 129.2 
(broad), 126.2, 125.4 (broad), 123.3 (broad), 122.0, 121.5, 120.1, 117.8 (broad), 111.1,
102.0, 82.0, 81.4 (broad), 79.9, 72.6 (broad), 59.4 (broad), 52.1, 38.6 (broad), 28.3, 28.1; 
IR (neat) 2979, 1716, 1604, 1481, 1393, 1160, 1018 cm-1; LRMS (ESI) calcd for 







Preparation of (25y3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(3-methyl-1#-indol-1-yl)- 
3,3a-dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1. 157-exo) and 
(2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(3-methyl-1#-indol-1-yl)-3,3a-
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1.157-endo). To a
solution of 1.148 (0.082 g, 0.17 mmol) and 1.152 (0.015 g, 0.11 mmol) in CH3CN (3 mL) 
at 0 °C was added KOtBu (0.22 mL, 1M in THF) dropwise and stirred for 20 min. The 
mixture was quenched with sat. NaHCO3 (1 mL) and diluted with CH2Cl2 (60 mL). The 
organic phase was washed with brine (20 mL), dried (MgSO4), and concentrated. Flash 
chromatography (10% EtOAc:hexanes) afforded 0.012 g (20%) of 1.157 -exo and 0.037 g 
(61%) of 1.157-endo. 1.157-exo: white foam; Rf 0.26 (10% EtOAc:hexanes); [a]D = 
+44.1 (c = 0.303); 1H NMR (300 MHz, CDQ3) 8 7.69 (bs, 1H), 7.58-7.42 (m, 4H), 7.29­
7.12 (m, 3H), 6.77 (s, 1H), 6.48 (s, 1H), 4.10 (dd, J  = 10.2, 7.2 Hz, 1H), 3.80 (s, 3H), 
3.30 (dd, J  = 12.6, 10.2 Hz, 1H), 2.94 (dd, J  = 12.6, 7.2 Hz, 1H), 2.16 (s, 3H), 1.44 (bs, 
18H); 13C NMR (125 MHz, CDQ3) 8 172.4, 152.2, 152.2, 142.8, 134.8, 130.9, 130.9,
130.4 (broad), 125.0, 124.0, 124.0 (broad), 122.2, 119.5, 119.5, 119.2 (broad), 111.6, 
110.8 (broad), 82.1, 81.5 (broad), 79.1, 71.3 (broad), 59.2, 52.4, 36.3 (broad), 28.2, 28.0, 
9.4; IR (neat) 2980, 1720, 1606, 1481, 1456, 1397, 1344, 1264, 1161, 1019, 907, 857 
cm-1; LRMS (ESI) calcd for C31H38N3O6 m/z (M+H+) 548.3, found 548.1. 1.157-endo: 
white foam; Rf 0.19 (10% EtOAc:Hexanes); [a]D = +41.6 (c = 0.202); 1H NMR (300 
MHz, CDCl3) 8 7.69 (bs, 1H), 7.54 (dd, J  = 8.4, 1.2 Hz, 1H), 7.39-7.05 (m, 6 H), 6.77 (s, 
1H), 6.73 (s, 1H), 4.89 (broad d, J  = 8.4 Hz, 1H), 3.51 (dd, J  = 12.6, 9.3 Hz, 1H), 3.22 (s, 
3H), 3.04 (d, J  = 12.9, 1H), 2.21 (s, 3H), 1.52 (s, 9H), 1.50 (s, 9H); 13C NMR (125 MHz, 
CDCl3) 8 171.1, 153.2 (broad), 152.0, 143.5, 134.9, 130.8, 130.7, 129.6 (broad), 125.4 
(broad), 123.7, 123.3 (broad), 122.0, 119.5, 119.4, 117.9 (broad), 111.3, 111.0, 82.0, 81.4 
(broad), 80.0, 72.5 (broad), 59.5 (broad), 52.1, 38.7 (broad), 28.3, 28.2, 9.4; IR (neat) 
2978, 1717, 1652, 1606, 1559, 1541, 1481, 1394, 1258, 1159, 1019 cm-1; LRMS (ESI)
49
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Preparation of (2^,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(3-(2-((tert- 
butoxycarbonyl)amino)ethyl)-1H-indol-1-yl)-3,3a-dihydropyrrolo[2,3-b]indole- 
1,2,8(2H,8aH)-tricarboxylate (1.158). To a solution of 1.148 (0.308 g, 0.62 mmol) and 
1.153 (0.108 g, 0.41 mmol) in CH3CN (12 mL) at 0 °C was added KOtBu (0.82 mL, 1M 
in THF) dropwise and stirred for 30 min. The mixture was quenched with sat. NaHCO3 
(1 mL) and diluted with CH2Cl2 (100 mL). The organic phase was washed with brine (20 
mL), dried (MgSO4), and concentrated. Flash chromatography (20% EtOAc:hexanes) 
afforded 0.135 g (48%) of 1.158. 1.158: white foam; R/ 0.18 (20% EtOAc:hexanes); [a]D 
= +33.0 (c = 0.283); 1H NMR (300 MHz, CDCk) 8 7.75 (bs, 1H), 7.59 (d, J  = 7.5 Hz, 
1H), 7.40-7.06 (m, 6 H), 6.78 (s, 1H), 6.77 (s, 1H), 4.90 (bd, J  = 8.7 Hz, 1H), 4.58 (bs, 
1H), 3.52 (dd, J  = 12.9, 9.3 Hz, 1H), 3.34 (broad dt, J  = 6.3, 6.0 Hz, 2H), 3.23 (s, 3H),
3.02 (d, J  = 13.2 Hz, 1H) 2.83 (t, J  = 6.9 Hz, 2H), 1.52 (s, 9H), 1.50 (s, 9H), 1.42 (s, 9H); 
13C NMR (75 MHz, CDCfe) 8 171.1, 155.9, 152.0, 152.0, 143.5, 135.0, 130.9, 130.0,
129.2 (broad), 125.4 (broad), 124.0, 123.4 (broad), 122.2, 119.8, 119.6, 117.9 (broad),
112.5, 111.5, 82.1, 81.5 (broad), 79.8, 79.1 (broad), 72.5 (broad), 59.4 (broad), 52.1, 40.9 
(broad) 38.6 (broad), 28.4, 28.3, 28.2, 25.7 (broad); IR (neat) 3397, 2979, 2930, 1755,
1711, 1605, 1507, 1482, 1457, 1394, 1265, 1164 cm-1; LRMS (ESI) calcd for 





Preparation of (2.K,3aK,8aK)-1,8-di-tert-butyl 2-methyl 3a-(3-((S)-2-((tert- 
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-indol-1-yl)-3,3a- 
dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (1.159). To a solution of
1.148 (0.111 g, 0.22 mmol) and 1.154 (0.047 g, 0.15 mmol) in CH3CN (4 mL) at 0 °C 
was added KOtBu (0.30 mL, 1M in THF) dropwise and stirred for 30 min. The mixture 
was quenched with sat. NaHCO3 (1 mL) and diluted with CH2Cl2 (100 mL). The organic 
phase was washed with brine (20 mL), dried (MgSO4), and concentrated. Flash 
chromatography (20-25% EtOAc:hexanes) afforded 0.043 g (39%) of 1.159. 1.159: white 
foam; Rf 0.28 (33% EtOAc:hexanes); [a]D = +50.7 (c = 1.389); 1H NMR (300 MHz, 
CDCl3) 8 7.69 (broad s, 1H), 7.53 (d, J  = 7.8 Hz, 1H), 7.39-7.06 (m, 6 H), 6.77 (s, 1H), 
6.71 (bs, 1H), 5.05 (broad d, J  = 7.2 Hz, 1H), 4.91 (broad d, J  = 8.7 Hz, 1H), 4.60-4.50 
(m, 1H), 3.59-3.50 (m, 4H), 3.22 (s, 3H), 3.22-2.97 (partially obscured m, 3H), 1.53 (s, 
9H), 1.51 (s, 9H), 1.42/1.40 (Boc rotamers, two singlets, 9H); 13C NMR (125 MHz, 
CDCl3) 8 (Note: Boc-rotamers give duplicities on some carbons) 172.3, 172.2, 170.8,
154.8, 152.9 (broad), 151.8, 143.5, 143.4, 134.6, 130.8, 130.8, 130.3, 130.2, 129.2. 128.9
(broad), 125.2 (broad), 124.7, 123.2, 123.2 (broad), 122.2, 119.8, 119.4, 118.0 (broad),
111.3, 109.6, 109.5, 81.9, 81.9, 81.2 (broad), 79.7, 79.7, 79.5 (broad), 72.5 (broad), 59.3 
(broad), 55.1, 54.1, 52.0, 51.9, 51.8, 38.5 (broad), 28.2, 28.0, 27.7 (broad); IR (neat) 
3438, 2979, 1715, 1605, 1483, 1393, 1164, 1062, 1019, 916, 856 cm-1; LRMS (ESI) 






Preparation of (2^,3aK,8aK)-1,8-di-ferf-butyl 2-methyl 3a-(3-(2-(4- 
bromobenzamido)ethyl)-1#-indol-1-yl)-3,3a-dihydropyrrolo[2,3-£]mdole- 
1,2,8(2#,8a#)-tricarboxylate (1.160). To a solution of 1.148 (0.586 g, 1.18 mmol) and 
1.155 (0.270 g, 0.79 mmol) in CH3CN (23 mL) at 0 °C was added KOtBu (1.51 mL, 1M 
in THF) dropwise and stirred for 30 min. The mixture was quenched with sat. NaHCO3 
(1 mL) and diluted with CH2Cl2 (120 mL). The organic phase was washed with brine (20 
mL), dried (MgSO4), and concentrated. Flash chromatography (30% EtOAc:hexanes) 
afforded 0.462 g (78%) of 1.160. 1.160: white foam; R/ 0.17 (33% EtOAc:hexanes); [a]D 
= +24.8 (c = 0.582); 1H NMR (300 MHz, CDCb) 8 7.70 (broad s, 1H), 7.60 (d, J  = 7.8 
Hz, 1H), 7.49 (s, 4H), 7.37 (dd, J  = 7.8, 7.8 Hz, 1 H), 7.30-7.18 (m, 3 H), 7.12 (dd, J  =
7.2, 7.2 Hz, 1 H), 7.04 (dd, J  = 7.5, 7.5 Hz, 1 H), 6.81 (s, 1H), 6.79 (s, 1H), 6.32-6.24 (m, 
1H), 4.90 (broad d, J  = 8.4 Hz, 1H), 3.65 (dt, J  = 6.3, 6.3 Hz, 2H) 3.50 (dd, J  = 13.2, 9.6 
Hz, 1H), 3.22 (s, 3H), 3.03 (d, J  = 13.2 Hz, 1H), 2.95 (t, J  = 6.3 Hz, 2H), 1.51 (s, 18H); 
13C NMR (125 MHz, CDCI3) 8 171.0, 166.3, 153.2 (broad), 152.0, 143.4, 135.0, 133.4,
131.7, 130.9, 129.9, 129.2 (broad), 128.4, 125.9, 125.3 (broad), 124.0, 123.4 (broad),
122.4, 119.9, 119.5, 117.8 (broad), 112.4, 111.6, 82.2, 81.4 (broad), 79.9, 72.6 (broad),
59.4 (broad), 52.1, 40.4, 38.6 (broad), 28.3, 28.2, 25.0; IR (neat) 3357, 2978, 1718, 1648, 
1593, 1538, 1481, 1394, 1260, 1158, 1069, 1015, 912, 853 cm-1; LRMS (ESI) calcd for 




methoxybenzyl)piperazine-2,5-dione (1.156). To a solution of ^-benzyl protected L- 
tryptophan methyl ester (0.306 g, 0.99 mmol) in CH2Cl2 (10 mL) at 0 °C was added Et3N 
(0.28 mL, 1.98 mmol) followed by a solution of chloroacetyl chloride (0.134 g, 1.19 
mmol) in CH2Cl2 (2 mL) dropwise. The resulting mixture was stirred at 0 °C for 6  h and 
then the reaction was quenched with 10% aq. NaHCO3 (20 mL). The organic phase was 
washed with H2O (20 mL), brine (20 mL), dried (MgSO4), and concentrated. The 
resulting residue was taken up in CH3CN (9 mL) and to this was added 4-methoxy- 
benzylamine (0.379 g, 2.76 mmol). The reaction mixture was heated to reflux for 6  h.
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After cooling, the reaction mixture was diluted with CH2Cl2 (20 mL) and washed 
sequentially with 10% KHSO4 (20 mL), H2O (20 mL), brine (20 mL). The organic phase 
was dried (MgSO4) and concentrated. Flash chromatography (50% EtOAc:hexanes) 
afforded 0.337 g (75% overall) of 1.156 as an oil. 1.156: clear oil; Rf 0.25 (33% 
EtOAc:hexanes); [a]D = -42.1 (c = 0.580); 1H NMR (300 MHz, CDQ3) 8 8.74 (bs, 1H),
7.58 (d, J  = 7.5 Hz, 1H), 7.38-7.11 (m, 8 H), 6.77-6.67 (m, 5H), 5.44 (d, J  = 14.7 Hz, 1 
H), 4.52 (d, J  = 14.4 Hz, 1H), 4.26 (t, J  = 3.6 Hz, 1H), 4.01 (d, J  = 14.7 Hz, 1H), 3.73 (s, 
3H), 3.56-3.50 (m, 2 H), 3.26 (partially obscured dd, J  = 15.0, 4.5 Hz, 1H), 3.25 (d, J  =
17.4 Hz, 1H), 2.24 (t, J  = 17.4 Hz, 1H); 13C NMR (125 MHz, CDCb) 8 166.3, 165.0,
159.1, 136.0, 135.3, 129.6, 128.9, 128.4, 128.1, 127.1, 126.6, 124.1, 122.4, 119.9, 118.9,
114.0, 111.2, 108.3, 59.9, 55.2, 48.4, 48.0, 46.8, 26.8; IR (neat) 3299, 2930, 1658, 1513, 
1468, 1325, 1248, 1176, 1101, 1032, 974, 817 cm-1; LRMS (ESI) calcd for C ^ H ^ O s  




Preparation of (2S,3a^,8aR)-1,8-di-tert-butyl 2-methyl 3a-(3-(((S)-1-benzyl-4-(4- 
methoxybenzyl)-3,6-dioxopiperazin-2-yl)methyl)-1H-indol-1-yl)-3,3a- 
dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (1.161). To a solution of
1.148 (0.199 g, 0.40 mmol) and 1.156 (0.121 g, 0.267 mmol) in CH3CN (8  mL) at 0 °C 
was added KOtBu (0.53 mL, 1M in THF) dropwise and stirred for 20 min. The mixture 
was quenched with sat. NaHCO3 (1 mL) and diluted with CH2Cl2 (120 mL). The organic 
phase was washed with brine (20 mL), dried (MgSO4), and concentrated. Flash 
chromatography (33% EtOAc:hexanes) afforded 0.177 g (76%) of 1.161 as 4.8:1 mixture 
of endo:exo isomers. The endo isomer of 1.161 was characterized from a 14:1 mixture of 
endo:exo diastereomers (from the reaction of 1.156 (1.2 eq) with 1.148 (1.0 eq) and 
KO/Bu (1.2 eq.) at 0 °C for 30 s, 17% yield); white foam; R/ 0.25 (33% EtOAc:hexanes); 
[a]D = -14.7 (c = 0.218); 1H NMR (300 MHz, CDCl3) 8 7.80-7.60 (partially obscured m, 
1H), 7.60 (d, J  = 7.5 Hz, 1H), 7.45-7.39 (m, 2H), 7.33-7.14 (m, 9H), 6.83 (s, 1H), 6.74­
6 .6 6  (m, 4H), 6.62 (s, 1H), 5.26 (d, J  = 14.7 Hz, 1H), 4.90-4.84 (partially obscured m, 
1H), 4.55 (d, J  = 14.4 Hz, 1H), 4.18 (broad dd, J  = 3.9 Hz, 3.0 Hz, 1H), 3.96 (d, J  = 15.0 
Hz, 1H), 3.76 (s, 3H), 3.46-3.39 (m, 2H), 3.29-3.21 (partially obscured m, 2H), 3.21 (s, 
3H), 3.00 (dd, J  = 15.0 Hz, 4.5 Hz, 1H), 2.85 (d, J  = 13.2 Hz, 1H), 2.05 (d, J  = 17.4 Hz, 
1H), 1.51 (bs, 18H); 13C NMR (125 MHz, CDQ3) 8 170.8 (broad), 166.1, 164.9, 159.2,
159.2, 151.9 (broad), 143.8, 135.4, 134.3, 131.2, 129.9, 129.7, 129.7, 128.9, 128.9, 128.5,
128.5, 128.1, 126.5, 126.5, 123.5 (broad), 122.8, 120.5, 120.0, 114.0, 111.5, 107.7, 82.1,
82.1, 79.2, 72.4 (broad), 59.8, 59.4 (broad), 55.2, 52.1, 48.3, 48.0, 46.8, 38.4 (broad),
28.3, 28.2, 26.4; IR (neat) 2977, 1755, 1717, 1663, 1610, 1553, 1513, 1458, 1393, 1368, 
1330, 1250, 1209, 1160, 1062, 854 cm-1; LRMS (ESI) calcd for C50H55N5O9N  m/z 
(M+Na+): 892.4, found 892.1.
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Enantiopurity of 1.149-endo was established through derivatization with (15)-(+)- 
camphorsulphonyl chloride as a chiral resolving agent:
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1.202
Preparation of (2^,3a^,8a^)-methyl 3a-(1#-mdol-1-yl)-1,2,3r3a,8,8a- 
hexahydropyrrolo[2,3-£]mdole-2-carboxylate (1.202). To a solution of heterodimer 
1.149-endo (0.125 g, 0.230 mmol) in CH3CN (5 mL) at 0 °C was added dropwise TMSI 
(0.08 mL, 0.58 mmol). The reaction mixture turned a dark yellow color and was 
quenched after 30 min with sat. NaHCO3 (2 mL). The organic phase was washed with 
H2O (10 mL), brine (10 mL), dried (MgSO4), and concentrated. Flash chromatography 
(75% EtOAc:hexanes) afforded 0.049 g (63%) of 1.202 as a colorless oil. 1.202: oil; R/ 
0.07 (50% EtOAc:hexanes); [ci]d = +13.4 (c = 0.294); 1H NMR (300 MHz, CDClj) 8 7 
7.62-7.59 (m, 1H), 7.47 (d, J  = 7.8 Hz, 1H), 7.22 (d, J  = 8.1 Hz, 1 H), 7.21 (d, J  = 7.2 Hz, 
1H), 7.19 (d, J  = 7.2 Hz, 1 H), 7.18-7.06 (m, 3H), 6.76 (t, J  = 8.1 Hz, 1H), 6 .6 8  (d, J  = 
8.1 Hz, 1 H), 6.45 (d, J  = 3.3 Hz, 1H), 5.52 (s, 1H), 4.50 (bs, 1H), 4.21 (dd, J  = 7.8, 2.4 
Hz, 1H), 3.48 (dd, J  = 13.2, 7.8 Hz, 1 H), 3.36 (s, 3 H), 2.95 (dd, J  = 13.2, 2.7 Hz, 1H), 
2.62 (broad s, 1H); 13C NMR (125 MHz, CDCfe) 8 173.8, 149.7, 134.9, 130.4, 130.3,
127.7, 126.1, 125.5, 121.6, 121.2, 119.7, 119.4, 112.0, 110.8, 101.2, 81.9, 75.8, 60.3,
52.0, 40.6; IR (neat) 3363, 2950, 1736, 1609, 1459, 1321, 1225, 1121, 1018, 960, 891 
cm-1; LRMS (ESI) calcd for C20H20N3O2 m/z (M+H+) 334.1, found 334.0.
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Preparation of (2^,3aK,8aS)-methyl 1-((((15)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)methyl)sulfonyl)-3a-(1#-indol-1-yl)-1,2,3,3a,8,8a- 
hexahydropyrrolo[2,3-#]indole-2-carboxylate (1.203). To a solution of bis-amine 
1.203 (0.024 g, 0.070 mmol), Et3N (0.015 mL, 0.11 mmol), and DMAP (0.001 g, 0.01 
mmol) in THF (3.6 mL) at 0 °C was added (15)-(+)-camphorsulfonyl chloride (0.020 g,
0.080 mmol). The reaction mixture was stirred for 1 h at 0 °C, diluted with CH2Cl2 (60 
mL), and washed sequentially with 10% KHSO4 (20 mL), 10% NaHCO3 (20 mL), H2O 
(20 mL), and brine (20 mL). The organic phase was dried (MgSO4) and concentrated. In 
addition to unreacted starting material, only a single diastereomer of the product could be 
detected from the crude 1H NMR. Flash chromatography (15-20% EtOAc:hexanes) 
afforded 0.027 g (6 8 %) of 1.203 as a white foam. 1.203: white foam; Rf 0.74 (50% 
EtOAc:hexanes); [a]D = +8.1 (c = 0.248); 1H NMR (300 MHz, CDCk) 8 7.61 (d, J  = 7.8 
Hz, 1H), 7.48 (d, J  = 8.1 Hz, 1H), 7.29-7.19 (m, 3H), 7.12 (dd, J  = 7.2, 7.2 Hz, 1 H), 6.98 
(d, J  = 3.3 Hz, 1H), 6.89 (dd, J  = 7.2, 7.2 Hz, 1H), 6.81 (d, J  = 7.5 Hz, 1H), 6.41 (d, J  =
3.6 Hz, 1H), 6.19 (d, J  = 1.2 Hz, 1H), 5.21 (broad s, 1H), 4.97 (dd, J  = 7.8, 1.2 Hz, 1H),
3.75 (d, J  = 15.0 Hz, 1H), 3.72 (dd, J  = 13.8, 9.3 Hz, 1H), 3.33 (s, 3H), 3.32 (partially 
obscured d, J  = 14.7 Hz, 1H), 3.11 (d, J  = 13.8 Hz, 1H), 2.47-2.34 (m, 2H), 2.11 (dd, J  =
4.2, 4.2 Hz, 1H), 2.12-1.98 (partially obscured m, 1H), 1.93 (d, J  = 18.3 Hz, 1H), 1.65 
(ddd, J  = 13.8, 9.3, 4.5 Hz, 1H), 1.40 (ddd, J  = 12.6, 9.6, 3.9 Hz, 1H), 1.14 (s, 3H), 0.97
(s, 3H); 13C NMR (125 MHz, CDQ3) 8 215.2, 171.3, 150.0, 134.7, 131.7, 130.7, 126.5,
126.2, 125.9, 122.4, 121.8, 120.4, 120.1, 111.9, 111.9, 102.1, 81.2, 75.8, 61.1, 59.2, 52.7,
52.3, 47.9, 43.6, 43.0, 39.8, 27.0, 27.0, 20.5, 20.2; IR (neat) 3380, 2957, 1744, 1611, 
1456, 1338, 1223, 1156, 1039, 859, 740 cm-1; LRMS (ESI) calcd for C30H34N3O5S m/z 





Preparation of di-tert-buty\ 3a-bromo-3,3a-dihydropyrro\o[2,3-£]indo\e- 
1,8(2#,8a#)-dicarboxy\ate (1.163). To a solution of bis-Boc protected tryptamine 1.162 
(0.999 g, 2.77 mmol) in CH2Cl2 (28 mL) at rt was added PPTS (0.697 g, 2.77 mmol) and 
NBS (0.498 g, 2.77 mmol). After stirring for 4 h the solution was diluted with CH2Cl2 
(25 mL) and washed with brine (50 mL). The organic phase was dried (MgSO4) and 
concentrated. Flash chromatography (5-10% EtOAc:hexanes) afforded 0.811 g (67%) of 
1.163. 1.163: white foam; Rf 0.50 (10% EtOAc:hexanes); 1H NMR (300 MHz, CDCL) 8
7.59 (broad d, J  = 5.7 Hz, 1H), 7.36 (d, J  = 7.5 Hz, 1H), 7.31-7.25 (m, 1H), 7.08 (dt, J  = 
7.8, 1.2 Hz, 1H), 6.44 (s, 1H), 3.73 (dd, J  = 9.6, 6.9 Hz, 1H), 2.85-2.69 (m, 3H), 
1.59/1.58 (s, 9H), 1.49 (s, 9H); 13C NMR (75 MHz, CDCL) 8 153.2, 151.9, 141.9, 132.5 
(broad), 130.1, 123.9, 123.6, 117.2 (broad), 83.7, 81.9, 80.5 (broad), 62.0, 46.0, 41.3 
(broad), 28.2, 28.1; IR (neat) 2977, 1715, 1652, 1605, 1558, 1541, 1478, 1394, 1256, 




Br\ /  T




Preparation of (25,3a5,8a5)-dimethyl 3a-bromo-2-methyl-8-(phenylsulfonyl)- 
3,3a,8,8a-tetrahydropyrrolo[2,3-£]indole-1,2(2#)-dicarboxylate (1.174). A solution of 
pyrroloindoline 1.173 (0.169 g, 0.39 mmol), NBS (0.071 g, 0.39 mmol), and AIBN 
(0.006 g, 0.04 mmol) in CCl4 (8 mL) were heated at reflux for 2.5 h. The resulting 
heterogeneous mixture was cooled to room temperature and concentrated. Flash 
chromatography (33% EtOAc:hexanes) afforded 0.156 g (78%) of 1.174. 1.174: white 
foam; R/ 0.37 (33% EtOAc:hexanes); [a]25D = +96.0 (c = 0.316, CHCk); 1H NMR (300 
MHz, CDCl3) 8 7.83-7.80 (m, 2H), 7.53-7.47 (m, 2H), 7.42-7.29 (m, 3H), 7.22-7.19 (m, 
1H), 7.15-7.10 (m, 1H), 6.39 (s, 1H), 3.64 (s, 3H), 3.40 (d, J  = 13.2 Hz, 1H), 3.05 (s, 3H), 
2.80 (d, J  = 13.5 Hz, 1H), 1.72 (s, 3H); 13C NMR (125 MHz, CDClj) 8 172.2, 153.3,
153.3, 141.8, 139.3, 133.8, 133.2, 130.8, 128.8, 127.5, 125.7, 124.3, 118.5, 88.5, 67.1,
57.7, 53.0, 52.3, 52.2, 25.1; IR (neat) 3065, 2953, 1751, 1724, 1601, 1444, 1367, 1291, 
1222, 1169 cm-1; LRMS (ESI) calcd for C21H22N2O6SBr m/z (M+H+) 509.0, found 508.9.
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1.170
Preparation of (1aK,2aS',7hK)-2,3-di-ferf-butyl 1a-methyl 1H- 
cyclopropa[3,4]azeto[2,3-b]indole-1a,2,3(1aH,2aH)-tricarboxylate (1.170). To a
solution of bromide 1.148 (1.00 g, 2.01 mmol) in THF (10 mL) at 0 °C was added 
KO/Bu (2.42 mL of a 1.0 M solution in THF, 2.4 mmol) dropwise over 1 h. The reaction 
was quenched with sat. aq. NH4Cl (6 mL) and the resulting mixture was diluted with 
CH2Cl2 (150 mL). After separation, the organic phase was washed with H2O (25 mL), 
brine (25 mL), and dried (MgSO4). Concentration afforded 0.799 g (95%) of 1.170 as an 
amorphous white solid that was used without further purification. 1.170: Rf 0.33 (20% 
EtOAc:hexanes); [a]D = +291.3 (c = 0.192, CHCk); 1H NMR (500 MHz, CDCL) 8 7.79 
(bs, 1H), 7.18 (ddd, J  = 8.2, 7.2, 1.7 Hz, 1H), 6.95 (ddd, J  = 7.4, 1.7, 0.6 Hz, 1H), 6.92 
(ddd, J  = 7.3, 7.3, 0.9 Hz, 1H), 5.85 (s, 1H), 3.61 (s, 3H), 2.80 (d, J  = 7.1 Hz, 1H), 2.22 
(d, J  = 7.1 Hz, 1H), 1.58 (s, 9H), 1.48 (s, 9H);13C NMR (125 MHz, CDCL) 8 166.8,
156.2, 152.1, 147.7, 128.9, 122.5, 122.3, 121.6, 115.0, 82.5, 81.1, 79.7, 56.3, 52.2, 39.8,
28.4, 28.1, 25.5; IR (neat) 2975, 1711, 1458, 1371, 1317, 1245, 1158, 1101, 1074, 758; 




Summary of nOe data for Cyclopropylazetoindoline 1.170 (500 MHz, CDCl3)
1. Irradiation of proton H-2 at 5.85 ppm showed a reciprocal nOe with proton H-5a at
2 .2 2  ppm.
2. Irradiation of proton H-5b at 2.80 ppm showed a reciprocal nOe with proton H-5a at
2 .2 2  ppm.
Lowest Energy Structure Calculations
21Calculations on 1.170 were completed using the Gaussian09 package using density
22functional theory (DFT) with the B3LYP exchange and correlation functionals and the
236-311G** basis set. The coordinates of the optimized geometry of this structure are 
provided below (Table 1.4) (coordinates given in Figure 1.4):
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Table 1.4. Coordinates for Energy Minimized Structure of 1.170
center atom X Y Z
1 C -3.937604 -3.325234 -0.430756
2 C -2.675531 -3.169307 -1.009797
3 C -2.028922 -1.950357 -0.882879
4 C -2.624048 -0.883365 -0.180117
5 C -3.875703 -1.034266 0.405796
6 C -4.519498 -2.268790 0.265105
7 H -4.459821 -4.270413 -0.519502
8 H -2.203260 -3.986253 -1.542124
9 H -4.326205 -0.220306 0.951680
10 H -5.497655 -2.398525 0.714608
11 C -0.705892 -1.494828 -1.316816
12 C -0.586514 0.013867 -1.025773
13 H -0.502797 0.732953 -1.840777
14 N -1.780823 0.263240 -0.207491
15 C 0.641367 -1.665777 -0.528677
16 N 0.686856 -0.223775 -0.321047
17 C 0.491274 -2.062185 -1.981836
18 H 0.484550 -3.135748 -2.126436
19 H 1.013303 -1.487407 -2.741203
2 0 C 0.860160 -2.684181 0.520767
21 O 0.726600 -3.871197 0.325319
2 2 O 1.173641 -2.140039 1.705953
23 C 1.344350 -3.075535 2.786977
24 H 0.420036 -3.627564 2.962081
25 H 2.143933 -3.781519 2.557989
26 H 1.600099 -2.470871 3.653863
27 C -2.157566 1.517747 0.249798
28 C 1.826703 0.556317 -0.430114
29 O -3.131805 1.717970 0.941983
30 O 1.818486 1.742962 -0.669886
31 O -1.291614 2.436947 -0.197248
32 O 2.909280 -0.211945 -0.208552
33 C -1.366487 3.851898 0.239204
34 C 4.266567 0.367775 -0.129393
35 C 4.331323 1.387725 1.009554
36 H 3.718013 2.260736 0.792821
37 H 3.986171 0.934277 1.942009
38 H 5.366140 1.711305 1.149863
39 C 4.652178 0.975415 -1.480183
40 H 4.548090 0.230927 -2.273796
41 H 4.027860 1.835239 -1.717096
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Table 1.4. continued
center atom X Y Z
42 H 5.697149 1.295868 -1.451615
43 C 5.126600 -0.855736 0.185478
44 H 5.035264 -1.602959 -0.605681
45 H 6.176384 -0.565222 0.270234
46 H 4.811995 -1.310119 1.127042
47 C -0.204411 4.491616 -0.518670
48 H 0.725336 3.965106 -0.304195
49 H -0.378987 4.444869 -1.596151
50 H -0.107617 5.541060 -0.229127
51 C -1.144280 3.923739 1.751108
52 H -1.102185 4.970543 2.063312
53 H -1.952086 3.432348 2.292228
54 H -0.195635 3.450154 2.014553
55 C -2.702378 4.465481 -0.186986
56 H -3.536523 4.022805 0.353802
57 H -2.682189 5.540992 0.009394
58 H -2.858451 4.321773 -1.259314
CN
1.176
Preparation of (2.K,3aK,8aK)-1,8-di-ferf-butyl 2-methyl 3a-(cyanomethyl)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.176). To a solution of
1.148 (0.256 g, 0.515 mmol) in CH3CN (4 mL) at 0 °C was added KO/Bu (0.57 mL, 1.0 
M solution in THF) dropwise over 5 min. The reaction was quenched with sat. NH4Cl (6  
mL) and the resulting mixture was diluted with CH2Cl2 (60 mL). After separation, the 
organic phase was washed with brine (25 mL), dried (MgSO4), and concentrated. Flash 
chromatography (12-40% EtOAc:hexanes) afforded 0.118 g (55%) of 1.170, 0.064 g
(25%) of 1.148, and 0.036 g (15%) of 1.176. 1.176: white foam; Rf 0.11 (25% 
EtOAc:hexanes); [a]D = -28.0 (c = 0.562, CHCb); 1H NMR (500 MHz, CDQ3) 8 7.58
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Preparation of (2.R,3aS',8aR)-1,8-di-fert-butyl 2-methyl 3,3a-dihydropyrrolo[2,3- 
b]indole-1,2,8(2H,8aH)-tricarboxylate (1.186). To a solution of cyclopropane 1.170 
(0.029 g, 0.070 mmol) in THF (1.5 mL) at rt was added NaBH4 (0.013 g, 0.34 mmol). 
After the reaction mixture was allowed to stir for 2 h, the reaction was quenched with 
H2O (6  mL). The resulting mixture was diluted with CH2Cl2 (5 mL), separated, dried 
(MgSO4), filtered, and concentrated. Flash chromatography (12-25% EtOAc:hexanes) 
afforded 0.011 g of 1.186 (75% yield) as a white foam. 1.186: Rf 0.20 (20% 
EtOAc:hexanes); [a]D = -3.0 (c = 0.172, CHClj); 1H NMR (400 MHz, CDQ3) 8 7.54 
(broad, 1H), 7.18 (t, J  = 7.2 Hz, 1H), 7.09 (d, J  = 7.6 Hz, 1H), 6.96 (t, J  = 7.2 Hz, 1H),
(bs, 1H), 7.29 (t, J  = 7.5 Hz, 1H), 7.22 (d, J  = 7.5 Hz, 1H), 7.04 (t, J  = 7.5 Hz, 1H), 6.15 
(s, 1H), 4.62 (d, J  = 7.5 Hz, 1H), 3.15 (s, 3H), 2.84 (d, J  = 13.0 Hz, 1H), 2.70 (s, 2H), 
2.55 (dd, J  = 12.5, 9.5 Hz, 1H), 1.59 (s, 9H), 1.47 (bs, 9H); 13C NMR (125 MHz, CDCLj)
52.3, 52.0, 37.7, 28.3, 28.2, 26.3; IR (neat) 2978, 2251, 1712, 1604, 1481, 1393, 1367, 
1332, 1272, 1159, 1067, 1025, 905, 858, 753, 737 cm-1; LRMS (ESI) calcd for 
C24H31N3O6Na m/z (M+Na+) 480.2, found 480.2.
Boc
1.186
6.42 (d, J  = 6 .8  Hz, 1H), 4.57 (d, J  = 8.4 Hz, 1H), 3.97 (dd, J  = 6 .8 , 6 .8  Hz, 1H), 3.14 (s, 
3H), 2.60 (d, J  = 13.2 Hz, 1H), 2.55-2.47 (m, 1H), 1.59 (s, 9H), 1.47 (s, 9H); 13C NMR 
(100 MHz, CDCl3) 8 172.2, 153.3, 152.4, 143.2, 131.6, 128.3, 123.9, 122.9, 117.0, 81.3,
80.6, 76.7, 59.3, 51.8, 44.7, 33.8, 29.6, 28.3, 28.3; IR (neat) 2978, 1716, 1604, 1482, 
1458, 1396, 1366, 1258, 1163, 1112, 1048, 1018, 935, 900, 859, 753 cm-1; LRMS (ESI) 





Preparation of (2^r3aK,8aK)-1,8-di-ferf-butyl 2-methyl 3a-azido-3,3a- 
dihydropyrrolo[2r3-#]mdole-1,2,8(2#,8a#)-tricarboxylate (1.187). A mixture of 
cyclopropane 1.170 (0.088 g, 0.21 mmol), sodium azide (0.137 g, 2.10 mmol), and PPTS 
(0.053 g, 0.21 mmol) and DMF (1 mL) was stirred at rt for 3 h after which it was diluted 
with Et2O (100 mL) and washed with water (3 x 10 mL). The organic layer was dried 
(MgSO4) and concentrated. Flash chromatography (20% EtOAc:hexanes) afforded 0.070 
g of 1.187 (72%) as a white foam. 1.187: R/ 0.35 (20% EtOAc:hexanes); [a]D = -104.1 (c 
= 0.593, CHCl3); 1H NMR (400 MHz, CDCl3) 8 7.62 (bs, 1H), 7.35 (dt, J  = 8.0, 1.2 Hz, 
1H), 7.23 (dd, J  = 7.6, 0.8 Hz, 1H), 7.08 (t, J  = 7.6 Hz, 1H), 6.19 (s, 1H), 4.62 (d, J  = 9.2 
Hz, 1H), 3.15 (s, 3H), 2.82 (d, J  = 12.8 Hz, 1H), 2.59 (dd, J  = 12.9, 9.4 Hz, 1H), 1.58 (s, 
9H), 1.46 (s, 9H); 13C NMR (100 MHz, CDCfe) 8 170.9, 153.0, 152.0, 143.8, 131.0,
127.9, 123.7, 123.6, 118.1, 82.1, 81.3, 80.9, 73.6, 59.1, 52.0, 37.8, 28.3, 28.2; IR (neat)
2978, 2102, 1719, 1604, 1479, 1393, 1367, 1335, 1255, 1162, 1090, 1065, 1018, 904, 





Preparation of (2.K,3aK,8aK)-1,8-di-ferf-butyl 2-methyl 3a-phenoxy-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.188). A solution of 
cyclopropane 1.170 (0.038 g, 0.090 mmol), phenol (0.043 g, 0.46 mmol), and DBU 
(0.014 mL, 0.090 mmol) in THF (1 mL) was stirred at rt for 6 h. Concentration and flash 
chromatography (5% EtOAc:hexanes) afforded 0.033 g of 1.188 (70%) as a white foam. 
1.188: Rf 0.40 (33% EtOAc:hexanes); [ci]d= -72.8 (c = 0.325, CHCL); 1H NMR (400 
MHz, CDCL) 8 7.50 (s, 1H), 7.28-7.23 (m, 2H), 7.11-7.06 (m, 2H), 7.01-6.93 (m, 2H), 
6.72-6.60 (m, 2H), 6.41 (s, 1H), 4.64 (d, J  = 8.8 Hz, 1H), 3.15 (s, 3H), 3.00 (dd, J  = 12.6,
9.0, 1H), 2.94 (broad d, J  = 11.7 Hz, 1 H), 1.49 (s, 9H), 1.46 (s, 9H); 13C NMR (100 
MHz, CDCL) 8 171.3, 154.6, 153.4, 151.8, 144.8, 130.8, 129.0, 128.9, 124.9, 124.2,
123.0, 122.1, 117.5, 91.3, 81.5, 81.0, 78.7, 58.7, 51.9, 39.6, 28.4, 28.2; IR (neat) 2976,
2930, 1760, 1705, 1591, 1489, 1479, 1389, 1365, 1253, 1153, 1067, 1012,905,858,752 






Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(4-methoxyphenoxy)- 
3,3a-dihydropyrrolo[2,3-^]indole-1,2,8(2H,8aH)-tricarboxylate (1.189). A solution of 
cyclopropane 1.170 (0.058 g, 0.14 mmol), p-methoxyphenol (0.087 g, 0.70 mmol) and 
DBU (0.021 mL, 0.14 mmol) in THF (1 mL) was stirred at rt for 10 h. Concentration and 
flash chromatography (7-20% EtOAc:hexanes) afforded 0.057 g of 1.189 (76%) as a 
white foam. 1.189: Rf 0.48 (33% EtOAc:hexanes); [a]D = -29.5 (c = 0.273, CHCl3); 1H 
NMR (400 MHz, CDCU) 8 7.46 (bs, 1H), 7.28-7.24 (m, 2H), 7.01 (t, J  = 7.7 Hz, 1H), 
6.65-6.58 (m, 4H), 6.36 (s, 1H), 4.64 (d, J  = 8.0 Hz, 1H), 3.66 (s, 3H), 3.13 (s, 3H), 3.00­
2.90 (m, 2H), 1.44 (s, 9H), 1.46 (s, 9H); 13C NMR (100 MHz, CDCU) 8 171.3, 156.1,
151.7, 151.7, 147.9, 145.0, 130.7, 129.1, 124.9, 123.5, 123.0, 117.8, 113.9, 91.3, 81.3,
81.0, 78.6, 58.6, 55.2, 51.8, 38.8, 28.4, 28.2; IR (neat) 2980, 2929, 2854, 1715, 1504, 
1392, 1367, 1264, 1205, 1159, 1068, 1013, 902, 732, 702 cm-1; LRMS calcd for 





Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(4-nitrophenoxy)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2H,8aff)-tricarboxylate (1.190). A solution of 
cyclopropane 1.170 (0.042 g, 0.10 mmol), p-nitrophenol (0.070 g, 0.50 mmol) and DBU 
(0.018 mL, 0.11 mmol) in THF (1 mL) was stirred at rt for 48 h. Concentration and flash 
chromatography (7-20% EtOAc:hexanes) afforded 0.039 g of 1.190 (70%) as a white 
foam. 1.190: Rf 0.44 (33% EtOAc:hexanes); [a]D= -96.4 (c = 0.452, CHQ 3); 1H NMR 
(400 MHz, CDQ3) 8 8.00-7.96 (m, 2H), 7.59 (broad s, 1H), 7.31 (dt, J  = 7.6, 1.2 Hz, 
1H), 7.25 (d, J  = 7.2 Hz, 1H), 7.02 (t, J  = 7.6 Hz, 1H), 6.77-6.73 (m, 2H), 6.45 (s, 1H),
4.76 (dd, J  = 7.0, 2.7 Hz, 1H), 3.21 (s, 3H), 3.06-2.97 (m, 2H), 1.52 (s, 9H), 1.47 (s, 9H); 
13C NMR (100 MHz, CDCU) 8 170.9, 160.2, 153.1, 151.7, 144.5, 143.4, 131.5, 127.5,
125.1, 124.5, 123.6, 120.8, 117.3, 92.3, 82.1, 81.4, 78.4, 58.6, 52.1, 40.9, 28.3, 28.2; IR 
(neat) 2977, 2927, 1758, 1707, 1590, 1519, 1479, 1390, 1342, 1244, 1153, 1009, 910,





Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(phenylthio)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1.191). A solution of 
cyclopropane 1.170 (0.060 g, 0.14 mmol), thiophenol (0.080 mL, 0.73 mmol) and DBU 
(0.022 mL, 0.14 mmol) in THF (1 mL) was stirred at rt for 5 h. Concentration and flash 
chromatography (10% EtOAc:hexanes) afforded 0.064 g of 1.191 (84%) as a white foam. 
1.191: Rf 0.33 (20% EtOAc:hexanes); [u]d = -16.8 (c = 0.631, CHCb); 1H NMR (400 
MHz, CDCl3) 8 7.38 (bs, 1H), 7.29-7.24 (m, 3H), 7.20-7.14 (m, 4H), 7.00-6.95 (m, 1H),
6.29 (s, 1H), 4.51 (d, J  = 8.8 Hz, 1H), 3.10 (s, 3H), 2.86 (d, J  = 13.0 Hz, 1H), 2.64 (dd, J  
= 12.8, 9.3 Hz, 1H), 1.53 (s, 9H), 1.42 (s, 9H); 13C NMR (100 MHz, CDCb) 8 171.4,
152.7, 151.8, 143.4, 136.6, 131.3, 129.8, 129.4, 128.7, 124.0, 123.0, 117.2, 82.0, 81.3,
80.8, 61.8, 59.1, 51.8, 38.9, 28.3, 28.2; IR (neat) 2976, 2950, 2931, 1760, 1705, 1506, 
1477, 1388, 1365, 1314, 1253, 1151, 1057, 1015, 913, 887, 856, 748 cm-1; LRMS calcd 





Preparation of (2.K,3a^,8a^)-1,8-di-ferf-butyl 2-methyl 3a-((4-nitrophenyl)thio)- 
3,3a-dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.192). A solution of 
cyclopropane 1.170 (0.060 g, 0.14 mmol), p-nitrobenzenethiol (0.108 g, 0.700 mmol) and 
DBU (0.021 ml, 0.14 mmol) in THF (1 mL) was stirred at rt for 1 h. Concentration and 
flash chromatography (10% EtOAc:hexanes) afforded 0.064 g of 1.192 (80%) as a white 
foam. 1.192: R/  0.24 (20% EtOAc:hexanes); [a]D= -41.2 (c = 0.527, CHCl3); 1H NMR 
(400 MHz, CDCl3) 8 7.96-7.93 (m, 2H), 7.36-7.24 (m, 4H), 7.19 (dt, J  = 7.6, 1.2 Hz, 1H),
7.03 (dt, J  = 7.6, 0.8 Hz, 1H), 6.33 (s, 1H), 4.59 (d, J  = 8 .8  Hz, 1H), 3.12 (s, 3H), 2.95 (d, 
J  = 12.8 Hz, 1H), 2.70 (dd, J  = 12.8, 9.1 Hz, 1H), 1.45 (s, 9H), 1.44 (s, 9H); 13C NMR 
(100 MHz, CDCl3) 8 171.1, 152.7, 151.4, 148.1, 143.4, 138.5, 136.3, 130.5, 130.0, 124.0,
123.4, 123.3, 117.1, 82.4, 81.7, 81.1, 62.3, 59.0, 51.9, 39.3, 28.3, 28.1; IR (neat) 2977,
2931, 1706, 1521, 1477, 1388, 1342, 1254, 1152, 1057, 1014, 915, 887, 852, 744 cm-1; 





Preparation of (2.K,3a5',8&K)-1,8-di-ferf-butyl 2-methyl 3a-methyl-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.193). To a solution of 
cyclopropane 1.170 (0.125 g, 0.300 mmol) in CH2Cl2 (5 mL) at -40 °C was added AlMe3 
(0.30 mL of a 2.0 M solution in PhMe, 0.60 mmol). The reaction mixture was allowed to 
warm to 0 °C for 0.5 h at which time the reaction was quenched with 30% Rochelle Salt 
(2 mL). The resulting mixture was diluted with CH2Cl2 (60 mL) and the phases were 
separated. The organic phase was washed with brine (20 mL, dried (MgSO4), and 
concentrated. Flash chromatography (12-15% EtOAc:hexanes) afforded 0.099 g of 1.193 
(76% yield) as a white foam. 1.193: R/ 0.33 (20% EtOAc:hexanes); [a]D = -5.6 (c = 
1.552, CHCl3); 1H NMR (500 MHz, CDCU) 8 7.53 (bs, 1H), 7.19 (t, J  = 7.3 Hz, 1H),
7.05 (d, J  = 7.3 Hz, 1H), 6.97 (t, J  = 7.8 Hz, 1H), 5.97 (s, 1H), 4.54 (d, J  = 7.3 Hz, 1H),
3.13 (s, 3H), 2.66 (d, J  = 12.7 Hz, 1H), 2.34 (dd, J  = 12.7, 9.3 Hz, 1H), 1.59 (s, 9H), 1.47 
(bs, 9H), 1.37 (s, 3H); 13C NMR (125 MHz, CDCU) 8 171.9, 152.6, 152.6, 142.3, 136.0,
128.3, 123.1, 122.5, 117.3, 82.1, 81.5, 80.8, 59.8, 59.6, 51.8, 40.1, 28.3, 28.3, 24.5; IR 
(neat) 2977, 1758, 1713, 1603, 1481, 1455, 1395, 1367, 1257, 1167, 1107, 1016, 906,





Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-cyano-3,3a- 
dihydropyrrolo[2,3-#]indole-1,2,8(2#,8aff)-tricarboxylate (1.194). A mixture of 
cyclopropane 1.170 (0.045 g, 0.11 mmol), KCN (0.071 g, 1.090 mmol), 18-crown-6 
(0.003 g, 0.01 mmol), PPTS (0.030 g, 0.12 mmol) and THF (1 mL) was stirred at rt for
3.5 h after which it was diluted with CH2Cl2 (8  mL), filtered, and concentrated. Flash 
chromatography (12-33% EtOAc:hexanes) afforded 0.034 g (70%) of 1.194 as a white 
foam. 1.194: Rf 0.32 (33% EtOAc:hexanes); [ci]d = -3.7 (c = 0.380, CHClj); 1H NMR 
(400 MHz, CDCl3) 8 7.62 (broad, 1H), 7.32 (dt, J  = 7.8, 1.5 Hz, 1H), 7.27 (dd, J  = 7.5, 
1.0 Hz, 1H), 7.07 (dt, J  = 7.5, 1.0 Hz, 1H), 6 .6 8  (s, 1H), 4.72 (d, J  = 8.3 Hz, 1H), 3.18 (s, 
3H), 3.18 (d, J  = 12.7 Hz, 1H), 2.89 (dd, J  = 13.2, 9.3 Hz, 1H), 1.60 (s, 9H), 1.48 (broad 
s, 9H); 13C NMR (100 MHz, CDCfe) 8 170.4, 152.4, 151.4, 142.8, 130.8, 126.4, 123.9,
123.8, 118.4, 117.5, 82.5, 81.9, 80.0, 59.0, 52.2, 47.1, 39.5, 28.2, 28.2; IR (neat) 2980, 
2243, 1719, 1482, 1392, 1369, 1325, 1258, 1158, 1090, 1060, 1017, 907, 857, 756 cm-1; 





Preparation of (2^,3a5,8a^)-1,8-di-^er^-butyl 2-methyl 3a-(nitromethyl)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.195). A solution of 
cyclopropane 1.170 (0.086 g, 0.21 mmol), DBU (0.063 mL, 0.42 mmol), and 
nitromethane (1 mL) in THF (4 mL) at rt was stirred for 6  h. The reaction mixture was 
diluted with CH2Cl2 (60 mL) and the reaction was quenched with 5% citric acid (25 mL). 
After separation, the organic phase was washed with brine (25 mL), dried (MgSO4), and 
concentrated. Flash chromatography (12-33% EtOAc:hexanes) afforded 0.050 g of 1.195 
(50%) as a white foam. 1.195: R/ 0.30 (33% EtOAc:hexanes); [a]D = -20.2 (c = 0.856, 
CHCl3); 1H NMR (~2:1 mix of rotamers, 500 MHz, CDCl3) major rotamer 8 7.62 (bs, 
1H), 7.32-7.26 (m, 1H), 7.08-7.04 (m, 1H), 7.04-6.98 (m, 1H), 6.41 (s, 1H), 4.63 (bs, 
1H), 4.61 (d, J  = 2.5 Hz, 2H), 3.14 (s, 3H), 2.84 (d, J  = 13.0 Hz, 1H), 2.56 (dd, J  = 13.0,
9.5 Hz, 1H), 1.59 (s, 9H), 1.46 (bs, 9H); 13C NMR (125 MHz, CDCl3) mix of rotamers 8
171.5, 171.1, 152.5, 152.1, 143.4, 143.2, 131.8, 130.6, 130.6, 130.2, 129.0, 124.4, 123.6,
123.3, 123.2, 117.5, 84.5, 82.1, 81.9, 81.7, 81.6, 81.3, 79.2, 59.2, 54.1, 52.3, 52.0, 51.9,
39.4, 36.8, 28.3, 28.2, 28.2; IR (neat) 2979, 1722, 1604, 1556, 1481, 1395, 1368, 1335, 
1257, 1160, 1017, 903, 858, 753, 737 cm-1; LRMS (ESI) calcd for C23H31N3O8N  m/z 
(M+Na+) 500.2, found 500.2.
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Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(dicyanomethyl)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1.196). A solution of 
cyclopropane 1.170 (0.078 g, 0.19 mmol), malononitrile (0.062 g, 0.94 mmol), and DBU 
(0.032 mL, 0.21 mmol) in THF (2 mL) was stirred for 1 h at rt. The reaction mixture was 
passed through a plug of silica gel and concentrated. Flash chromatography (10% 
EtOAc:hexanes) afforded 0.055 g of 1.196 (60%) as a white foam. 1.196: Rf 0.15 (33% 
EtOAc:hexanes); [ci]d = -15.3 (c = 0.694, CHCk); 1H NMR (400 MHz, CDCk) 8 7.58 
(broad, 1H), 7.39-7.34 (m, 2H), 7.09 (t, J  = 7.6 Hz, 1H), 6.33 (s, 1H), 4.65 (d, J  = 8.1 Hz, 
1H), 4.23 (s, 1H), 3.16 (s, 3H), 2.94 (d, J  = 12.8 Hz, 1H), 2.72-7.67 (m, 1H), 1.57 (s, 9H), 
1.47 (s, 9H); 13C NMR (100 MHz, CDCk) 8 170.5, 152.7, 151.8, 143.7, 131.2, 127.1,
123.9, 118.4, 110.5, 110.2, 82.6, 81.8, 79.3, 59.1, 55.3, 52.1, 36.3, 30.6, 28.3, 28.2; IR 
(neat) 2981, 2891, 1723, 1604, 1481, 1394, 1369, 1331, 1274, 1161, 1093, 1072, 1020, 






Preparation of (2.K,3a^,8a^)-1,8-di-fert-butyl 2-methyl 3a-(1-methoxy-1,3- 
dioxobutan-2-yl)-3,3a-dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate 
(1.197). A solution of cyclopropane 1.170 (0.833 g, 2.01 mmol), methyl acetoacetate 
(0.43 mL, 4.0 mmol), and DBU (0.30 mL, 2.0 mmol) in THF (10 mL) was stirred for 12 
h at rt. The reaction mixture was passed through a plug of silica gel and concentrated. 
Flash chromatography (15-40% EtOAc:hexanes) afforded 0.799 g of 1.197 (75%) as a 
white foam. 1.197: R/ 0.09 (20% EtOAc:hexanes); [a]D = -20.4 (c = 0.812, CHCl3); 1H 
NMR (mixture of isomers and tautomers, 500 MHz, CDCl3) 8 7.50 (bs, 3.2H), 7.29-7.24 
(m, 2.3H), 7.21 (t, J  = 7.3 Hz, 2.3H), 7.11 (t, J  = 6 .8  Hz, 2.3H), 7.02-7.07 (m, 1.1H), 6.96 
(t, J  = 6 .8  Hz, 1.3H), 6.94 (t, J  = 6 .8  Hz, 1.3H), 6.46 (s, 1H), 6.41 (s, 1H), 6.29 (bs,
0.4H), 6.25 (s, 0.4H), 4.60 (bs, 2.3H), 3.94- 3.76 (m, 4.3H), 3.72 (s, 3.5H), 3.70 (s, 3.7H), 
3.67-3.62 (m, 4.2H), 3.13 (s, 6.7H), 2.94 (dd, J  = 6 .8 , 12.7 Hz, 1H), 2.86-2.76 (m, 4.7H), 
2.52 (dd, J  = 11.7, 11.7 Hz, 1H), 2.15 (s, 1.3H), 2.08 (s, 6.2H), 2.01 (s, 1.4H), 1.59 (s, 
31H), 1.46 (s, 31H); 13C NMR (mixture of isomers and tautomers, 125 MHz, CDCl3) 8
172.0, 167.9, 167.7, 152.4, 143.5, 143.4, 142.3, 131.8, 129.7, 124.9, 124.4, 124.3, 123.3,
117.9, 81.9, 81.7, 80.0, 79.4, 63.0, 62.8, 59.4, 59.3, 53.0, 52.9, 52.4, 52.1, 37.0, 36.1,
31.6, 31.4, 28.5; IR (neat) 2979, 1722, 1603, 1481, 1455, 1435, 1394, 1367, 1328, 1267, 
1201, 1159, 1018, 906, 859, 753, 737 cm-1; LRMS (ESI) calcd for C27H37N2O9N  m/z 





Preparation of (2^,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-(p-tolyl)-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8a#)-tricarboxylate (1.198). To a suspension of 
CuCN (0.197 g, 2.19 mmol) in THF (3.5 mL) at -78 °C was added p-tolylmagnesium 
bromide (3.66 mL of a 0.5 M solution in Et2O, 1.83 mmol). The reaction mixture was 
allowed to warm to 0 °C for 20 min. and was then cooled back to -78 °C. To the 
resulting solution was added a solution of cyclopropane 1.170 (0.152 g, 0.366 mmol) in 
THF (3.5 mL) dropwise. The resulting reaction mixture was allowed to stir for 15 min. at 
which time the reaction was quenched with sat. NH4Cl (6 mL) and then diluted with 
CH2Cl2 (150 mL). After separation the organic phase was washed sequentially with water 
(25 mL) and brine (25 mL), and then dried (MgSO4), and concentrated. Flash 
chromatography (10-15% EtOAc:hexanes) afforded 0.130 g (70%) of 1.198 as a white 
foam. 1.198: R  0.26 (15% EtOAc:hexanes); [ci]d = -39.2 (c = 0.186, CHCk); 1H NMR 
(500 MHz, CDCL) 5 7.49 (bs, 1H), 7.20 (t, J  = 7.5 Hz, 1H), 7.11-7.05 (m, 5H), 6.96 (dd, 
J  = 7.5, 7.5 Hz, 1H), 6.42 (s, 1H), 4.70 (bs, 1H), 3.16 (s, 3H), 3.08-3.02 (m, 1H), 2.86 
(dd, J  = 12.8, 9.0 Hz, 1H), 2.28 (s, 3H), 1.57 (s, 9H), 1.48 (bs, 9H); 13C NMR (125 MHz, 
CDCL) 5 171.9, 152.4, 152.4, 142.6, 139.2, 136.9, 129.5, 128.6, 125.3, 124.0, 123.4,
118.4, 117.0, 82.6, 82.6, 81.5, 59.5, 51.9, 40.1, 38.6, 28.4, 28.3, 20.9; IR (neat) 2977, 
1758, 1712, 1601, 1515, 1480, 1393, 1367, 1323, 1257, 1158, 1017, 928, 859, 752 cm-1; 
LRMS (ESI) calcd for CMH36N2O6Na m/z (M+Na+) 531.2, found 531.2.
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Preparation of (3a5',8aK)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3- 
^jindole (1.200). A mixture of 1.193 (0.220 g, 0.517 mmol), NaOH (0.083 g, 2.1 mmol), 
and THF:MeOH:H2O (10:5:2 mL) was stirred at 40 °C for 4 h. The mixture was 
concentrated and the resulting residue was diluted with EtOAc (60 mL) and 5% aq. citric 
acid (25 mL). After separation, the organic phase was washed with H2O (25 mL), brine 
(25 mL), dried (MgSO4) and concentrated to give acid 1.204 which was used without 
further purification.
To an aluminum foil covered flask containing a mixture of acid 1.204 (0.517 mmol), 
EDC-HCl (0.119 g, 0.620 mmol), and 2-mercaptopyridine-N-oxide (0.078 g, 0.62 mmol) 
in CH2Cl2 (6  mL) at rt was added Et3N (0.16 mL, 1.1 mmol). After the reaction mixture 
had stirred for 1.5 h, /-BuSH (0.29 mL, 2.6 mmol), the aluminum foil was removed and 
the resulting mixture was irradiated under a sun lamp (250 W) for 1.5 h. The reaction 
mixture was diluted with CH2Cl2 (60 mL) and the organic phase was sequentially washed 
with 5% aq. citric acid (25 mL), 5% NaOH (25 mL), H2O (25 mL), and brine (25 mL). 
The organic phase was dried (MgSO4), and concentrated. Flash chromatography (5% 
EtOAc:hexanes) afforded 0.101 g of pyrroloindoline 1.199 (52% yield) as a pale yellow
oil.
To a solution of 1.199 (0.410 g, 1.10 mmol) in CH3CN (6  mL) at 0 °C was added 
TMSI (0.75 mL, 5.5 mmol). After the reaction mixture had stirred for 1 h, the reaction 
was quenched with sat. NaHCO3 (6  mL) and the resulting mixture was diluted with 
CH2Cl2 (60 mL). The phases were separated and the organic phase was washed with sat. 
NaHCO3 (25 mL), brine (25 mL), dried (Na2SO4), and concentrated to afford bis-amine 
1.205 which was used in the subsequent reaction without additional purification.
To a solution of bis-amine 1.205 in EtOAc:MeOH (10 mL, 2:1) at rt was added 37% 
aq. formalin (8  mL). After stirring for 0.5 h, 10% Pd/C (0.2 g, 50% water content) was 
added to the reaction mixture. The mixture was then stirred for 12 h under H2 (1 atm.) 
After 12 h, additional 37% aq. formalin (4 mL) and 10% Pd/C (0.1 g, 50% water content) 
were added and the reaction mixture was stirred for an additional 8 h. The mixture was 
filtered through a plug of celite and the celite was rinsed with EtOAc:MeOH (10 mL, 
1:1). The filtrate was concentrated and the resulting residue was purified by prep TLC 
(CH2Cl2:MeOH:Et3N, 100:2:0.5) to afford 0.131 g (59%, 2 steps) of bis-methylamine
1.200 as a yellow oil. 1.200: R/ 0.22 (5% MeOH:CH2Cl2); [a]D = -72.2 (c = 0.416 , 
CHCl3); 1H NMR (500 MHz, CDCl3) 8 7.08 (t, J  = 7.8 Hz, 1H), 6.99 (d, J  = 7.3 Hz, 1H),
6.67 (t, J  = 7.3 Hz, 1H), 6.42 (d, J  = 7.8 Hz, 1H), 4.12 (s, 1H), 2.95 (s, 3H), 2.60-2.75 (m, 
2H), 2.56 (s, 3H), 1.95-2.00 (m, 2H), 1.44 (s, 3H); 13C NMR (125 MHz, CDQ3) 8 151.9,
136.6, 127.7, 122.2, 117.5, 106.5, 97.5, 53.2, 52.6, 40.8, 38.4, 36.5, 27.3; IR (neat) 3360, 
3049, 2957, 2928, 2864, 2792, 1680, 1606, 1492, 1374, 1299, 1255, 1124, 957, 896 
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CHAPTER 2
TOTAL SYNTHESES OF KAPAKAHINES E and F 
Introduction
Kapakahines A-G are a family of cyclic peptide natural products isolated from the 
marine sponge Cribrochalina olemda by Nakao, Scheuer, and co-workers (Figure 2.1) . 1 
Initial cytotoxicity testing of the natural isolates against P388 murine leukemia cells 
showed that the most active members were kapakahines A, B, C, and E with in vitro IC50 
values of 5.1, 5.9, 4.7, 5.0 p,M, respectively. Additional biological testing acquired by 
Baran and co-workers showed that synthetic kapakahine B displayed moderate activity 
against the breast cancer cell line DU4475 (IC5o value of 11.7 ^M), however, synthetic 
kapakahines B and F did not show significant toxicity against the NCI 60-cell line.
Structurally, the kapakahines are unique as they contain a C(3)-N(1') heterodimeric 
linkage between two tryptophan residues and a tetracyclic framework containing an a- 
carboline and strained imidazolone (Figure 2.1). The sensitivity of the imidazolone ring 
toward nucleophiles in this type of framework is well-documented (see 2.8 to 2.9, Figure 
2.1) .3,4 Elucidation of the structures of the Kapakahines by Nakao, Scheuer, and co­
workers was accomplished using a combination of degradation experiments with 
extensive NMR and FAB MS/MS. The structures of kapakahine F and B were 
unambiguously confirmed through total synthesis by Baran and coworkers in 2009 (vide
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kapakahine E (2.4) kapakahine B (2.6), R=L-phenylalanine kapakahine G (2.7)
Figure 2.1. The Kapakahines and Their Strained Architecture
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Previous Work
The methodology for Baran’s construction of the C(3)-N(1') bond of heterodimeric 
indolines was introduced in Chapter 1 (Scheme 1.16) and was utilized in their total 
synthesis of (±)-psychotrimine. They brilliantly adapted this work for their completion of
2 5the total syntheses of kapakahines F and B. From the retrosynthesis it is seen that the 
success relied on a late-stage architectural shift from pyrroloindoline 2 .1 0  to a 
macrocyclic a-carboline before conversion to kapakahine F (Scheme 2.1). The precursor
2 .1 0  comes from a Larock indole synthesis between alkyne 2.11 and pyrroloindoline 
2 .1 2 , which in turn comes from a diastereoselective oxidative cyclization between 
tryptophan 2.13 and 2-iodoaniline.
Baran’s synthesis began with the synthesis of Larock indole synthesis coupling partner
2.11 (Scheme 2.2). This tripeptide was completed by coupling TES protected 
bromoalkyne 2.15 with serine-derived iodide 2.14 to form alkyne 2.16. Hydrolysis of the 
ester and peptide coupling with dipeptide 2.17 then provided tripeptide 2.11. The other 
Larock indole synthesis coupling partner 2.12 was formed through an oxidative 
cycloaddition of 2-iodoaniline, activated with N-iodosuccinimide, on tryptophan 2.13 
providing iodo-aniline 2.12 as a single diastereomer. The Larock indole synthesis 
performed smoothly to afford amino acid 2 .1 0  after hydrogenolysis of the benzyl and 
Cbz protecting groups. The amino acid 2.10 was then ready to undergo the crucial 
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Scheme 2.1. Baran’s Retrosynthesis of Kapakahine F
After considerable experimentation they found that using non-basic peptide coupling 
conditions could yield the desired a-carboline macrocycle 2.21 in good yield (Scheme 
2.3). They proposed a mechanism that involved a rapid equilibrium between 2.10 and 
theoretical intermediates 2.19 and/or 2.20. This allowed the starting material to be 
converted to the desired a-carboline macrocycle versus the pyrroloindoline macrocycle 
(i.e. Curtin-Hammett Principle) .7 With the desired a-carboline macrocycle 2.21 in hand, 
imidazolone incorporation and deprotection provided kapakahine F in 12 steps from L- 
serine. Kapakahine F was converted into kapakahine B in 2 steps through peptide 
coupling and deprotection (Scheme 2.4).
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Scheme 2.3. Baran’s Pyrroloindoline to a-Carboline Rearrangement
1. LiOH, THF/H20/Me0H




2.21 kapakahine F (2.5)
Scheme 2.4. Baran’s Total Synthesis of Kapakahine F
Retrosynthesis
Our group initially chose Kapakahine E and B as targets because of their promising 
biological activities as well as the fact that a convergent synthesis could be envisioned to 
complete both natural products and analogs from the common bis-tryptophan 
heterodimer 2.23 (Scheme 2.5) .9 The proposed retrosynthesis began with the generation 
of ‘generic’ kapakahine macrocycle 2.22 from bis-tryptophan heterodimer 2.23 through 
peptide manipulation and lewis acid induced rearrangement to provide the macrolactam. 
The heterodimer 2.23 in turn could come from a pyrroloindoline to a-carboline 
rearrangement of 2.24 followed by concomitant imidazolone formation. This differs from 
Baran’s proposal in that macrolactamization does not occur concurrently with, and is not 
required for, a-carboline synthesis. Finally, heterodimer 2.24 could come from peptide 
coupling and protecting group removal following our heterodimerization reaction as 
previously described in Chapter 1.
Pyrroloindoline to a-Carboline Rearrangement 
At the time of commencement of this work, the only precedent on the rearrangement 
of a pyrroloindoline like architecture into an a-carboline had been published by Omura 
and coworkers in their synthesis of the neoxaline/oxaline core (Scheme 2.6). The 
mechanism they proposed for this transformation involved lewis acid coordination to the 
oxygen of the furan in furanoindoline 2.28 followed by ring opening to the iminium ion
2.29 and then ring closing to the more thermodynamically stable a-carboline 2.30. 
















Scheme 2.6. Omura’s a-Carboline Synthesis
Given the similarity of Omura and coworkers' furanoindoline to a-carboline 
transformation to our desired pyrroloindoline to a-carboline transformation, and the fact 
that no precedent existed at the time for the pyrroloindoline to a-carboline 
transformation, we decided to synthesize bromofuranoindoline 2.34 as an analog to 
bromopyrroloindoline 1.148 and attempt to engage it in the heterodimerization reaction 
as well as cyclopropyloxetindoline (2.35) formation (Scheme 2.7). Bromofuranoindolines 
2.34 -exo and 2.34-endo were synthesized from known indole lactic acid derivative 2.33 
by cyclization with NBS and acid catalyst.
Though a tedious separation of the isomers is possible at this stage, 2.34 was used 
directly in the next step in part due to the mechanistic proposal that either isomer should 
be a substrate for the formation of 2.35 and 2.36. Unfortunately, the conditions that were 
successful for 1.148 only led to decomposition of 2.34 (Scheme 2.7). In this case, the 
mechanism by which bromofuranoindoline 2.34 decomposes is still unclear and it is not 
known whether or not cyclopropyloxetindoline 2.35 is produced in the process of 
decomposition.9
In light of our results with 2.34, we reexamined bromopyrroloindoline 1.148 as a 
starting point in the total synthesis. We believed that placing an electron-withdrawing 
group on the pyrrolo-nitrogen would allow it to act as good leaving group in the same 
fashion as the furan oxygen in Omura and coworker’s furanoindoline to a-carboline 
transformation (Scheme 2.8) . 10
With this hypothesis, we synthesized furanoindoline mimic 2.42 as a model substrate 
to test the feasibility of the pyrroloindoline to a-carboline transformation (Scheme 2.9). 
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Scheme 2.7. Synthesis of 2.34 and Attempted Heterodimerization
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2.40Accessible furanoindoline mimic (2.39)
Scheme 2.8. Furanoindoline Mimic for a-Carboline Synthesis
separable mixture of endo and exo isomers (1.149-endo and 1.149-exo). After separation
and conversion of isomer 1.149-exo into isomer 1.149-endo, the methyl ester was
18hydrolyzed and coupled with L-phenylalanine ethyl ester. The Boc-protecting groups 
were removed using TMSI and CH3CN and the pyrrolo-nitrogen was selectively 
protected with PhSO2Cl to give heterodimer 2.42 (Scheme 2.9).
Once the desired furanoindoline mimic 2.42 was in hand, the rearrangement was 
attempted using Omura and coworker’s conditions. It was found that trimethylaluminum 
could elicit the expected a-carboline formation with the additional effect of inducing 
imidazolone formation by way of condensation between the aniline nitrogen and the 




indole, KOfBu, CH3CN, 0 °C 
----------------------------►
(82%) exo.endo = (1.0:3.0)
1.149-exo 1.149-endo
1. NaOH, THF/Me0H/H20  
(2:1:1), 40 °C
-------------------------------»
2. Et3N, isobutyl chloroformate, 




LHMDS, THF, -78 °C to 
0 °C to -78 °C; 
MeOH (quantitative)
1. TMSI, CH3CN, 0 °C
2. Et3N, DMAP, PhS02CI, 
CH2CI2, 0 °C
(85% overall)
Scheme 2.9. Synthesis of Heterodimer 2.42 for Rearrangement
Under mild conditions (0 °C to rt) an excess of trimethylaluminum (10 eq.) appeared 
to give a complex mixture of compounds including starting material. Under more forcing 
conditions (0 °C to rt to 32 °C, sonication) an excess of trimethylaluminum (7 eq.) not 
only elicited tetracycle formation, but also elimination of sulfinate from the sulfonamide 
to give conjugated enamines 2.43 and 2.44 as an inseparable mixture in 80% yield 
(Scheme 2.10).15d,e The rearrangement of 2.42 to 2.43 and 2.44 proved to be quite 







Scheme 2.10. Rearrangement Results for 2.42
variable ratios of 2.43:2.44 (0.5-1.5:1.0). Production of ketone 2.44 is thought to proceed 
by reaction of the strained imidazolone with excess trimethylaluminum. Numerous 
attempts to circumvent formation of 2.44 by using different lewis acids (BF3 OMe2, 
Et3Al, Me2AlCl, MeAlCl2, Sc(OTf)3, Yb(OTf)3) and/or electron-withdrawing groups 
(triflyl, p-nosyl, dimethylsulfamoyl, carbobenzyloxy, tert-butylcarbonyl) on the pyrrolo- 
nitrogen were unsuccessful and only resulted in lower yields or sluggish reactivity.
We proposed that AlMe3 induced a reversible conversion of pyrroloindoline into a- 
carboline but that imidazolone formation was irreversible (Scheme 2.11). We proposed 
that after imidazolone formation, elimination of sulfinate from 2.48 and/or 2.50 through 
enol 2.49 produced enamine 2.51. We then proposed that enamine 2.51 reacts with 
AlMe3 giving a mixture of 2.43 and 2.44.
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Scheme 2.11. Proposed Mechanism for Rearrangement of 2.42
Elimination of the sulfinate was thought to be an advantageous event because it solved 
the problem of removing the sulfonyl group later in the synthesis. In the absence of the 
elimination the stereochemistry at the ester would be epimeric for the kapakahines and 
we believed that reduction of the resulting enamine could be accomplished 
stereoselectively using substrate control to give the desired stereoisomer. In the event, a 
variety of reducing conditions were explored (NaBH3CN/AcOH, NaBH(OAc)3/AcOH, 
Et3SiH/TFA, H2/Pd/C, Al/Hg/AcOH, Zn/AcOH) and it was found that NaBH3CN/AcOH 
was most effective (Scheme 2.12) . 11 This gave the desired isomer as the major product, 
however, the overall yield remained low (15-33% yield from 2.42 for the desired isomer 
after introduction of the protecting group) and the selectivity could not be improved 
beyond 2:1 for the desired isomer. 19 The undesired isomer 2.54 was isolated after this 
capricious three step sequence in 5-16% yield and was found to be resistant to protection 
under the conditions that were effective for the protection of the desired isomer. The 
relatively low selectivity for the reduction can be explained due to the competing steric 
hindrance of the Burgi-Dunitz trajectory from either face of the transient iminium ion 
(Figure 2.2) . 12
With this promising model study in hand, a direct introduction of a tryptophan 
derivative in place of indole was examined (Scheme 2.13). Tryptophan derivative 2.56 
was designed and used due to stability reasons (tryptophan derivative 1.154 performed 
poorly in the heterodimerization reaction) and the orthogonal functionality it imparted to 
the product 2.57. Thus, L-tryptophan was reduced with LAH and protected as a TIPS 
ether and the amine converted to an azide to afford 2.56. Heterodimerization with the 





2. NaBH3CN, AcOH, CH2CI2
3. FmocCI, NaHC03, CH2CI2 
 »
(15-32% overall of 2.53) 
(5-16% overall of 2.54)
Scheme 2.12. Rearrangement, Reduction, and Protection from 2.42
Figure 2.2. Proposed Transition State for Reduction of Enamine 2.43
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Scheme 2.13. Design of Tryptophan 2.56 and Synthesis of 2.60
manipulation then gave 2.60.
Attempts to affect tandem rearrangement and enamine formation of advanced 
heterodimer 2.60, unfortunately, proved fruitless. Given these results, we decided to 
pursue tetracyclic compound 2.53 for functionalization at the C(3) indolic position in an 
attempt to perform a tryptophan synthesis from indole.
Tryptophan Synthesis 
There have been numerous approaches to the synthesis of tryptophan by way of
13functionalizing the C(3) position of indole (Scheme 2.14). Approaches have included 
utilizing the high nucleophilicity of the C(3) position to undergo nucleophilic additions to 
various substrates including unsaturated systems and activated aziridine rings.
The Negishi coupling using serine derived organozinc reagents such as 2.67 and aryl 
halides to make various phenylalanine derivatives has been reported. 14 We decided to use 
this methodology toward the synthesis of tryptophan which involved the Negishi 
coupling of 2.67 with a C(3)-halogen substituted indole (Scheme 2.14). There have been 
numerous reports in the literature of using these types of organozinc reagents to 
synthesize various p-substituted-alanine derivatives, but no synthesis of a tryptophan 
derivative had been reported. 15
Using the natural C(3) nucleophilicity of indole, 2.53 reacted with mercuric acetate 
followed by iodine giving iodoindole 2.69 in essentially quantitative conversion (Scheme 
2.15). Reaction of 2.69 with organozinc reagent 2.67 under the coupling conditions gave 
tryptophan 2.70 in 74% yield. The synthesis of compound 2.70 is significant as the 




Scheme 2.14. Various Syntheses of Tryptophans from Indoles
Hg(OAc)2, l2,
_  _ _  CH2CI2, 0 ° C
2 .5 3 ----------------- ►
(>95%)
Scheme 2.15. Synthesis of Tryptophan 2.70 using the Negishi Coupling
Endgame
Tryptophan 2.70 was subjected to hydrogenolysis in a mixture of EtOH/THF using 
10% Pd/C under hydrogen at atmospheric pressure keeping the mixture at about 5 °C 
(Scheme 2.16). Such mild conditions were used to prevent the hydrogenolysis of the 
Fmoc protecting group. 16,17 The Fmoc group was chosen based on its resistance to the 
hydrogenolysis conditions used for benzyl ester deprotection, and if hydrogenolysis
could not be used to induce global deprotection in the final stage, strong amine bases may
18be used to remove the Fmoc protecting group. The resulting free acid from 2.70 was 
then coupled to tetrapeptide 2.73 and dipeptide 2.74 to yield macrocyclization precursors
2.71 and 2.72, respectively (Scheme 2.16).
The next step involved a one-pot global deprotection of both the benzyl ester and 
Fmoc protecting groups using hydrogenolysis. We wished to avoid strongly nucleophilic 
amine bases to remove the Fmoc group due to the perceived sensitivity of the strained 
imidazolone ring toward nucleophiles. A number of additives were employed in the 
hydrogenolysis step (formic acid, acetic acid, ammonium formate) and it was noted that 
ammonium formate had a pronounced effect on the efficiency of the hydrogenolysis step. 
With formic and acetic acid additives, the global deprotection was very sluggish and led 
to incompletely deprotected material.
The resulting amino acids from 2.71 and 2.72 were subjected to macrolactamization 
with HATU in CH2Cl2/DMF followed by deprotection of the Boc group using TFA in 
CH2Cl2 to afford kapakahine E and kapakahine F, respectively (Scheme 2.17). The total 
synthesis of kapakahines E and F required 18 steps from L-tryptophan methyl ester 
hydrochloride (longest linear sequence) and were completed with overall yields of 3.3%
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Scheme 2.16. Synthesis of Peptides 2.71 and 2.72
and 6 .0 %, respectively.
Kapakahine E represented a problem in terms of matching the NMR spectra of the 
natural material reported by Nakao, Scheuer, and coworkers due to the non-precise 
conditions reported for the acquisition of their spectra and the limited quantity of material 
that they had isolated. After struggling with conditions, we had to rely on HPLC 
coinjection analysis with the natural material generously provided by Professor Yoichi 
Nakao, HRMS, and LC-MS/MS as well as matching the spectra of our synthetic 
kapakahine F to that of synthetic kapakahine F reported by Baran.
Conclusions
A general total synthesis of the kapakahine family has been established and verified 
by matching the spectra of our synthetic kapakahine E and F to that of natural kapakahine 
E and synthetic kapakahine F. Verification of the total synthesis of kapakahine E was 
done using HPLC coinjection analysis and MS/MS fragmentation studies. Verification of 
the total synthesis of kapakahine F was done by matching the spectra of that reported by 
the Baran group. In the process, a novel lewis acid mediated rearrangement of 
pyrroloindolines to a-carbolines with concomitant imidazolone formation has been 
developed and a synthesis of highly substituted tryptophans from 3-iodo indoles using the 
Negishi coupling reaction has been established. Biological activities of the synthetic 





1. H2, 10% Pd/C, NH4HCO2, 
EtOAc/EtOH (1:2), rt
2. HATU, EtN/'Pr2, CH2CI2/DMF (2:1), 
0 °C-rt
------------------------------------- »
3. TFA/CH2CI2, (1:10), rt
(50% overall)
1. H2, 10% Pd/C, NH4HC02, 
EtOAc/EtOH (1:2), rt
2. HATU, EtN/Pr2, CHjClg/DMF (2:1), 
0 °C-rt------------------------------------- »
3. TFA/CH2CI2, (1:10), rt
(78% overall)
kapakahine F (2.5) 
Scheme 2.17. Total Syntheses of Kapakahines E and F
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Experimental Section
Chemicals were either used as received or purified according to Purification o f 
Common Laboratory Chemicals}9 Glassware was dried in an oven at 130 °C or flame 
dried and cooled under a dry atmosphere prior to use. All reactions were performed using 
common dry, inert atmosphere techniques. Reactions were monitored by TLC and 
visualized by a dual short wave/long wave UV lamp and stained with an ethanolic 
solution of potassium permanganate or p-anis aldehyde. Column flash chromatography 
was performed using 230-400 mesh silica gel. NMR spectra were recorded on Varian 
Unity-300, Varian VXR-500, or Varian Inova-500 spectrometers. Chemical shifts for 1H 
NMR were reported as 8 , parts per million, relative to the signal of tetramethylsilane at 0
13ppm. Chemical shifts for C NMR were reported as 8 , parts per million, relative to the 
center line signal of the CDCl3 triplet at 77 ppm. Proton and carbon assignments were
1 13established using spectral data of similar compounds, H nOe analysis, and C DEPT 
NMR. The abbreviations s, bs, d, dd, bd, ddd, t, q, bq, and m stand for the resonance 
multiplicity singlet, broad singlet, doublet, doublet of doublets, broad doublet, doublet of 
doublet of doublets, triplet, quartet, broad quartet, and multiplet, respectively. IR spectra 
were recorded on a Bruker Tensor 27 FT-IR spectrometer. Optical rotations were
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obtained on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell with a 1 
decimeter path length. Mass spectra were recorded at the Mass Spectrometry Facility at 
the Department of Chemistry of the University of Utah at Salt Lake City on a Finnigan 
MAT 95 double focusing high resolution mass spectrometer. Concentration refers to 
removal of solvent under reduced pressure (house vacuum at ca. 2 0  mmHg).
Preparation of (±)-8 -fert-butyl 2-methyl 3a-bromo-3,3a-dihydro-2#-furo[2,3- 
£]indole-2,8(8a#)-dicarboxylate (2.34). To a solution of indole lactate 2.33 (0.173 g, 
0.541 mmol) in CH2Cl2 (10 mL) at rt was added Na2SO4 (excess), NBS (0.097, 0.54 
mmol), and p-TsOHH2O (0.010 g, 0.054 mmol). The reaction was quenched after 3 h 
with 10% aq. NaHCO3 (10 mL) and diluted with CH2Cl2 (40 mL) and brine (50 mL). The 
organic layer was dried (MgSO4) and concentrated. Flash chromatography (10% 
EtOAc:hexanes) afforded 0.051 g (24%) of 2.34-exo and 0.112 g (52%) of 2.34-endo as 
white foams. 2.34-exo: R/ 0.35 (33% EtOAc:hexanes); 1H NMR (500 MHz, CDCl3) 8  
7.82 (bs, 1H), 7.41 (d, J  = 7.8 Hz, 1H), 7.31 (t, J  = 7.3 Hz, 1H), 7.10 (t, J  = 8.3 Hz, 1H), 
6.38 (bs, 1H), 4.21 (dd, J  = 10.3, 5.4 Hz, 1H), 3.76 (s, 3H), 3.13 (dd, J  = 12.7, 4.9 Hz, 
1H), 2.99 (dd, J  = 11.2, 11.2 Hz, 1H), 1.60 (s, 9H); 13C NMR (125 MHz, CDCl3) 8  170.0,
151.5, 141.3, 131.4, 130.8, 124.7, 124.0, 115.3, 100.9, 82.7, 76.5, 59.8, 52.5, 47.6, 28.3; 
IR (neat) 2979, 2954, 2932, 1759, 1717, 1604, 1482, 1440, 1388, 1350, 1287, 1253, 




420.1, found 420.0. 2.34-endo: Rf 0.30 (33% EtOAc:hexanes); 1H NMR (500 MHz, 
CDCl3) 8  7.82 (bs, 1H), 7.36 (d, J  = 7.8 Hz, 1H), 7.28 (t, J  = 7.3 Hz, 1H), 7.05 (t, J  = 7.3 
Hz, 1H), 6.26 (bs, 1H), 4.69 (d, J  = 8 . 8  Hz, 1H), 3.34-3.17 (m, 5H), 1.62 (s, 9H); 13C 
NMR (125 MHz, CDCU) 8  170.9, 151.6, 142.6, 130.8, 124.8, 123.7, 115.1, 101.6, 82.5,
78.0, 60.0, 52.4, 47.0, 28.6; IR (neat) 2979, 2952, 2933, 1760, 1721, 1604, 1482, 1446, 
1390, 1353, 1166, 1067, 1019 cm-1; LRMS (ESI) calcd for CnH 20BrNO5Na m/z 
(M+Na+) 420.1, found 420.0.
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1.149-exo 1.149-encfo
Preparation of (2.K,3aK,8aK)-1,8-di-fert-butyl 2-methyl 3a-bromo-3,3a- 
dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (1.149-endo) from 
(2S',3aR,8aR)-1,8-di-ferf-butyl 2-methyl 3a-bromo-3,3a-dihydropyrrolo[2,3-£]indole- 
1,2,8(2#,8aff)-tricarboxylate (1.149-exo). To a solution of 1.149-exo (0.675 g, 1.26 
mmol) in THF (7 mL) at -78 °C was added LHMDS (3.8 mL of a 1.0 M solution in 
THF, 3.8 mmol) dropwise. The reaction mixture was allowed to warm to 0 °C and stirred 
at 0 °C for 30 min after which it was re-cooled to -78 °C. The reaction was quenched 





Preparation of (2^,3aK,8aK)-di-ferf-butyl 2-(((5)-1-ethoxy-1-oxo-3-phenylpropan-2- 
yl)carbamoyl)-3a-(1#-mdol-1-yl)-3,3a-dihydropyrrolo[2,3-£]mdole-1,8(2#,8a#)- 
dicarboxylate (2.41). To a solution of 1.149-endo (1.609 g, 3.016 mmol) in 
THF:MeOH:H2O (2:1:1, 40 mL) was added NaOH (0.483 g, 12.1 mmol). The resulting 
mixture was heated at 40 °C for 2 h and then cooled to rt. The reaction mixture was 
diluted with EtOAc (100 mL) and neutralized with citric acid (5% aq., 100 mL). The 
aqueous layer was extracted with EtOAc (2 x 50 mL) and the combined organic extracts 
were washed with H2O (50 mL) and brine (50 mL). The extracts were dried (MgSO4) and 
concentrated. To a solution of the resulting residue in THF (12 mL) at 0 °C was added 
Et3N (0.84 mL, 6.0 mmol) and isobutyl chloroformate (0.43 mL, 3.3 mmol). After 
stirring for 5 min, a solution of L-phenylalanine ethyl ester (1.166 g, 6.032 mmol) in 
EtOAc (10 mL) was added at once. The resulting mixture was allowed to warm to rt and 
then diluted with CH2Cl2 (150 mL). The reaction was quenched with citric acid (5% aq., 
50 mL) and the aqueous layer was extracted with CH2Cl2 (2 x 50 mL). The organic 
extracts were washed with H2O (50 mL), and brine (50 mL), dried (MgSO4), and 
concentrated. Flash chromatography (25% EtOAc:hexanes) afforded 1.781 g (85% 
overall) of 2.41 as a white foam. 2.41: R/ 0.5 (33% EtOAc:hexanes); [a]D = +78.9° (c = 
0.096, CHCl3); 1H NMR (300 MHz, CDCl3) 8  7.63-7.60 (m, 1H), 7.46 (d, J  = 8.1 Hz,
1H), 7.36 (dd, J  = 7.8, 0.9 Hz, 1H), 7.26-7.04 (m, 10H), 7.01 (d, J  = 7.4 Hz, 1H), 6.90 (d, 
J  = 6.7 Hz, 1H), 6 . 8 6  (s, 1H,), 6.42 (dd, J  = 3.6, 0.3 Hz, 1H), 4.93 (dd, J  = 9.0, 1.5 Hz, 
1H), 4.21-3.99 (m, 3H), 3.42 (dd, J  = 13.0, 8 . 8  Hz, 1H), 3.27 (dd, J  = 13.0, 1.4 Hz, 1H),
2.99 (dd, J  = 13.6, 5.7 Hz, 1H), 2.92 (dd, J  = 13.6, 5.3 Hz, 1H), 1.52 (s, 9H), 1.50 (s, 9H), 
1.20 (t, J =  7.2 Hz, 3H); 13C NMR (125 MHz, CDQ 3) 8  170.0, 169.4, 154.0, 151.7,
142.4, 135.8, 134.4, 130.5, 130.4, 129.4, 129.1, 128.2, 126.8, 126.2, 126.0, 123.7, 122.0,
121.6, 120.1, 117.1, 111.4, 101.9, 82.3, 82.3, 81.0, 73.1, 62.0, 61.2, 53.5, 38.5, 38.1,
28.1, 14.1; IR (neat) 3408, 2979, 1718, 1513, 1482, 1456, 1371, 1328, 1255, 1157, 1016 
cm-1; LRMS (ESI) calcd for C40H47N4O7 m/z (M+H+) 695.3, found 695.4.
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2.42
Preparation of (5)-ethyl 2-((2^,3a^,8a5)-3a-(1#-mdol-1-yl)-1-(phenylsulfonyr)- 
1,2,3,3a,8,8a-hexahydropyrrolo[2,3-£]indole-2-carboxamido)-3-phenylpropanoate 
(2.42). To a solution of amide 2.41 (1.781 g, 2.563 mmol) in CH3CN (12 mL) at 0 °C 
was added TMSI (1.76 mL, 12.8 mmol) dropwise. The reaction was quenched after 1 h 
with sat. NaHCO3 (aq, 50 mL) and diluted with CH2Cl2 (150 mL) and brine (50 mL). The 
aqueous phase was extracted with CH2Cl2 (3 x 25 mL) and the combined organic extracts 
were washed with sat. NaHCO3 (aq, 50 mL) and brine (50 mL). The extracts were dried 
(MgSO4) and concentrated. To a solution of the resulting residue that contained the crude
bis-amine from 2.41 in CH2Cl2 (20 mL) at 0 °C was added Et3N (0.71 mL, 5.1 mmol), 
DMAP (0.157 g, 1.28 mmol), and PhSO2Cl (0.49 mL, 3.8 mmol). The reaction mixture 
was stirred at 0 °C until complete consumption of the starting material was observed by 
TLC upon which the mixture was diluted with CH2Cl2 (100 mL). The reaction was 
quenched with 5% citric acid (aq, 20 mL) and the aqueous phase was washed with 
CH2Cl2 (50 mL). The organic phases were combined, washed with brine (50 mL), dried 
(MgSO4), and concentrated. Flash chromatography (25% EtOAc:hexanes) afforded 1.381 
g (85% overall) of 2.42 as a white foam. 2.42: R/ 0.40 (33% EtOAc:hexanes); [a]D = 
+84.4° (c = 0.428, CHCU); 1H NMR (300 MHz, CDQ 3) 8  7.83 (dd, J  = 7.4, 1.0 Hz, 2H), 
7.75 (t, J  = 7.5 Hz, 1H), 7.56 (t, J  = 7.8 Hz, 2 H), 7.53 (d, J  = 7.9 Hz, 1 H), 7.33-7.26 (m, 
3H), 7.20-7.08 (m, 5H), 7.02 (t, J  = 7.2 Hz, 1H), 6.81-6.75 (m, 2H), 6.69 (d, J  = 3.3 Hz, 
1H), 6.61 (d, J  = 7.8 Hz, 1H), 6.28 (d, J  = 8.4 Hz, 1H), 6.24 (d, J  = 3.6 Hz, 1H), 5.84 (s, 
1H), 4.97 (s, 1H), 4.56 (dd, J  = 9.0, 2.6 Hz, 1H), 4.24 (dd, J  = 13.3, 6.0 Hz, 1H), 4.06 (q, 
J  = 7.2 Hz, 2H), 3.24 (dd, J  = 13.8, 9.3 Hz, 1H), 3.07 (dd, J  = 13.6, 2.6 Hz, 1H), 3.01 (d, 
J  = 5.9 Hz, 2H), 1.15 (t, J  = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) 8  170.3, 169.3,
148.2, 136.8, 135.7, 134.0, 133.9, 130.6, 130.6, 129.9, 129.6, 128.4, 127.4, 126.9, 126.2,
125.7, 125.6, 121.6, 121.6, 120.0, 119.8, 111.4, 111.0, 101.8, 83.0, 74.4, 62.8, 61.2, 53.5,
38.2, 38.1, 14.0; IR (neat) 3403, 3060, 2981, 1737, 1670, 1611, 1516, 1472, 1452, 1352, 
1208, 1168, 1119, 1092, 1069, 1027, 910 cm-1; LRMS (ESI) calcd for C36H35N4O5S m/z 
(M+H+) 635.2. found 635.3.
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Preparation of (9#-fluoren-9-yl)methyl ((25',2a1K,45',5aR)-2-benzyl-5a-(1#-indol-1- 
yl)-1,3-dioxo-2,2a1,3,4,5,5a-hexahydro-1#-2a,9b-diazacyclopenta[/A:]fluoren-4- 
yl)carbamate (2.53) and (25',2a1K,4.K,5aK)-4-amino-2-benzyl-5a-(1#-indol-1-yl)- 
2a1,4,5,5a-tetrahydro-1#-2a,9b-diazacyclopenta[/A:]fluorene-1,3(2#)-dione (2.54).
To a solution of 2.42 (0.399 g, 0.628 mmol) in CH2Cl2 (10 mL) at 0 °C was added AlMe3 
(1.1 mL of a 2.0 M solution in PhMe, 2.2 mmol) dropwise. The resulting mixture was 
stirred for 0.5 h, allowed to warm to rt for 1 h and then sonicated to 32 °C in an ultrasonic 
cleaning bath. The mixture was then cooled to 0 °C and another aliquot of AlMe3 (1.1 
mL of a 2.0 M solution in PhMe, 2.2 mmol) was added dropwise. The mixture was 
stirred for an additional 0.5 h, allowed to warm to rt for 1 h and then sonicated to 
maintain a temperature between 26-32 °C. After consumption of the starting material 
(TLC) the mixture was cooled to 0 °C and the reaction was quenched using Rochelle’s 
salt (30% aq, 2 mL). The resulting mixture was allowed to stir for 0.5 h after which it 
was diluted with CH2Cl2 (150 mL). The mixture was washed with brine (100 mL) and the 
aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts 
were washed again with brine (50 mL), dried (MgSO4) and concentrated to afford an 
inseparable mixture of 2.43 and 2.44 (1.5:1.0) as a pale yellow oil.
To a solution of 2.43 and 2.44 from above in CH2Cl2 (12 mL) at 0 °C was added
AcOH (0.8 mL, 1.25 mL/mmol starting amide) followed by NaCNBH3 (0.190 g, 2.83 
mmol). The resulting mixture was allowed to stir until the starting material was 
consumed (TLC). The reaction mixture was then diluted with CH2Cl2 (100 mL) and 
washed with sat. NaHCO3 (aq, 50 mL) and brine (50 mL). After gas evolution had 
ceased, FmocCl (0.244 g, 0.942 mmol) was added and the organic layer separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 25 mL) and the combined organics were 
washed with sat. NaHCO3 (20 mL) and brine (20 mL), dried (MgSO4) and concentrated. 
Flash chromatography (15-50% EtOAc:hexanes) afforded 0.145 g (33% overall) of 2.53 
as a colorless glass and 0.042 g (16% overall) of 2.54 also as a colorless glass. 2.53: R/ 
0.20 (33% EtOAc:hexanes); [ci]d = -69.3 (c = 0.494, CHQ 3); 1H NMR (500 MHz, 
CDCl3) 8  8.52 (d, J  = 3.4 Hz, 1H), 7.72-7.69 (m, 3H), 7.60-7.55 (m, 3H), 7.37-7.23 (m, 
6 H), 7.18 (d, J  = 7.0 Hz, 2H), 7.09 (t, J  = 7.5 Hz, 2H), 7.01 (t, J  = 7.5 Hz, 2H), 6.91 (t, J  
= 7.5 Hz, 1H), 6.80 (t, J  = 7.5 Hz, 1H), 6.71 (d, J  = 7.5 Hz, 1H), 6.67 (d, J  = 3.0 Hz, 1H), 
6.24 (d, J  = 8.4 Hz, 1H), 6.20 (d, J  = 4.0 Hz, 1H), 5.56 (s, 1H), 5.14 (dd, J  = 5.4, 5.4 Hz, 
1H), 4.47-4.40 (m, 2H), 4.22 (dd, J  = 7.2 Hz, 1H), 3.62 (dd, J  = 14.8, 2.9 Hz, 1H), 3.24 
(dd, J  = 14.3, 5.8 Hz, 1H), 3.19 (dd, J  = 14.3, 5.5 Hz, 1H), 1.90 (dd, J  = 14.6, 13.0 Hz, 
1H); 13C NMR (125 MHz, CDCl3) 8  170.3, 167.0, 156.1, 143.5, 143.4, 141.2, 141.2,
137.7, 134.8, 134.4, 134.1, 130.3, 130.3, 129.1, 128.5, 127.7, 127.5, 127.4, 127.0, 127.0,
126.4, 126.2, 125.0, 124.9, 124.6, 123.7, 121.8, 121.2, 120.1, 120.0, 119.9, 114.8, 110.8,
103.2, 81.7, 67.2, 65.1, 65.1, 48.5, 46.9, 37.3, 36.3; IR (neat) 3400, 3063, 1726, 1679, 
1484, 1456, 1342, 1295, 1219, 1078 cm-1; LRMS (ESI) calcd for C43H34N4O4N  m/z 
(M+Na+) 693.3, found 693.2. 2.54: R/ 0.25 (50% EtOAc:hexanes); [a]D = -216.6 (c = 
0.216, CH3OH); 1H NMR (500 MHz, CD3OD) 8  7.85 (d, J  = 3.6 Hz, 1H), 7.62 (d, J  = 8.0
113
Hz, 1H), 7.51 (d, J  = 8.0 Hz, 1H), 7.36-7.30 (m, 1H), 7.22 (d, J  = 7.5 Hz, 2H), 7.08 (t, J  
= 7.5 Hz, 2H), 6.99-6.94 (m, 3H), 6.84-6.80 (m, 1H), 6.75 (t, J  = 7.5 Hz, 1H), 6.62 (d, J  
= 3.5 Hz, 1H), 6.14 (d, J  = 8.3 Hz, 1H), 5.43 (s, 1H), 5.10 (dd, J  = 5.0, 5.0 Hz, 1H), 3.78 
(dd, J  = 13.2, 2.6 Hz, 1H), 3.70 (dd, J  = 14.9, 2.5 Hz, 1H), 3.17 (dd, J  = 14.0, 5.5 Hz, 
1H), 2.29 (dd, J  = 14.5, 14.5 Hz, 1H); 13C NMR (125 MHz, CD3OD) 8  172.7, 168.5,
139.9, 136.8, 136.1, 135.8, 132.0, 131.7, 130.7, 129.8, 128.9, 127.5, 126.4, 125.1, 123.1,
122.5, 121.4, 115.9, 112.2, 104.2, 83.4, 66.9, 66.9, 53.1, 37.5, 34.8; IR (neat) 3189, 2421, 
1732, 1680, 1603, 1484, 1458, 1294, 1217, 1136 cm-1; LRMS (ESI) calcd for 
C28H24N4O2 m/z (M+H+) 449.2, found 449.2.
114
2.43-acetamide 2.44-acetamide
Characterization of 2.43 and 2.44 as their Acetamide: Preparation of N- 
((25,,2a1R,5aR)-2-benzyl-5a-(1H-mdol-1-yl)-1r3-dioxo-2,2a1,3,5a-tetrahydro-1H- 
2a,9b-diazacydopenta[/k]fluoren-4-yl)acetamide (2.43-acetamide) and N-((4aR,9aS)- 
4a-(1H-indol-1-yl)-2-oxo-1-((S)-3-oxo-1-phenylbutan-2-yl)-2,4a,9,9a-tetrahydro-1H- 
pyrido[2,3-^]indol-3-yl)acetamide (2.44-acetamide). To a mixture of 2.43 and 2.44 
(0.044 g) in CH2CI2 (2 mL) at 0 °C was added Et3N (30 p,L) and AcCl (14 p,L). After 0.5 
h the mixture was diluted with CH2Cl2 (40 mL) and the reaction was quenched with citric 
acid (5% aq, 10 mL). The organic phase was washed with brine, dried (MgSO4), and
concentrated. Flash chromatography (15-25% EtOAc:hexanes) afforded 0.030 g (61%) of 
2.43-acetamide as an oil and 0.010 g (20%) of 2.44-acetamide as an oil. 2.43-acetamide: 
Rf 0.29 (33% EtOAc:hexanes); [ci]d = -23.1° (c = 0.200, CHCU); 1H NMR (500 MHz, 
CDCl3) 8  8.10 (s, 1H), 7.78 (s, 1H), 7.72 (d, J  = 8.5 Hz, 1H), 7.64 (d, J  = 7.5 Hz, 1H),
7.47 (dt, J  = 7.5, 1.5 Hz, 1H), 7.41 (d, J  = 8.0 Hz, 1H), 7.25-7.22 (m, 3H), 7.18-7.14 (m, 
4H), 7.10-7.06 (m, 2H), 6 . 8 6  (bs, 1H), 6.48 (d, J  = 3.5 Hz, 1H), 5.55 (s, 1H), 5.08 (dd, J  
= 8.4, 5.0 Hz, 1H), 3.27 (dd, J  = 14.5, 5.2 Hz, 1H), 3.17 (dd, J  = 14.1, 8.5 Hz, 1H), 2.10 
(s, 3H); 13C NMR (125 MHz, CDQ 3) 8  173.5, 169.2, 159.2, 139.1, 135.3, 134.3, 132.4,
131.3, 130.9, 129.0, 128.6, 127.3, 126.3, 126.0, 126.0, 125.8, 122.2, 121.6, 120.5, 116.4,
115.3, 111.2, 102.6, 80.7, 66.7, 63.4, 34.5, 24.6; IR (neat) 3371, 3064, 1737, 1668, 1511, 
1481, 1450, 1367, 1293, 1232, 1195, 1017 cm-1; LRMS (ESI) calcd for C30H24N4O3N  
m/z (M+Na+) 511.2, found 511.2. 2.44-acetamide: Rf 0.19 (33% EtOAc:hexanes); [a]D = 
-154.2 (c = 0.076, CHCl3); 1H NMR (500 MHz, CDCU) 8  8.14 (s, 1H), 7.59 (d, J  = 8.0 
Hz, 1H), 7.37 (s, 1H), 7.23-7.16 (m, 5H), 7.06 (t, J  = 7.0 Hz, 1H), 6.95-6.91 (m, 2H), 
6.88-6.87 (m, 2H), 6.80 (t, J  = 7.5 Hz, 1H), 6.64 (d, J  = 8.4 Hz, 1H), 6.61 (d, J  = 8.0 Hz, 
1H), 6.45 (d, J  = 3.4 Hz, 1H), 5.58 (d, J  = 4.5 Hz, 1H), 4.73 (broad s, 1H), 4.23 (bs, 1H),
3.06 (dd, J  = 14.3, 6.0 Hz, 1H), 2.63 (dd, J  = 14.4, 9.3 Hz, 1H), 2.14 (s, 3H), 1.95 (s, 3H); 
13C NMR (125 MHz, CDCU) 8  206.6, 173.0, 169.0, 161.0, 146.6, 136.4, 134.0, 130.8,
129.7, 129.0, 128.8, 127.2, 127.0, 126.6, 124.7, 121.5, 121.4, 121.2, 120.0, 113.9, 112.6,
110.3, 102.3, 77.4, 6 6 .6 , 65.3, 33.8, 28.8, 24.7; IR (neat) 3371, 2925, 1719, 1640, 1514, 





Preparation of (S)-3-(2-azido-3-((triisopropylsilyl)oxy)propyl)-1#-mdole (2.56). To
a suspension of L-tryptophan (1.000 g, 4.90 mmol) in THF (25mL) at 0 °C was 
cautiously added lithium aluminum hydride (0.743 g, 0.020 mmol) and allowed to warm 
to rt and refluxed overnight. After cooling to 0 °C, the mixture was quenched by the 
addition of sat. Na2SO4 and partitioned between EtOAc (100 mL) and H2O (50 mL). The 
aqueous layer was separated and extracted with EtOAc (5 x 25 mL) and the organic 
extracts were combined and washed with H2O (15 mL), brine (25 mL), dried (Na2SO4), 
and concentrated to afford 0.793 g of crude amino alcohol. To the crude material in 
MeOH (25 mL) was added K2CO3 (1.165 g, 8.43 mmol), CuSO4 -5H2O (0.011 g, 0.0421 
mmol), and imid-SO2N3-HCl (1.05 g, 5.06 mmol). The mixture was stirred for 6  h, 
concentrated, diluted with CH2Cl2 (50 mL) and washed with dilute HCl (10 mL), H2O 
(10 mL), brine (10 mL), dried (MgSO4), and concentrated to afford 0.681 g of crude 
azido alcohol. To the crude material in CH2Cl2 (12 mL) was added DMAP (1.54 g, 12.6 
mmol) and ~90% TIPSCl (1.2 mL). After stirring at rt overnight, the mixture was diluted 
with CH2Cl2 (50 mL) and washed with dilute HCl (10 mL), H2O (10 mL), brine (10 mL), 
dried (MgSO4), and concentrated. Flash chromatography (5% EtOAc:hexanes) afforded
1.11 g (61% overall) of 2.56. 2.56: oil; R/ 0.53 (20% EtOAc:hexanes); [a]D = -14.1 (c = 
2.714, CHCl3); 1H NMR (300 MHz, CDCb) 8  8.02 (bs, 1H), 7.61 (d, J  = 7.5 Hz, 1H),
7.37 (d, J  = 7.8 Hz, 1H), 7.21 (dt, J  = 6.9, 1.2 Hz, 1H), 7.16-7.08 (m, 2H), 3.87 (dd, J  =
10.2, 4.2 Hz, 1H), 3.79 (dd, J  = 10.2, 5.7 Hz, 1H), 3.74-3.64 (m, 1H), 3.08 (dd, J  = 14.7,
6.0 Hz, 1H), 2.93 (dd, J  = 15.0, 7.8 Hz, 1H), 1.16-1.03 (m, 21H); 13C NMR (75 MHz, 
CDCl3) 8  136.1, 127.3, 122.7, 122.0, 119.4, 118.6, 111.7, 111.2, 66.1, 63.8, 26.2, 17.9,
17.6, 11.8; IR (neat) 3418, 2942, 2866, 2360, 2342, 2105, 1457, 1253, 1120, 882 cm-1; 




Preparation of (3a^,8a^)-1,8-di-tert-butyl 2-methyl 3a-(3-((5)-2-azido-3- 
((triisopropylsilyl)oxy)propyl)-1#-mdol-1-yl)-3,3a-dihydropyrrolo[2,3-£]mdole-
1,2,8(2#,8a#)-tricarboxylate (2.57). To a solution of 1.148 (0.444 g, 0.892 mmol) and 
2.56 (0.220 g, 0.600 mmol) in CH3CN ( 6  mL) at 0 °C was added dropwise KO/Bu (1.2 
mL, 1M solution in THF, 1.2 mmol). The mixture was stirred for 15 min. and then 
quenched with sat. NaHCO3 (1 mL), concentrated, and diluted with CH2Cl2 (50 mL). The 
solution was washed with brine (15 mL), dried (MgSO4), and concentrated. Flash 
chromatography (10% EtOAc:hexanes) afforded 0.378 g (80%) of 2.57 as a mixture (4:1) 
of endo and exo isomers, respectively. 2.57-endo isomer: foam; Rf 0.40 (20% 
EtOAc:hexanes); [a]D = +22.0 (c = 1.246, CHCb); 1H NMR (500 MHz, CDCb) 8  7.70 
(bs, 1H), 7.59 (d, 7.5 Hz, 1H), 7.37 (t, J  = 7.0 Hz, 1H), 7.30 (d, J  = 7.0 Hz, 1H), 7.25 (d, 
J  = 6.0 Hz, 1H), 7.19 (t, J  = 6.5 Hz, 1H, 7.14 (t, J  = 7.5 Hz, 1H), 7.08 (t, J  = 7.5 Hz, 1H),
6.85 (s, 1H), 6.78 (s, 1H), 4.91 (bs, 1H), 3.79 (dd, J  = 10.0, 4.0 Hz, 1H), 3.73 (dd, J  =
10.5, 6.0 Hz, 1H), 3.64-3.58 (m, 1H), 3.52 (dd, J  = 13.0, 9.0 Hz, 1H), 3.23 (s, 3H), 3.03 
(d, J  = 13.0 Hz, 1H), 2.95 (dd, J  = 15.0, 6.0 Hz, 1H), 2.80 (dd, J  = 15.0, 8.0 Hz, 1H), 1.53 
(s, 9H), 1.50 (s, 9H), 1.1-1.0 (m, 21H); 13C NMR (125 MHz, CDQ 3) 8  171.0, 151.9,
151.9, 143.6, 134.9, 130.9, 130.0, 129.2, 125.3, 124.8, 123.4, 122.3, 119.9, 119.4, 117.7,
111.6, 111.2, 82.0, 82.0, 79.9, 72.6, 66.0, 63.8, 59.4, 52.1, 38.9, 28.3, 28.2, 26.2, 17.9,
11.9; IR (neat) 2943, 2866, 2100, 1718, 1481, 1457, 1393, 1368, 1257, 1159, 1016, 752; 




Preparation of (3a.R,8a^)-di-fert-butyl 3a-(3-((S)-2-azido-3-
((triisopropylsilyl)oxy)propyl)-1#-mdoM-yl)-2-(((S')-1-ethoxy-1-oxo-3- 
phenylpropan-2-yl)carbamoyl)-3,3a-dihydropyrrolo[2,3-£]indole-1,8(2#,8a#)- 
dicarboxylate (2.58). To a solution of 2.57 (0.493 g, 0.627 mmol) in THF/MeOH/H2O 
(20 mL, 1:1:1) at rt was added NaOH (0.156 g, 3.90 mmol). The mixture was stirred for 2 
h at 40 °C, then cooled to rt and diluted with EtOAc (60 mL). The organic layer was 
washed with 5% citric acid (20 mL) and the aqueous layer was extracted with EtOAc (2 x 
10 mL). The combined organic extracts were washed with H2O (10 mL), brine (25 mL), 
dried (MgSO4), and concentrated to afford 0.484 g (100%) of acid. The acid was
dissolved in THF ( 6  mL) and Et3N (0.18 mL, 1.25 mmol) was added dropwise at 0°C 
followed by isobutyl chloroformate (0.090 mL, 0.69 mmol). After stirring for 5 min, a 
solution of L-phenylalanine ethyl ester (0.363 g, 1.88 mmol) in EtOAc ( 6  mL) was added 
at once. The resulting mixture was allowed to warm to rt and then diluted with CH2Cl2 
(100 mL). The reaction was quenched with citric acid (5% aq., 50 mL) and the aqueous 
layer was extracted with CH2Cl2 (2 x 25 mL). The organic extracts were washed with 
H2O (25 mL), and brine (25 mL), dried (MgSO4), and concentrated. Flash 
chromatography (20% EtOAc:hexanes) afforded 0.504 g (8 6 % overall) of 2.58 as a 
mixture (5:1) of endo and exo isomers. 2.58-endo: foam; R /0.36 (20% EtOAc:hexanes); 
[a]D = +34.1 (c = 1.974, CHCl3); 1H NMR (300 MHz, CDQ 3) 8  7.59 (d, J  = 7.2 Hz, 1H), 
7.45 (d, J  = 8.1 Hz, 1H), 7.33 (d, J  = 7.2 Hz, 1H, 7.28-7.12 (m, 7H), 7.10-7.02 (m, 3H), 
6.90 (d, J  = 7.5 Hz, 1H), 6.89 (s, 1H), 6.84 (s, 1H), 4.93 (d, J  = 8.4 Hz, 1H), 4.20-4.05 
(m, 2H), 4.01 (dd, J  = 12.0, 5.7 Hz, 1H), 3.79 (dd, J  = 10.2, 4.5 Hz, 1H), 3.72 (dd, J  =
10.5, 6.0 Hz, 1H), 3.61 (p, J  = 5.4 Hz, 1H), 3.40 (dd, J  = 12.9, 9.0 Hz, 1H), 3.25 (d, J  =
12.6 Hz, 1H), 3.02-2.88 (m, 3H), 2.80 (dd, J  = 14.7, 7.2 Hz, 1H), 1.52 (s, 9H), 1.50 (s, 
9H), 1.20 (t, J  = 7.2 Hz, 3H), 1.11-1.01 (m, 21H); 13C NMR (75 MHz, CDCl3) 8  170.1,
169.4, 154.0, 151.7, 142.4, 135.8, 134.8, 130.4, 129.9, 129.4, 129.0, 128.2, 126.8, 126.0,
124.8, 123.7, 122.2, 119.8, 119.5, 117.1, 111.5, 111.1, 82.3, 82.2, 81.0, 73.0, 65.9, 63.6,
62.0, 61.2, 53.6, 38.5, 38.1, 28.1, 28.1, 17.9, 14.1, 11.8; IR (neat) 3408, 3336, 2942, 
2867, 2099, 1721, 1510, 1457, 1369, 1255, 1157, 882, 740 cm-1; LRMS (ESI) calcd for 





Preparation of (S)-ethyl 3-phenyl-2-((2^,3a^,8a5)-1-tosyl-3a-(3-((5)-2-(2,2,2- 
trifluoroacetamido)-3-((triisopropylsilyl)oxy)propyl)-1#-mdol-1-yl)-1,2,3,3a,8,8a- 
hexahydropyrrolo[2,3-£]indole-2-carboxamido)propanoate (2.60). To a solution of
2.58 (0.500 g, 0.536 mmol) in THF/ H2O (11 mL, 10:1) at rt was added PPh3 (0.169 g, 
0.643 mmol) and the mixture refluxed for 3 h. The mixture was concentrated, diluted 
with CH2Cl2 (50 mL), washed with brine (15 mL), dried (MgSO4), and concentrated to 
afford crude amine. The crude amine was dissolved in CH2Cl2 (10 mL) and Et3N (0.11 
mL, 0.80 mmol) was added dropwise at 0 °C followed by TFAA (0.076 mL, 0.54 mmol). 
After stirring for 5 min, the mixture was diluted with CH2Cl2 (40 mL). The organic layer 
was washed with 5% citric acid (10 mL), H2O (5 mL), brine (10 mL), dried (MgSO4), 
and concentrated to afford crude trifluoroacetamide. To the crude trifluoroacetamide in 
CH3CN (4 mL) at 0 °C was added TMSI (0.29 mL, 0.50 mmol). The mixture was stirred 
at 0 °C for 0.5 h and then quenched with sat. NaHCO3 (1 mL), concentrated, and diluted 
with CH2Cl2 (50 mL). The organic solution was washed with brine (10 mL), dried 
(NaSO4), and concentrated to afford crude bisamine 2.59. To the crude material in DCM 
(12 mL) was added DMAP (0.131 g, 1.07 mmol) and ~90% TIPSCl (0.3 mL). After 
stirring at rt overnight, the mixture was diluted with CH2Cl2 (50 mL) and washed with 
dilute HCl (10 mL), H2O (10 mL), brine (10 mL), dried (MgSO4), and concentrated. The
residue was dissolved in CH2Cl2 (5 mL) and Et3N (0.15 mL, 1.1 mmol), DMAP (0.013 g,
0.11 mmol), and TsCl (0.153 g, 0.804 mmol) were added at rt. The mixture was stirred 
until completion (TLC) and then diluted with CH2Cl2 (40 mL). The organic layer was 
washed with 5% citric acid (10 mL), H2O (5 mL), brine (10 mL), dried (MgSO4), and 
concentrated. Flash chromatography (20% EtOAc:hexanes) afforded 0.318 g (61% 
overall) of 2.60 as the endo isomer. 2.60: foam; Rf 0.50 (33% EtOAc:hexanes); [a]D = 
+17.4 (c = 0.718, CHCl3); 1H NMR (500 MHz, CDCU) 8  7.80 (d, J  = 8.5 Hz, 2H), 7.71 
(d, J  = 8.0 Hz, 1H), 7.43 (d, J  = 8.0 Hz, 2H), 7.30-7.26 (m, 2H), 7.25-7.20 (m, 1H), 7.17­
7.05 (m, 6 H), 6.81 (t, J  = 7.5 Hz, 1H), 6.74 (t, J  = 8.0 Hz, 1H), 6.73 (d, J  = 7.5 Hz, 1H), 
6.64 (d, J  = 8.0 Hz, 1H), 6.50 (s, 1H), 6.21 (d, J  = 8.0 Hz, 1H), 5.72 (s, 1H), 4.98 (s, 1H), 
4.55 (dd, J  = 9.5, 2.0 Hz, 1H), 4.19-4.14 (m, 2H), 4.07 (q, J  = 7.5 Hz, 2H), 3.65 (dd, J  =
10.0, 2.5 Hz, 1H), 3.57 (dd, J  = 10.0, 4.0 Hz, 1H), 3.23 (dd, J  = 13.5, 9.5 Hz, 1H), 3.10 
(d, J  = 13.5 Hz, 1H), 3.02-2.92 (m, 2H), 2.91-2.80 (m, 2H), 2.58 (s, 3H), 1.17 (t, J  = 7.5 
Hz, 3H), 1.10-0.90 (m, 21H) ; 13C NMR (125 MHz, CDCl3) 8  170.2, 169.3, 148.5, 145.1,
135.7, 134.3, 133.9, 130.8, 130.6, 130.1, 129.6, 128.3, 127.7, 126.9, 125.9, 125.2, 125.1,
121.7, 120.1, 119.9, 119.8, 111.7, 111.0, 110.1, 82.3, 74.1, 62.6, 62.0, 61.2, 53.6, 51.1,
38.4, 37.3, 26.1, 21.8, 17.9, 14.0, 11.8; IR (neat) 3404, 3310, 2944, 2867, 1724, 1668, 
1613, 1522, 1470, 1351, 1208, 1166, 1121, 1030, 883, 739 cm-1; LRMS (ESI) calcd for 




Preparation of (9#-fluoren-9-yl)methyl ((2S,2a1^,45,5a^)-2-benzyl-5a-(3-iodo-1^- 
mdol-1-yl)-1,3-dioxo-2,2a1,3,4,5,5a-hexahydro-1#-2a,9b-diazacyclopenta[/A:]fluoren- 
4-yl)carbamate (2.69). To a solution of 2.53 (0.100 g, 0.149 mmol) in CH2Cl2 (5 mL) at 
0 °C was added Hg(OAc) 2 (0.071 g, 0.22 mmol). The resulting mixture was allowed to 
warm to rt for 0.5 h. Once the starting material had been consumed (TLC), the mixture 
was cooled to 0 °C and 1.1 eq I2 (0.045 g, 0.16 mmol) in CH2Cl2 (1 mL) was added 
dropwise. The reaction mixture was immediately diluted with CH2Cl2 (100 mL) and the 
reaction was quenched with sat. sodium bisulfite (aq, 15 mL). The organic phase was 
washed with brine (20 mL), dried (MgSO4), and concentrated. Flash chromatography 
(15% EtOAc:hexanes) afforded 0.119 g (100%) of 2.69 as a colorless glass. 2.69: R/ 0.33 
(33% EtOAc:hexanes); [a]D = -102.6° (c = 0.900, CHCl3); 1H NMR (500 MHz, CDQ 3) 
8  8.69 (s, 1H), 7.75 (d, J  = 7.5 Hz, 2H), 7.71 (d, J  = 8.0 Hz, 1H), 7.62 (d, J  = 7.1 Hz, 1H),
7.61 (d, J  = 7.1 Hz, 1H), 7.41-7.29 (m, 6 H), 7.21 (d, J  = 7.3 Hz, 2H), 7.12-7.08 (m, 3H), 
7.02-6.95 (m, 2H), 6 . 8 6  (t, J  = 7.8 Hz, 1H), 6.77 (d, J  = 7.5 Hz, 1H), 6.17 (d, J  = 8.4 Hz, 
1H), 6.15 (d, J  = 3.7 Hz, 1H), 5.39 (s, 1H), 5.16 (dd, J  = 5.0, 5.0 Hz, 1H), 4.51 (dd, J  =
11.6, 7.1 Hz, 1H), 4.48 (dd, J  = 9.8, 7.5 Hz, 1H), 4.41 (dt, J  = 12.7, 3.0 Hz, 1H), 4.25 (dd, 
J  = 7.5, 7.5 Hz, 1H), 3.63 (dd, J  = 14.9, 2.7 Hz, 1H), 3.28 (dd, J  = 14.2, 5.3 Hz, 1H), 3.21 
(dd, J  = 14.2, 5.2 Hz, 1H),1.95 (dd, J  = 14.8, 12.9 Hz, 1H); 13C NMR (125 MHz, CDCU)
5 170.4, 167.0, 156.1, 143.6, 143.5, 141.3, 141.3, 137.7, 134.8, 134.1, 133.9, 132.1,
130.7, 130.6, 129.2, 128.6, 127.8, 127.7, 127.7, 127.1, 127.0, 126.4, 125.1, 125.0, 123.8,
123.0, 121.8, 121.1, 120.0, 120.0, 115.0, 110.9, 81.8, 67.4, 65.8, 65.2, 58.8, 48.5, 47.0,
37.3, 36.4; IR (neat) 3395, 3117, 2925, 2854, 1732, 1680, 1484, 1453, 1334, 1297, 1220, 
1083, cm-1; LRMS (ESI) calcd for C43H33IN4O4Na m/z (M+Na+) 819.2, found 819.0.
123
Preparation of (S)-benzyl 3-(1-((2S',2a1R,4S',5a^)-4-((((9#-fluoren-9- 
yl)methoxy)carbonyl)amino)-2-benzyl-1,3-dioxo-2,2a1,3,4,5,5a-hexahydro-1^-2a,9b- 
diazacydopenta[/A:]fluoren-5a-yl)-1H-mdol-3-yl)-2-((fert-
butoxycarbonyl)amino)propanoate (2.70). To a slurry of Zn dust (0.0315 g, 0.481 
mmol) in ^,^-dimethylacetamide (3 mL, degassed using the freeze-pump-thaw method) 
was added 1,2-diiodoethane (0.007 g, 0.02 mmol) and TMSCl (1.5 p,L, 0.012 mmol). The 
mixture was sonicated for 0.5 h followed by the addition of L-serine derived iodide 
(0.126 g, 0.312 mmol) and sonicated for an additional 0.5 h. To the resulting zincate 2.67 
was added Pd2dba3 (0.016 g, 0.018 mmol), P(o-tol) 3 (0.065 g, 0.21 mmol), CuBr-DMS 
(0.002 g, 0.009 mmol), followed by 2.69 (0.142 g, 0.178 mmol) in DMA (3 mL) and the 
mixture was sonicated for 2 h at a temperature that ranged from 22-38 °C. The resulting
reaction mixture was then diluted with CH2Cl2 (100 mL) and the reaction was quenched 
with a 1:1 mixture of water and brine (20 mL). After separation the aqueous layer was 
extracted with CH2Cl2 (2 x 20 mL) and the combined organic extracts were washed with 
brine (20 mL), dried (MgSO4), and concentrated. Flash chromatography (25% 
EtOAc:hexanes) afforded 0.125 g (74%) of 2.70 as a colorless glass and 0.0140 g (12%) 
of recovered 2.53. 2.70: Rf 0.25 (33% EtOAc:hexanes); [a]D = -56.5° (c = 0.670, 
CHCl3); 1H NMR (500 MHz, CDCl3) 8  8.36 (s, 1H), 7.76 (d, J  = 7.7 Hz, 2H), 7.70 (d, J  =
8.0 Hz, 1H), 7.57 (t, J  = 8.3 Hz, 1H), 7.52 (d, J  = 7.9 Hz, 1H), 7.40 (t, J  = 7.5 Hz, 2H), 
7.36-7.27 (m, 4H), 7.23-7.19 (m, 7H), 7.11 (t, J  = 7.4 Hz, 2H), 7.06-6.98 (m, 3H), 6.85 
(dt, J  = 8.3, 1.0 Hz, 1H), 6.74 (d, J  = 7.5 Hz, 1H), 6.22 (d, J  = 8.4 Hz, 1H), 6.16 (d, J  =
3.8 Hz, 1H), 5.53 (s, 1H), 5.50 (d, J  = 8.1 Hz, 1H), 5.19 (d, J  = 12.5 Hz, 1H), 5.17 (dd, J  
= 5.5, 5.5 Hz, 1H), 5.05 (d, J  = 12.4 Hz, 1H), 4.78 (dd, J  = 13.1, 5.2 Hz, 1H), 4.43-4.38 
(m, 3H), 4.22 (dd, J  = 7.0, 7.0 Hz, 1H), 3.62 (d, J  = 14.8 Hz, 1H), 3.38 (broad s, 2H), 
3.28 (dd, J  = 13.9, 5.5 Hz, 1H), 3.24 (dd, J  = 14.2, 5.3 Hz, 1H), 1.97 (dd, J  = 13.2, 13.2 
Hz, 1 H), 1.36 (s, 9H); 13C NMR (125 MHz, CDQ 3) 8  171.8, 170.4, 167.2, 156.1, 155.2,
143.7, 143.4, 141.3, 141.3, 137.7, 135.4, 134.9, 134.4, 130.5, 129.2, 128.6, 128.4, 128.2,
128.1, 127.8, 127.6, 127.1, 126.4, 125.1, 125.1, 123.8, 122.2, 120.1, 120.0, 119.6, 114.9,
111.0, 110.9, 81.7, 79.6, 67.5, 66.9, 65.2, 65.2, 54.4, 48.6, 47.0, 37.5, 36.4, 28.3, 27.9; IR 
(neat) 3361, 2976, 1715, 1682, 1485, 1457, 1345, 1294, 1219, 1167, 1060 cm-1; LRMS 
(ESI) calcd for C58H53N5O8Na m/z (M+Na+) 970.4, found 970.4.
124
125
Preparation of (S)-benzyl 2-((S)-2-((ferf-butoxycarbonyl)amino)-3-(4- 
hydroxyphenyl)propanamido)propanoate (2.77). To a solution of acid 2.76 (0.385 g,
1.37 mmol) in CH2Cl2 (15 mL) at 0 °C was added HOBtH2O (0.241 g, 1.78 mmol), 
DCC (0.311 g, 1.51 mmol), Et3N (0.38 mL, 2.7 mmol), and 4A molecular sieves. The 
resulting mixture was stirred for 0.5 h and then a solution of amine 2.75 (0.200 g, 0.684 
mmol) in CH2Cl2 (5 mL) was added at once. The resulting mixture was allowed to warm 
to rt over 4 h, after which it was diluted with CH2Cl2 (100 mL). The reaction was 
quenched with citric acid (5% aq, 20 mL) and the organic phase was washed with sat. 
NaHCO3 (20 mL), brine (20 mL), dried (MgSO4), and concentrated. Flash 
chromatography (30-40% EtOAc:hexanes) afforded 0.207 g (68%) of 2.77 as a colorless
oil. 2.77: Rf 0.25 (50% EtOAc:hexanes); [a]D = +2.9° (c = 0.552, CHCL); 1H NMR (500 
MHz, CDCl3 , c = 0.0553 g/mL) 8 7.37-7.30 (m, 5H), 6.99 (d, J  = 8.2 Hz, 2H), 6.96 (bs, 
1H), 6.71 (d, J  = 8.5 Hz, 2H), 6.65 (broad d, J  = 6.9 Hz, 1H), 5.14 (s, 3H), 4.54 (broad s, 
1H), 4.33 (broad s, 1H), 2.94 (d, J  = 5.5 Hz, 2H), 1.40 (s, 9H), 1.34 (d, J  = 7.0 Hz, 3H); 
13C NMR (125 MHz, CDCl3 , c = 0.0553 g/mL) 8 172.3, 171.3, 155.6, 155.3, 135.2,
130.4, 128.6, 128.4, 128.1, 127.6, 115.6, 80.4, 67.2, 55.7, 48.2, 37.6, 33.8, 28.2, 18.2; IR 
(neat) 3308 (broad), 2980, 2935, 1742, 1661, 1517, 1453, 1368, 1248, 1163, 1050 cm-1; 
LRMS (ESI) calcd for C24H30N2O6Na m/z (M+Na+) 465.2, found 465.2.
126
Preparation of (S)-benzyl 2-((S)-2-((S')-1-((S')-2-((ferf-butoxycarbonyl)amino)-3- 
phenylpropanoyl)pyrrolidine-2-carboxamido)-3-(4-
hydroxyphenyl)propanamido)propanoate (2.79). To a solution of 2.77 (0.722 g, 1.58 
mmol) in CH2Cl2 (2 mL) was added TFA (2 mL) and allowed to stir until the starting 
material had been consumed (TLC, ~1 h). The mixture was concentrated under vacuum. 
In a separate vessel, to a solution of acid 2.78 (0.658 g, 1.82 mmol) in CH2Cl2 (15 mL) at 
0 °C was added HOBtH2O (0.344 g, 2.54 mmol), EDC-HCl (0.418 g, 2.18 mmol), 
EtN/Pr2 (0.60 mL, 3.6 mmol), and 4A molecular sieves. The resulting mixture was stirred 
for 0.5 h and to this was added a solution of the TFA salt from 2.77 in THF (5 mL). The 
reaction mixture was allowed to warm to rt over 4 h after which it was diluted with 
CH2Cl2 (100 mL). The reaction was quenched with citric acid (5% aq, 20 mL) and the 
organic phase was washed with sat. NaHCO3 (20 mL), brine (20 mL), dried (MgSO4), 
and concentrated. Flash chromatography (50-80% EtOAc:hexanes) afforded 0.651 g 
(60%) of 2.79 as a white solid. 2.79: mp = 154-156°C, uncorrected; R/ 0.39 (80% 
EtOAc :hexanes); [a]D = -39.1 (c = 0.094, CHCL); 1H NMR (500 MHz, CDCL, c = 
0.0638 g/mL) 5 (1.5:1.0 mix of rotamers) 8.32 (s, 1H), 7.85 (d, J  = 7.0 Hz, 1H), 7.44 (s, 
0.73H), 7.40-7.18 (m, 24.5H), 7.04-6.96 (m, 4.8H), 6.86-6.80 (m, 3.5H), 6.76-6.70 (m,
2.8H), 5.35 (d, J  = 5.5 Hz, 1.2H), 5.30( d, J  = 8.5Hz, 0.9H), 5.25-5.12 (m, 4.4H), 4.66­
4.47 (m, 5.4H), 4.40 (dd, J  = 8.0, 4.0 Hz, 1H), 4.35-4.29 (m, 1.3H), 3.58 (dd, J  = 16.5,
7.0 Hz, 0.9H), 3.52 (d, J  = 7.0 Hz, 1.2H), 3.34-3.27 (m, 1.2H), 3.22 (dd, J  = 14.5, 5.0 Hz, 
1.3H), 3.16-3.04 (m, 3H), 3.02-2.82 (m. 6.7H), 2.11 (s, 1.2H), 1.98-1.72 (m, 4.2H), 1.40­
1.30 (m, 25H); 13C NMR (125 MHz, CDCl3, c = 0.0638 g/mL) 5 mix of rotamers 
(1.5:1.0) 172.8, 172.3, 172.2, 172.0, 171.2, 171.1, 170.4, 170.4, 170.2, 156.6, 156.0,
155.7, 155.2, 136.2, 135.4, 134.9, 130.3, 129.8, 129.4, 129.0, 128.6, 128.6, 128.5, 128.4,
128.3, 128.1, 128.1, 128.0, 127.7, 127.6, 127.0, 115.5, 80.9, 80.0, 67.1, 67.1, 60.8, 60.6,
57.1, 54.6, 54.5, 53.4, 48.3, 48.0, 47.4, 46.7, 46.4, 38.8, 38.5, 36.7, 35.6, 32.8, 30.3, 28.3,
28.2, 24.8, 21.1, 18.5, 18.0; IR (neat) 3301 (broad), 2979, 1740, 1642, 1517, 1451, 1368, 








carboxamido)-3-(4-hydroxyphenyl)propanamido)propanoate (2.71). To a solution of 
2.79 (0.105 g, 0.153 mmol) in CH2Cl2 (2 mL) was added TFA (2 mL). The resulting 
mixture was stirred until the starting material was consumed (TLC, ~2 h). The reaction 
mixture was concentrated to provide 2.73 (0.107g, 0.153 mmol) as an oil. To a solution 
of 2.70 (0.058 g, 0.061 mmol) in THF (1.5 mL) and EtOH (1.5 mL) at 0 °C was added 
10% Pd/C (~50% H2O, 0.058 g). The resulting mixture at 0 °C was stirred under H2 (1 
atm) until the starting material was consumed (TLC) after which the mixture was diluted 
with EtOAc (5 mL) and filtered through a plug of celite. The filtrate was concentrated 
and the resulting residue taken up in CH2Cl2 (3 mL) and cooled to 0 °C. To this was 
added HOBtH2O (0.021 g, 0.15 mmol), EDC-HCl (0.023 g, 0.12 mmol), EtNzPr2 (0.32 
mL, 0.18 mmol), and 4A molecular sieves. The resulting mixture was stirred for 0.5 h 
and then a solution of 2.73 (0.107 g, 0.153 mmol) in THF (3 mL) was added at once. The 
reaction mixture was allowed to warm to rt over 6 h and was then diluted with CH2Cl2 
(100 mL). The reaction was quenched with citric acid (5% aq, 20 mL) and the organic 
phase was washed with sat. NaHCO3 (aq, 20 mL), brine (20 mL), dried (MgSO4), and 
concentrated. Flash chromatography (60% EtOAc:hexanes) afforded 0.052 g (60%) of
2.71 as a milky glass. Rf 0.31 (66% EtOAc:hexanes); LRMS (ESI) calcd for 




Preparation of (65,95,125)-benzyl 6-((1-((2S',2a1R,4S',5aR)-4-((((9H-fluoren-9- 
yl)methoxy)carbonyl)amino)-2-benzyl-1,3-dioxo-2,2a1,3,4,5,5a-hexahydro-1H-2a,9b- 
diazacyclopenta[/^]fluoren-5a-yl)-1H-indol-3-yl)methyl)-12-isobutyl-2,2,9-trimethyl- 
4,7,10-trioxo-3-oxa-5,8,11-triazatridecan-13-oate (2.72). To a solution of 2.70 (0.106 
g, 0.111 mmol) in THF (3 mL) and EtOH (3 mL) at 0 °C was added 10% Pd/C (~50% 
H2O, 0.106 g). The resulting mixture was stirred under H2 (1 atm) until the starting 
material had been consumed (TLC) after which the reaction mixture was diluted with 
EtOAc (10 mL) and filtered through a plug of celite. The filtrate was concentrated, the 
resulting residue taken up in CH2Cl2 (5 mL) and cooled to 0 °C. To this was added 
HOBt H2O (0.038 g, 0.28 mmol), EDC-HCl (0.043 g, 0.22 mmol), EtNzPr2 (0.58 mL,
0.33 mmol), and 4A molecular sieves. After 0.5 h a solution of 2.74 (0.113 g, 0.279 
mmol) in CH2Cl2 was added at once. The reaction mixture was allowed to warm to rt 
over 4 h and then was diluted with CH2Cl2 (100 mL). The reaction was quenched with 
citric acid (5% aq, 20 mL). The organic phase was washed with sat. NaHCO3 (aq, 20 
mL), brine (20 mL), dried (MgSO4), and concentrated. Flash chromatography (33% 
EtOAc:hexanes) afforded 0.0890 g (71%) of 2.72 as a colorless glass. 2.72: R/ 0.10 (33%
EtOAc:hexanes); [a]D = -104.2° (c = 0.910, CHQ 3); 1H NMR (500 MHz, CDCl3) 5 8.50 
(s, 1H), 7.82-7.74 (partially obscured m, 1H), 7.77 (d, J  = 7.5 Hz, 2H), 7.68 (d, J  = 8.1 
Hz, 1H), 7.65 (d, J  = 7.2 Hz, 1H), 7.68-7.64 (partially obscured m, 1H), 7.47 (d, J  = 7.8 
Hz, 1H), 7.40 (t, J  = 7.5 Hz, 2H), 7.32 (t, J  = 7.4 Hz, 2 H), 7.30-7.22 (m, 7H), 7.20 
(broad d, J  = 7.3 Hz, 3H), 7.12 (t, J  = 7.5 Hz, 2H), 7.01 (t, J  = 7.7 Hz, 1H), 7.00 (t, J  =
7.6 Hz, 1H), 6.93 (t, J  = 7.5 Hz, 1H), 6.78 (t, J  = 7.3, 1H), 6.73-6.67 (m, 1H), 6.29 (broad 
s, 1H), 6.17 (d, J  = 8.4 Hz, 1H), 5.56-5.50 (m, 1H), 5.40 (s, 1H), 5.15 (dd, J  = 5.1, 5.1 
Hz, 1H), 5.07 (dd, J  = 12.1, 12.1 Hz, 1H), 5.04 (dd, J  = 12.1, 12.1 Hz, 1H), 4.82 (broad s, 
1H), 4.64 (broad s, 1H), 4.52 (d, J  = 12.8 Hz, 1H), 4.42-4.28 (m, 4H), 3.89 (d, J  = 14.5 
Hz, 1H), 3.33 (dd, J  = 15.3, 9.2 Hz, 1H), 3.30-3.21 (m, 2H), 3.10 (d, J  = 12.8 Hz, 1H),
1.97 (dd, J  = 13.8, 13.8 Hz, 1H), 1.43-1.26 (partially obscured m, 2H), 1.35 (s, 9H), 1.16 
(s, 3H), 0.61 (s, 3H), 0.41 (s, 3H); 13C NMR (125 MHz, CDCb) 5 172.4, 172.1, 171.6,
170.6, 167.0, 156.7, 155.2, 143.8, 143.3, 141.3, 141.2, 137.8, 135.3, 134.9, 134.3, 130.3,
129.9, 129.2, 128.6, 128.5, 128.3, 128.2, 127.8, 127.6, 127.2, 127.1, 126.4, 125.2, 125.1,
124.9, 124.1, 122.2, 120.0, 119.8, 119.2, 114.6, 110.9, 110.7, 82.0, 79.7, 67.8, 66.9, 65.3,
65.0, 53.2, 51.0, 48.9, 48.7, 47.0, 40.7, 37.5, 36.4, 28.7, 28.2, 24.5, 22.4, 21.4, 17.1; IR 
(neat); 3342, 2960, 1712, 1677, 1503, 1456, 1367, 1222, 1164, 1083 cm-1; LRMS (ESI) 




Preparation of Kapakahine E (2.4). To a solution of 2.71 (0.040 g, 0.028 mmol) in 
EtOH (2 mL) and EtOAc (1 mL) at rt was added 10% Pd/C (~50% H2O, 0.080 g). The 
resulting mixture was stirred under H2 (1 atm) until the starting material was consumed 
(TLC) after which ammonium formate (0.026 g, 0.420 mmol) was added in three 
portions over 1 h. After the starting material had been consumed (TLC) the reaction 
mixture was diluted with EtOAc (3 mL) and EtOH (3 mL). The insolubles were removed 
by centrifugation, rinsing with EtOH, and concentration. The resulting residue was 
purified by prep TLC (60% EtOAc:hexanes, desired material extracted from SiO2 using 
MeOH). To the resulting residue in CH2Cl2 (9.3 mL) and DMF (4.7 mL) was added 
HATU (0.053 g, 0.14 mmol), EtN/Pr2 (0.024 mL, 0.14 mmol), and 4A molecular sieves. 
The reaction mixture was allowed to stir at rt for 1.5 d after which it was diluted with 
CH2Cl2 (80 mL). The reaction was quenched with a mixture of 5% citric acid:brine (40 
mL, (1:1)) and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic extracts were concentrated. Flash chromatography (80% EtOAc:hexanes)
afforded 0.015 g (50%) of .N-Boc-Kapakahine E as a colorless glass. ^-Boc- 
Kapakahine E: R/ 0.28 (80% EtOAc:hexanes); [a]D = -91.8° (c = 0.114, CH3OH); 1H 
NMR (500 MHz, CD3CN) 5 7.83 (s, 1H), 7.59 (d, J  = 8.0 Hz, 1H), 7.44 (broad d, J  = 5.8 
Hz, 1H), 7.39 (t, J  = 8.4 Hz, 3H), 7.36-7.30 (m, 4H), 7.23 (d, J  = 7.3 Hz, 2H), 7.18 (d, J  
= 8 . 8  Hz, 1H), 7.15 (t, J  = 7.4 Hz, 2H), 7.07 (t, J  = 7.4 Hz, 1H), 7.01-6.94 (m, 4H), 6.93 
(d, J  = 7.6 Hz, 1H), 6.80 (t, J  = 7.6 Hz, 1H), 6.69 (bs, 1H), 6 . 6 6  (d, J  = 8.5 Hz, 2H), 6.53 
(d, J  = 7.4 Hz, 1H), 6.30 (d, J  = 8.5 Hz, 1H), 6.05 (d, J  = 6.9 Hz, 1H), 5.67 (s, 1H), 4.98­
4.94 (m, 2H), 4.80-4.71 (m, 2H), 4.70-4.65 (m, 1H), 4.51-4.49 (m, 1H), 4.35 (dd, J  =
11.5, 6.5 Hz, 1H), 4.00-3.94 (m, 1H), 3.88 (dd, J  = 8.0, 8.0 Hz, 1H), 3.75 (dd, J  = 16.5,
8.5 Hz, 1H), 3.63 (d, J  = 15.0 Hz, 1H), 3.33 (dd, J  = 15.0, 7.0 Hz, 1H), 3.22 (dd, J  = 14.0,
5.5 Hz, 1H), 3.13 (dd, J  = 14.0, 5.5 Hz, 1H), 3.10-3.03 (m, 2H), 2.98 (dd, J  = 14.5, 5.0 
Hz, 1H), 2.90 (dd, J  = 14.0, 3.5 Hz, 1H), 2.56 (dd, J  = 14.0, 11.0 Hz, 1H), 2.38 (dd, J  =
14.5, 14.5 Hz, 1H), 2.12-2.00 (m 3H), 1.73-1.64 (m, 1H), 1.40 (s, 9H), 1.36 (d, J  = 6.5 
Hz, 3H) ; 13C NMR (125 MHz, CD3CN) 5 175.0, 173.5, 173.3, 172.9, 172.0, 171.3,
168.9, 157.4, 156.0, 140.5, 137.9, 137.5, 136.5, 135.8, 132.1, 131.7, 131.6, 130.9, 130.6,
130.1, 129.7, 128.9, 128.4, 128.4, 127.1, 126.5, 124.2, 123.1, 121.0, 120.6, 116.6, 115.9,
112.3, 111.4, 83.0, 80.2, 67.7, 66.1, 64.7, 55.8, 55.2, 54.4, 49.3, 49.3, 48.7, 38.4, 38.2,
37.5, 36.1, 30.5, 28.9, 26.5, 18.2; IR (neat) 3410, 3333, 2924, 1671, 1521, 1485, 1458, 
1368, 1165 cm-1; LRMS (ESI) calcd for C62H65N9O10Na m/z (M+Na+) 1118.5, found
1118.5,
To a solution of N-Boc-Kapakahine E (0.015 g, 0.014 mmol) in CH2Cl2 (3 mL) at rt 
was added freshly distilled TFA (0.3 mL). Toluene (3 mL) was added to the resulting 
after 1.5 h and the resulting mixture was concentrated to give 15 mg of Kapakahine E
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(100% yield) as a yellow TFA salt. Kapakahine E: yellow solid; R/ 0.33 (50% 
CH3CN:H2O, 0.1% TFA on C18 reverse phase silica gel); [a]D = -82.8° (c = 0.288, 
CH3OH); 1H NMR (500 MHz, CD3CN) 5 7.84 (bs, 1H), 7.78 (s, 1H), 7.68 (d, J  = 8.0 Hz, 
1H), 7.59 (d, J  = 8.0 Hz, 1H), 7.43-7.37 (m, 4H), 7.34 (t, J  = 7.0 Hz, 1H), 7.34-7.31 
(partially obscured m, 1 H), 7.33 (d, J  = 8.4 Hz, 1H), 7.26 (d, J  = 7.4 Hz, 2H), 7.16 (d, J  
= 7.0 Hz, 1H), 7.14 (d, J  = 7.7 Hz, 1H), 7.12-7.06 (m, 2H), 7.05-6.98 (partially obscured 
m, 2H), 7.01 (d, J  = 8.1 Hz, 2H), 6.90 (d, J  = 7.4 Hz, 1H), 6.85 (t, J  = 7.4 Hz, 1H), 6 . 6 8  
(d, J  = 8.4 Hz, 2H), 6.58 (d, J  = 7.4 Hz, 1H), 6.36 (d, J  = 8.4 Hz, 1H), 6.21 (d, J  = 6.1 Hz, 
1H), 5.74 (s, 1H), 4.97 (t, J  = 5.8 Hz, 1H), 4.73 (ddd, J  = 11.1, 4.4, 4.4 Hz, 1 H), 4.70­
4.63 (m, 2H), 4.39 (bs, 1H), 4.31 (dd, J  = 12.4, 6.4 Hz, 1H), 3.99-3.93 (m, 1H), 3.90 (t, J  
= 8.1 Hz, 1H), 3.77 (dd, J  = 17.1, 7.1 Hz, 1H), 3.67-3.51 (m, 2H), 3.50-3.43 (m, 2H), 
3.23 (dd, J  = 14.1, 5.4 Hz, 1H), 3.14 (dd, J  = 13.7, 4.7 Hz, 1H), 3.10-2.99 (m, 2H), 2.99 
(dd, J  = 15.5, 4.5 Hz, 1H), 2.72 (dd, J  = 14.6, 10.7 Hz, 1H), 2.47 (dd, J  = 15.1, 13.4 Hz, 
1H), 2.14-1.99 (m, 2H), 1.75-1.66 (m, 1H), 1.58-1.50 (m, 1H), 1.37 (d, J  = 7.0 Hz, 3H) ; 
13C NMR (125 MHz, CD3CN) 5 174.5, 173.8, 173.1, 172.7, 171.1, 169.0, 168.7, 157.1,
140.3, 137.4, 137.2, 135.9, 135.8, 131.5, 131.3, 130.6, 130.2, 130.0, 129.9, 129.4, 129.3,
128.5, 128.3, 128.2, 127.1, 126.9, 126.3, 124.1, 123.2, 121.4, 120.0, 116.3, 115.6, 112.2,
107.4, 82.4, 68.0, 65.7, 64.5, 56.2, 54.9, 54.7, 49.1, 48.6, 48.3, 37.9, 37.3, 37.2, 35.7,
30.4, 30.1, 26.2, 17.9; IR (neat) 3369, 1731, 1681, 1455, 1173 cm-1; HRMS (ESI) calcd 





Preparation of Kapakahine F (2.5). To a solution of 2.72 (0.045 g, 0.040 mmol) in 
EtOH:EtOAc (4 mL, (2:1)) at rt was added 10% Pd/C (~50% H2O, 0.090 g). The 
resulting mixture was stirred under H2 (1 atm) until the starting material was consumed 
(TLC) after which ammonium formate (0.038 g, 0.600 mmol) was added in three 
portions over 1 h. The mixture was diluted with EtOAc (3 mL) and EtOH (3 mL) and the 
insolubles were removed by centrifugation. Following concentration, the resulting 
residue was dissolved in CH2Cl2:DMF (20 mL, (2:1)). To this was added HATU (0.076 
g, 0.20 mmol), EtN/Pr2 (0.035 mL, 0.20 mmol), and 4A molecular sieves. After stirring 
at rt for 1.5 d the resulting mixture was diluted with CH2Cl2 (80 mL) and the reaction was 
quenched with a 5% citric acid:brine solution (40 mL, (1:1)). The aqueous phase was 
extracted with CH2Cl2 (2 x 20 mL), and the organic extracts were combined and 
concentrated. Flash chromatography (75% EtOAc:hexanes) afforded 0.025 g (78%) of N- 
Boc-Kapakahine F as a colorless glass. N-Boc-Kapakahine F: R/ 0.22 (75% 
EtOAc:hexanes); [a]D = -178.6° (c = 0.104, CH3OH); 1H NMR (500 MHz, CD3CN) S
7.59 (d, J  = 8.3 Hz, 1H), 7.46 (d, J  = 7.8 Hz, 1H), 7.33 (t, J  = 7.8 Hz, 2H), 7.27 (d, J  =
7.3 Hz, 2H), 7.26 (s, 1H), 7.20 (bs, 1H), 7.17 (t, J  = 7.8 Hz, 2H), 7.10 (t, J  = 7.3 Hz, 1H),
6.99 (t, J  = 7.8 Hz, 1H), 6.98-6.90 (m, 2H), 6.81 (t, J  = 7.9 Hz, 1H), 6.65 (broad d, J  = 
6.4 Hz, 1H), 6.31 (d, J  = 8.3 Hz, 1H), 5.70 (s, 1H), 5.51 (broad d, J  = 7.9 Hz, 1H), 4.96 
(t, J  = 5.8 Hz, 1H), 4.78 (dd, J  = 12.2, 8.3 Hz, 1H), 4.44-4.30 (m, 3H), 3.38 (dd, J  = 15.2,
8.3 Hz, 1H), 3.22 (dd, J  = 14.2, 5.3 Hz, 1H), 3.14 (dd, J  = 14.2, 5.9 Hz, 1H), 2.95 (d, J  =
14.6 Hz, 1H), 2.84 (d, J  = 14.7 Hz, 1H), 2.63 (t, J  = 13.2 Hz, 1H), 1.70-1.50 (m, 3H), 
1.41 (s, 9H), 1.38 (d, J  = 7.8 Hz, 3H), 0.96 (d, J  = 6.4 Hz, 3H), 0.94 (d, J  = 6.3 Hz, 3H); 
13C NMR (125 MHz, CD3CN) 5 174.9, 174.4, 173.1, 172.8, 169.1, 156.6, 140.6, 137.5,
135.6, 135.3, 132.2, 131.6, 130.9, 129.7, 128.5, 127.1, 126.8, 124.9, 122.9, 121.1, 120.2,
115.9, 112.2, 83.3, 80.5, 69.3, 65.6, 56.1, 53.5, 52.4, 49.2, 41.1, 39.3, 37.7, 28.9, 28.4,
26.1, 23.5, 22.8, 18.1; IR (neat) 3360, 1666, 1520, 1451, 1363, 1225, 1167 cm-1; LRMS 
(ESI) calcd for C45H51N7O7Na m/z (M+Na+) 824.3, found 824.4.
To a solution of N-Boc-Kapakahine F (0.023 g, 0.029 mmol) in CH2Cl2 (5 mL) was 
added freshly distilled TFA (0.5 mL). Toluene (5 mL) was added after 1.5 h and the 
resulting mixture was concentrated to give Kapakahine F as a white TFA salt. 
Kapakahine F: [a]D = -142.5° (c = 0.36, CH3OH); 1H NMR (500 MHz, (CD3CN: 
CD3OH:AcOH 200:100:1)) 5 8.26 (d, J  = 7.8 Hz, 1H), 8.04 (d, J  = 7.8 Hz, 1H), 7.60 
(partially obscured broad s, 1H), 7.59 (d, J  = 7.8 Hz, 1H), 7.57 (d, J  = 8.3 Hz, 1H), 7.34 
(t, J  = 7.3 Hz, 1H), 7.24 (d, J  = 7.3 Hz, 2H), 7.15 (s, 1H), 7.12 (t, J  = 7.3 Hz, 2H), 7.04 (t, 
J  = 7.6 Hz, 2H), 6.98 (t, J  = 7.3 Hz, 1H), 6 . 8 6  (d, J  = 7.4 Hz, 1H), 6.82 (t, J  = 7.9 Hz, 
1H), 6.28 (d, J  = 8.3 Hz, 1H), 5.55 (s, 1H), 4.98 (dd, J  = 5.4 Hz, 1H), 4.67 (dd, J  = 12.8,
8 . 8  Hz, 1H), 4.59 (ddd, J  = 15.2, 7.8, 7.8 Hz, 1H), 4.30 (dd, J  = 3.2, 3.2 Hz, 1H), 4.18 
(dd, J  = 13.3, 7.0 Hz, 1H), 3.42 (d, J  = 3.9 Hz, 2H), 3.22 (dd, J  = 14.2, 4.9 Hz, 1H), 3.12 
(dd, J  = 14.5, 6.0 Hz, 1H), 2.96 (d, J  = 14.6 Hz, 1H), 2.57 (dd, J  = 14.6, 13.2 Hz, 1H),
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1.70-1.60 (m, 3H), 1.42 (d, J  = 7.5 Hz, 1H), 0.96 (d, J  = 6.0 Hz, 3H), 0.92 (d, J  = 6.0 Hz, 
3H); 13C NMR (125 MHz, (CD3CN: CD3OH:AcOH 200:100:1)) 8  175.8, 174.2, 173.1,
169.6, 169.4, 140.6, 137.2, 135.5, 135.2, 132.1, 131.7, 130.8, 129.7, 128.5, 127.5, 127.0,
125.4, 123.3, 121.4, 119.8, 115.8, 112.3, 106.4, 83.5, 69.2, 65.7, 54.5, 54.4, 51.1, 49.9,
39.8, 39.0, 37.5, 26.0, 25.8, 23.3, 22.7, 17.8; IR (neat) 3287, 2924, 1674, 1484, 1455, 
1292, 1201, 1134 cm-1; LRMS (ESI) calcd for C40H44N7O5 m/z (M+H+) 702.3, found
702.3.
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CHAPTER 3
TOWARD THE TOTAL SYNTHESIS OF CHETOMIN 
Introduction
The class of natural products containing the epidithiodiketopiperazine moiety is a very 
diverse subset and includes the title compound chetomin (Figure 3.1-3.2) . 1 Chetomin, 
isolated from Chaetomium cocliodes in 1944, represents one of the first C(3)-N(1') 
heterodimeric indoline natural products to be isolated and was shown to have 
antibacterial properties. More recently it was shown to be an inhibitor of the binding of 
HIF-1a to p300, thus a disruptor of protein-protein interactions within tumors.2a-1 The 
structure was originally proposed to be 3.1, but was revised to 3.2 after extensive NMR 
evaluation (Figure 3.1).2c,d
Originally Proposed Structure Revised Structure
Safe and Taylor (1972) Mclnnes, Taylor, and Walter (1976)
Figure 3.1. The Structure of Chetomin
139
sporidesmin A (3.3)
H y s r  “  
°  ' - O H  
gliotoxin (3.4)





O ^  n ^ , q
aranotin (3.8)
Figure 3.2. Representative Epidithiodiketopiperazine Natural Products
Previous Work
The epidithiodiketopiperazines represent a class of compounds that are notoriously 
difficult to synthesize and manipulate.1g Synthesis of epidithiodiketopiperazines from the 
parent diketopiperazine has been the premier method of their synthesis and the early 
methods that were developed came in the late 1960s and 1970s. Later methods of the 
synthesis of epidithiodiketopiperazines relied on improvements to the previous methods 
or invention of new methods.4 The most common methods are outlined in Scheme 3.1. 
The formation of the disulfide bridge usually represents an endpoint in the synthesis 
because disulfide bridges are generally unstable (vide supra). The following total 
syntheses give a representative view of the different approaches to 
epidithiodiketopiperazines.
Kishi and Fukuyama devised an ingenious approach toward installing the disulfide 
bridge by introducing a way to mask the disulfide with a protecting group, in this case 
anisaldehyde to afford a dithiane, that was acid and base stable and could be unmasked to 
give the disulfide with relative ease (Scheme 3.2). The deprotection step involved 
oxidation of the dithiane to the mono-sulfoxide and reacting this immediately with a 
lewis acid or strong protic acid. This methodology allowed them to complete a number of 
complex natural products containing the epidithiodiketopiperazine motif including 
sporidesmin A (Scheme 3.3).3g-j
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General Methods fo r Epidithiodiketopiperazine Synthesis from  Diketopiperazines
o „ __  o o
R3
Br2 or NBS . n Br „ i l l  a
X ^ R 4 radical initiator R ' NX j > 4 thiolation R ' N A ^ R
I  I ' -----------------------
N>R2 R31 V N'R 2 then oxidation R3' ,\ f «'N*‘ R2
o Bro O
3.10 3.11 3.12
O O /S® °
elementafsuffur r 1^ n A ^ R 4 reduction ^  R 'N ' ^ > ^ R4
-^ S ^ Nhr 2  R34 SV ' N'R 2 th6n 0Xidati0n R3' ^ H ' N'R 2
O ©S' S"8 o
3.10 3 .13 3.12
R3
0  °  n  °
R ^ N ^ R 4 C-H oxidation R ^ M - X p ^ 4 thiolation R ^ J ^ s ^ R 4
R34 j ^ N'R 2 then oxidation R3-^C^ N«»R2
O °  O O
3.10 3.14 3.12
Scheme 3.1. Synthesis of Epidithiodiketopiperazines from Diketopiperazines
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Kishi/Fukuvama Method g f Epidithioketopjperazine Synthesis
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Scheme 3.3. Kishi’s Total Synthesis of Sporidesmin A
The Movassaghi group developed a very elegant protocol for the introduction of sulfur 
at the alpha position of the diketopiperazine which relied on selective C-H oxidation of 
the methine protons using a permanganate oxidant, followed by thiolation and oxidation. 
This methodology allowed them to complete a number of complex molecules including 
(+)-11,1 r-dideoxyverticillin A and chaetocins A and C (Scheme 3.4).4i,k Key to this 
synthesis was the discovery of the ability of permanganate salts to smoothly oxidize 
diketopiperazines through a fast hydrogen atom abstraction/oxidation rebound 
mechanism .5
Nicolaou and coworkers completed a total synthesis of epicoccin G (Scheme 3.5).'4m 
Their synthesis relied on trapping an enolate with electrophilic sulfur, in this case 
elemental sulfur, to give a bis-polysulfide similar to the Schmidt synthesis of 
epidithiodiketopiperazines. The polysulfide is reduced to the dithiol with sodium 
borohydride and either oxidized to the disulfide or converted into a bis-methylsulfide.
The Overman group elegantly completed a total synthesis of both gliocladin C and 
gliocladine C (Schemes 3.6 and 3.7). Starting from known indole dimer 3.39, they 
rapidly constructed 3.42 using a desymmetrization process that involved carbonyl 
migration. Imide reduction and conversion of the ester to an aldehyde afforded 3.44 that 
was coupled to masked trioxopiperazine 3.45. Lewis acid mediated cyclization gave 
trioxopiperazine 3.47. Selective addition of MeMgCl to the trioxopiperazine gave a 
tertiary alcohol that could be converted to the disulfide natural product gliocladine C. 
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1. TFAA, Et3N, DMAP,
CH3CN, -40 °C-rt (69%) 
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2. Pd(PPh3)3, K2C 0 3, 
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Scheme 3.5. Nicolaou’s Total Synthesis of Epicoccin G
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1. TFA, Et3SiH, CH2CI2, rt























1. NaBH4, MeOH, 0 °C (81%)
2. HC(OMe)3, 10 mol% PPTS, 
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3.43
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Scheme 3.6. Overman’s Synthesis of Indole Dimer 3.44
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Scheme 3.7. Overman’s Total Syntheses of Gliocladin C and Gliocladine C
Retrosynthesis
Our retrosynthetic plan for the total synthesis of chetomin was devised to implement a 
direct oxidation of diketopiperazines to hydroxylated diketopiperazines that could then be 
converted to epidithiodiketopiperazines. From the retrosynthesis, the first disconnection 
was determined by the known instability of the disulfide bridges, so the introduction of 
the disulfide bridge was designed to come late in the synthesis (Scheme 3.8). The next 
disconnection was the introduction of the hydroxyl groups through the direct C-H 
oxidation of the bis-diketopiperazine 3.51. The bis-diketopiperazine 3.51 could be 
synthesized by introduction of the pyrroloindoline fused diketopiperazine from 3.52 
following the C(3)-N(1') bond formation between bromopyrroloindoline 1.148 and 
tryptophan 3.53.
A potential problem with this synthetic route is that the stability of the substrate 3.51 
toward the oxidative conditions required to give tetraol 3.50 is unknown. The indole- 
[2,3]-n double bond is quite sensitive to oxidants such as permanganate, chromium, 
mercury, and lead salts and could potentially give unwanted by-products. Therefore, a 
series of experiments were devised to test the sensitivity of the indole-[2,3]-n double 
bond toward oxidative conditions (Scheme 3.9). We hypothesized that an electron- 
withdrawing group at the C(3)-position of indole in 3.54 would be more stable toward 
oxidation than the parent indole.
Model Study
A model study was performed to test the spectrum of reactivity in the indole series 






Scheme 3.8. Retrosynthetic Analysis of (-)-Chetomin
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Model Compounds for Oxidation Study
Predicted sensitivity toward oxidation : R1 = H > alkyl > EWG 
Scheme 3.9. Model Study Design
(Scheme 3.10). Synthesis of model compound 3.56 began with the acylation of known 
heterodimer 1.202 to provide chloroacetamide 3.55. Addition of methyl amine and in situ 
ring closure gives the diketopiperazine 3.56. Synthesis of model compound 3.59 proceeds 
in an identical fashion.
When C(3)-ester substituted indole 3.59 was subjected to Pb(OAc)4 in refluxing 
benzene, miniscule yields of mono-acetoxy compounds 3.60 and 3.61 were obtained as 
single isomers with the majority of the mass balance being recovered starting material, 
however di-acetoxy material was not detected.6 Unsurprisingly, when C(3)-unsubstituted 
indole 3.56 was subjected to the same conditions, only decomposition was noted 
presumably through oxidation of the sensitive indole-[2,3]-n double bond (Scheme 
3.11).7 In light of this result, heterodimer 3.56 was not pursued as a viable substrate for 
oxidation and it was deemed worthwhile to have an electron-withdrawing group at the 
C(3)-position of indole to prevent excessive oxidation.
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Scheme 3.11. Oxidation Results of Heterodimers 3.56 and 3.59
Given these successful yet synthetically nonviable results, a second model substrate 
was examined in the hopes that it would be converted into the appropriately oxidized 
material more efficiently. Thus, bromopyrroloindoline 1.148 was converted to the
cyclopropylazetoindoline, allowed to react with indole-3-carboxylic acid methyl ester,
8
and after Boc group removal gave bisamine 3.57 (Scheme 3.12). Reaction of the 
bisamine with acyl chloride 3.62 and cyclization using methylamine gave the 
hydroxylated diketopiperazine 3.64. After a protection and deprotection sequence the
desired substrate 3.65 was obtained. This substrate was designed to contain a hydroxyl 
group at the alpha position whereas in substrate 3.59 there resides a methylene group. It 
was envisioned that this compound could be used to either direct oxidation to the other 
methine position or be iteratively oxidized and then reduced to give an identical product 
(Scheme 3.13).
In the event, 3.65 was reacted with Pb(OAc)4 in refluxing benzene to yield 
trioxopiperazine 3.70 directly as an isomeric mixture along with acetate 3.61 (Scheme 
3.14). While the exact mechanism for this oxidation is unclear, it is believed to proceed 
in the fashion shown in either Scheme 3.14 or Scheme 3.15.9 Ligand exchange with lead 
tetraacetate affords 3.71 which undergoes homolytic scission to form hydroxy radical
3.72 (Scheme 3.14). Hydrogen abstraction by an acetate radical can produce 
trioxopiperazine 3.73. Another ligand exchange with lead tetraacetate gives 3.74, 
followed by homolytic scission and trapping the carbon centered radical with an acetate 
radical affords 3.70. Alternatively, a 1,5-hydrogen abstraction involving hydroxy radical
3.72 is possible if the hydroxy radical has the desired stereochemistry shown in 3.76 
(Scheme 3.15). Trapping the generated carbon centered radical in 3.77 gives 3.78 and 
then oxidation of the aminal follows that shown in Scheme 3.14.
Synthesis of trioxopiperazine 3.70 is fortuitous because the Overman group has shown 
the possibility of the selective addition of Grignard reagents to one of the carbonyls of a 
related trioxopiperazine (3.47) (Scheme 3.7). Thus, we examined the addition of 





1. KOf-Bu, THF, 0 °C
2. KOf-Bu, THF/CH3CN, 
indole-3-carboxylic acid 
methyl ester, 0 °C
--------------------------- *











40% aq. MeNH2, MeOH, 
0 °C
1. TBSOTf, Et3N, CH2CI2, 0 °C
2. TFAA, Et3N, CH2CI2, 0 °C 
 »
3. TBAF, PPTS, THF, 0 °C
(63%, 5 steps)
Scheme 3.12. Synthesis of Heterodimer 3.65
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Scheme 3.14. Oxidation of Heterodimer 3.65 and Mechanistic Rationale
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I
Scheme 3.15. Alternative Mechanism Involving 1,5-Hydrogen Abstraction
Scheme 3.16. Grignard Addition to 3.70 and Disulfide Synthesis
Fortunately, the Grignard addition to trioxopiperazine 3.70-exo acetate was very 
efficient and we did not observe byproducts relating to the addition of MeMgBr to the 
ester or trifluoroacetamide groups. Due to the perceived instability of 3.79, we 
immediately converted it to the dithiol followed by oxidation to the 
epidithiodiketopiperazine 3.80 using Overman’s protocol (Scheme 3.16).
Given this promising result, in addition to the ease with which 3.65 could be prepared 
on a large scale with few chromatography events, we were led to revise our retrosynthetic 
plan (Scheme 3.17). The plan involves synthesis of chetomin from the deprotection of 
bis-dithiane 3.81 using the Kishi protocol. The bis-dithiane 3.81 could be synthesized 
from ester 3.84 by converting the ester to a good leaving group and alkylation with 
dithiane 3.82. Finally, 3.84 is made by Grignard addition to trioxopiperazine 3.86, 
thiolation, and protection of the dithiol as a dithiane.
Conclusions
A model study on the synthesis of a C(3)-N(1') heterodimeric indoline containing an 
epidithiodiketopiperazine was successfully executed. This involved the development of a 
novel oxidation protocol for the synthesis of a highly functionalized trioxopiperazine, the 
successful application of a selective Grignard addition to the trioxopiperazine, and the 
conversion of the resulting diol to an epidithiodiketopiperazine. Further studies will focus 












Scheme 3.17. Revised Retrosynthetic Analysis of (-)-Chetomin
Experimental Section
Chemicals were either used as received or purified according to Purification of 
Common Laboratory Chemicals.10 Glassware was dried in an oven at 130 °C or flame 
dried and cooled under a dry atmosphere prior to use. All reactions were performed using 
common dry, inert atmosphere techniques. Reactions were monitored by TLC and 
visualized by a dual short wave/long wave UV lamp and stained with an ethanolic 
solution of potassium permanganate or p-anis aldehyde. Column flash chromatography 
was performed using 230-400 mesh silica gel. NMR spectra were recorded on Varian 
Unity-300, Varian VXR-500, or Varian Inova-500 spectrometers. Chemical shifts for 1H 
NMR were reported as 8 , parts per million, relative to the signal of tetramethylsilane at 0
13ppm. Chemical shifts for C NMR were reported as 8 , parts per million, relative to the 
center line signal of the CDCl3 triplet at 77 ppm. Proton and carbon assignments were
1 13established using spectral data of similar compounds, H nOe analysis, and C DEPT 
NMR. The abbreviations s, bs, d, dd, bd, ddd, t, q, bq, and m stand for the resonance 
multiplicity singlet, broad singlet, doublet, doublet of doublets, broad doublet, doublet of 
doublet of doublets, triplet, quartet, broad quartet, and multiplet, respectively. IR spectra 
were recorded on a Bruker Tensor 27 FT-IR spectrometer. Optical rotations were 
obtained on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell with a 1 
decimeter path length. Mass spectra were recorded at the Mass Spectrometry Facility at 
the Department of Chemistry of the University of Utah at Salt Lake City on a Finnigan 
MAT 95 double focusing high resolution mass spectrometer. Concentration refers to 









£]indole-1,4(10b#)-dione (3.56). To a solution of bisamine 1.202 (0.115 g, 0.300 mmol) 
in CH2Cl2 (6 mL) at 0 °C was added Et3N (0.09 mL, 0.6 mmol) followed by chloroacetyl 
chloride (0.02 mL, 0.3 mmol). The reaction mixture was quenched with dil. HCl (10 mL) 
after completion (TLC) and diluted with CH2Cl2 (30 mL). The organic layer was washed 
with H2O (10 mL), sat. NaHCO3 (10 mL), brine (10 mL), and dried (Na2SO4). After 
concentration, the residue was dissolved in THF/MeOH (3 mL/3 mL) and cooled to 0 °C 
whereupon methylamine (1.2 mL, 15 mmol, 40 wt.% in H2O) was added. The reaction 
was allowed to warm to room temperature over 1 h and stirred until completion (TLC). 
The reaction mixture was then diluted with CH2Cl2 (30 mL) and washed with H2O (10 
mL), brine (10 mL), and dried (Na2SO4). After concentration, flash chromatography 
(50% EtOAc:hexanes-33% acetone:CH2Cl2) afforded 0.073 g (65% overall) of 3.87 an 
beige solid. The diketopiperazine 3.87 (0.082 g, 0.22 mmol) was then dissolved in
CH2Cl2 (3 mL) and cooled to 0 °C whereupon DMAP (0.027 g, 0.22 mmol), Et3N (0.15 
mL, 1.1 mmol), and TFAA (0.09 mL, 0.7 mmol) were added sequentially. The reaction 
was complete immediately and was diluted with CH2Cl2 (30 mL) and washed with dil. 
HCl (10 mL), sat. NaHCO3 (10 mL), brine (10 mL), and dried (Na2SO4). Concentration 
afforded 3.56 in quantitative yield. 3.87: R/ 0.22 (80% EtOAc:hexanes); [a]D = -186.5° 
(c = 0.196, CHCl3); 1H NMR (500 MHz, CDCb) 8 7.62 (d, J  = 7.8 Hz, 1H), 7.41 (d, J  = 
3.4 Hz, 1H), 7.23 (t, J  = 7.3 Hz, 1H), 7.08 (t, J  = 7.3 Hz, 1H), 7.00 (t, J  = 7.8 Hz, 1H), 
6.96 (d, J  = 7.3 Hz, 1H), 6.78-6.72 (m, 3H), 6.59 (d, J  = 3.4 Hz, 1H), 6.10 (d, J  = 3.9 Hz, 
1H), 5.47 (d, J  = 3.4 Hz, 1H), 4.68 (dd, J  = 10.8, 6.4 Hz, 1H), 4.17 (dd, J  = 17.1, 1.5 Hz, 
1H), 3.83 (d, J  = 17.1 Hz, 1H), 3.69 (dd, J  = 14.7, 6.3 Hz, 1H), 3.00 (s, 3H), 2.78 (dd, J  =
14.7, 11.2 Hz, 1H); 13C NMR (125 MHz, CDC^) 8 166.2, 164.2, 146.7, 135.1, 130.3,
130.3, 128.2, 124.2, 123.5, 122.0, 121.4, 120.3, 120.1, 112.0, 110.3, 102.7, 82.3, 73.7,
57.6, 53.6, 40.1, 33.7; IR (neat) 3338, 3051, 2926, 1668, 1611, 1455, 1402, 1346, 1321, 
1261, 1215, 1178, 1081, 961 cm-1; LRMS (ESI) calcd for C22H2()N4O2Na m/z (M+Na+)
395.2, found 395.1. 3.56: R/ 0.34 (80% EtOAc:hexanes); [a]D = +260.8° (c = 1.288, 
CHCl3); 1H NMR (300 MHz, CDC^) 8 8.21 (d, J  = 8.1 Hz, 1H), 7.67 (d, J  = 8.2 Hz, 1H), 
7.52 (dt, J  = 7.7, 1.4 Hz, 1H), 7.44-7.36 (m, 2H), 7.30-7.17(m, 2H), 6.74 (s, 1H), 6.55 (d, 
J  = 3.4 Hz, 1H), 6.40 (dd, J  = 3.4, 0.7 Hz, 1H), 4.75 (dd, J  = 7.0, 7.0 Hz, 1H), 4.16 (d, J  = 
16.7 Hz, 1H), 3.70-3.59 (m, 3H), 2.84 (s, 3H); 13C NMR (75 MHz, CDCl3) 8 165.5,
164.8, 156.6, 140.5, 133.9, 131.6, 130.8, 130.3, 126.9, 126.6, 126.5, 122.3, 120.6, 119.1,
117.6, 110.2, 102.6, 78.9 (q, J  = 5.0 Hz), 71.4, 57.2, 53.6, 33.9, 33.0; IR (neat) 2951, 
1757, 1694, 1601, 1540, 1484, 1436, 1399, 1381, 1354, 1312, 1255, 1203, 1150, 1110, 




Preparation of (2.K,3aK,8aK)-1,8-di-ferf-butyl 2-methyl 3a-(3-(methoxycarbonyl)- 
1#-indol-1-yl)-3,3a-dihydropyrrolo[2,3-£]indole-1,2,8(2#,8aff)-tricarboxylate (3.97) 
and (2.K,3aK,8aK)-methyl 3a-(3-(methoxycarbonyl)-1#-indol-1-yl)-1,2,3,3a,8,8a- 
hexahydropyrrolo[2,3-£]indole-2-carboxylate (3.57). To a solution of 
bromopyrroloindoline 1.148 (1.514 g, 3.045 mmol) in THF (24 mL) at 0 °C was added 
dropwise KO/Bu (4.0 mL, 1M solution in THF, 4.0 mmol) over 30 min. via syringe 
pump in duplicate. The reaction mixtures were quenched with sat NaHCO3 (2 ml each), 
combined, and the volatiles removed under reduced pressure no more than 40 °C. The 
residue was diluted with CH2Cl2 (120 mL), washed with brine (20 mL), dried (sat. 
Na2SO4), and concentrated. The residue was dissolved in THF (12 mL) and added at once 
to a solution of methyl indole-3-carboxylate (1.840 g, 10.50 mmol) and KO/Bu (7.2 mL, 
1M solution in THF, 7.2 mmol) in THF:CH3CN (1:1, 24 mL) at 0 °C and stirred for 5 
min. before being quenched by sat. NaHCO3 (2 ml) and the volatiles removed under 
reduced pressure to provide crude adduct 3.88 (an analytical sample was obtained by 
flash chromatography (20% EtOAc:hexanes)). The residue was dissolved in CH2Cl2 (120 
mL), washed with brine (20 mL), dried (Na2SO4), and concentrated. To this mixture in
CH3CN (24 mL) at 0 °C was added TMSI (5.7 mL, 41 mmol) and the mixture was stirred 
for 1.0 h at 0 °C. The reaction mixture was then quenched with sat. NaHCO3 (40 mL) and 
the volatiles removed under reduced pressure. The residue was dissolved in CH2Cl2 (120 
mL) and washed with sat. NaHCO3 (60 mL), brine (20 mL), dried (Na2SO4), and 
concentrated. Flash chromatography (50-100% EtOAc:hexanes) afforded 1.250 g (53% 
from 1.148) of bis-amine 3.57 as an oil. 3.88: foam; R/ 0.33 (33% EtOAc:hexanes); [a]D 
= +37.5 (c = 0.722, CHCb); 1H NMR (500 MHz, CDQ3) 5 8.23-8.20 (m, 1H), 7.69 (s, 
1H), 7.68 (bs, 1H), 7.42 (t, J  = 7.3 Hz, 1H), 7.35-7.26 (m, 4H), 7.13 (t, J  = 7.3 Hz, 1H), 
6.84 (s, 1H), 4.93 (bs, 1H), 3.84 (s, 3H), 3.54 (dd, J  = 13.2, 9.3 Hz, 1H), 3.23 (s, 3H),
3.03 (d, J  = 13.2 Hz, 1H), 1.53 (s, 9H), 1.51 (s, 9H); 13C NMR (125 MHz, CDQ3) 5
170.6, 164.9, 152.9, 151.6, 143.6, 134.8, 132.7, 131.3, 128.1, 127.8, 125.4, 123.6, 123.6,
123.2, 122.2, 118.0, 111.7, 107.5, 82.2, 81.5, 79.5, 72.9, 59.2, 52.0, 50.8, 38.3, 28.1, 
28.0; IR (neat) 2979, 2951, 1757, 1710, 1604, 1538, 1482, 1456, 1393, 1368, 1337, 1268, 
1211, 1159, 1098, 928, 856 cm-1; LRMS (ESI) calcd for C32H37^ O 8Na m/z (M+Na+)
614.3, found 614.2. 3.57: foam; R/ 0.15 (50% EtOAc:hexanes); [a]D = -38.2 (c = 0.206, 
CHCl3); 1H NMR (500 MHz, CDCl3) 5 8.19 (d, J  = 8.3 Hz, 1H), 7.95 (s, 1H), 7.58 (d, J  =
8.3 Hz, 1H), 7.28-7.23 (m, 1H), 7.23-7.18 (m, 2H), 7.15 (d, J  = 7.3 Hz, 1H), 6.82 (t, J  =
7.3 Hz, 1H), 6.71 (d, J  = 7.8 Hz, 1H), 5.57 (s, 1H), 4.58 (s, 1H), 4.24 (dd, J  = 8.3, 2.4 Hz, 
1H), 3.88 (s, 3H), 3.48 (dd, J  = 13.2, 7.8 Hz, 1H), 3.35 (s, 3H), 3.00 (dd, J  = 13.2, 2.4 Hz, 
1H); 13C NMR (125 MHz, CDCl3) 5 173.6, 165.4, 149.9, 135.4, 132.8, 131.0, 128.1,
126.3, 125.6, 122.8, 122.1, 122.0, 119.8, 112.5, 111.0, 107.1, 81.6, 76.4, 60.3, 52.1, 51.1, 
40.6; IR (neat) 3360, 3053, 2949, 1733, 1698, 1608, 1536, 1485, 1459, 1436, 1380, 1322, 
1265, 1215, 1168, 1119, 1100, 1036, 1020, 931, 747 cm-1; LRMS (ESI) calcd for
165








Preparation of methyl 1-((5aK,10bK,11aK)-2-methyl-1,4-dioxo-6-(2,2,2- 
trifluoroacetyl)-2,3,4,5a,6,10b,11,11a-octahydro-1#-pyrazino[r,2':1,5]pyrrolo[2,3- 
£]indol-10b-yl)-1#-indole-3-carboxylate (3.59). To a solution of bisamine 3.57 (0.395 
g, 1.01 mmol) in CH2Cl2 (10 mL) at 0 °C was added Et3N (0.28 mL, 2.0 mmol) followed 
by chloroacetyl chloride (0.084 mL, 1.1 mmol). The reaction was quenched with dil. HCl 
(20 mL) after completion (TLC) and diluted with CH2Cl2 (60 mL). The organic layer was 
washed with H2O (20 mL), sat. NaHCO3 (20 mL), brine (20 mL), and dried (Na2SO4). 
After concentration, the residue was dissolved in THF/MeOH (6 mL/6 mL) and cooled to 
0 °C whereupon methylamine (1.9 mL, 25 mmol, 40 wt.% in H2O) was added. The 
reaction was allowed to warm to room temperature over 1 h and stirred until completion 
(TLC). The reaction mixture was then diluted with CH2Cl2 (100 mL) and washed with 
H2O (20 mL), brine (20 mL), and dried (Na2SO4). After concentration, flash
chromatography (50% EtOAc:hexanes-33% acetone:CH2Cl2) afforded 0.337 g (78% 
overall) of 3.89 an beige solid. The diketopiperazine 3.89 (0.293 g, 0.681 mmol) was 
then dissolved in CH2Cl2 (6 mL) and cooled to 0 °C whereupon DMAP (0.083 g, 0.68 
mmol), Et3N (0.47 mL, 3.4 mmol), and TFAA (0.29 mL, 2.0 mmol) were added 
sequentially. The reaction was complete immediately and was diluted with CH2Cl2 (30 
mL) and washed with dil. HCl (10 mL), sat. NaHCO3 (10 mL), brine (10 mL), and dried 
(Na2SO4). Concentration afforded 3.59 in quantitative yield. 3.89: R/ 0.15 (80% 
EtOAc:hexanes); [a]o = -178.2° (c = 1.010, CHQ3); 1H NMR (300 MHz, CDQ3) 8 8.23 
(s, 1H), 8.18 (d, J  = 7.8 Hz, 1H), 7.23 (t, J  = 7.3 Hz, 1H), 7.20 (t, J  = 7.7 Hz, 1H), 6.99 (t, 
J  = 7.7 Hz, 1H), 6.91 (d, J  = 7.6 Hz, 1H), 6.82-6.70 (m, 3H), 6.11 (d, J  = 3.6 Hz, 1H), 
5.78 (d, J  = 3.7 Hz, 1H), 4.54 (dd, J  = 11.5, 5.9 Hz, 1H), 4.16 (d, J  = 17.3 Hz, 1H), 3.93 
(s, 3H), 3.81 (d, J  = 17.0 Hz, 1H), 3.71 (dd, J  = 15.0, 6.0 Hz, 1H), 2.97 (s, 3H), 2.76 (dd, 
J  = 15.0, 11.7 Hz, 1H); 13C NMR (75 MHz, CDCb) 8 165.8, 165.1, 164.2, 146.9, 135.5,
131.0, 130.6, 127.9, 127.1, 123.2, 123.1, 122.4, 122.0, 120.1, 112.4, 110.4, 108.1, 82.0,
74.3, 57.2, 53.4, 51.2, 39.9, 33.7; IR (neat) 3336, 3122, 3054, 2948, 1670, 1611, 1536, 
1484, 1457, 1440, 1402, 1380, 1320, 1266, 1214, 1119, 1058, 750 cm-1; LRMS (ESI) 
calcd for C24H23N4O4 m/z (M+H+) 431.2, found 431.2. 3.59: R/ 0.28 (80% 
EtOAc:hexanes); [a]D = +201.1° (c = 1.116, CHCb); 1H NMR (300 MHz, CDCl3) 8 
8.29-8.19 (m, 2H), 7.68 (dd, J  = 7.6, 1.2 Hz, 1H), 7.57 (dt, J  = 7.7, 1.4 Hz, 1H), 7.45 (dd, 
J  = 7.7, 1.1 Hz, 1H), 7.44-7.32 (m, 3H), 7.25 (s, 1H), 6.78 (s, 1H), 4.76 (dd, J  = 8.7, 6.3 
Hz, 1H), 4.16 (d, J  = 17.0 Hz, 1H), 3.82 (s, 3H), 3.66 (d, J  = 17.0 Hz, 1H), 3.61 (dd, J  =
8.7, 3.3 Hz, 1H), 2.84 (s, 3H); 13C NMR (75 MHz, CDQ3) 8 165.5, 165.1, 165.0, 156.8,
140.8, 134.5, 133.2, 132.5, 129.3, 128.7, 127.6, 127.1, 123.9, 123.5, 123.1, 119.6, 110.9,
167
108.5, 79.1 (q, J  = 5.5 Hz), 72.0, 57.6, 53.9, 51.4, 34.2, 33.2; IR (neat) 2951, 1757, 1694, 
1601, 1540, 1484, 1436, 1454, 1381, 1354, 1399, 1312, 1255, 1203, 1150, 1110, 1060, 
1009 cm-1; LRMS (ESI) calcd for C26H22F3N4O5 m/z (M+H+) 527.2, found 527.2.
168
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Preparation of methyl 1-((5aK,10bK,11aK)-3-acetoxy-2-methyl-1,4-dioxo-6-(2,2,2- 
trifluoroacetyl)-2,3,4,5a,6,10b,11,11a-octahydro-1#-pyrazino[r,2':1,5]pyrrolo[2,3- 
£]indol-10b-yl)-1#-indole-3-carboxylate (3.60) and methyl 1-((5aS,10bR)-11a- 
acetoxy-2-methyl-1,4-dioxo-6-(2,2,2-trifluoroacetyl)-2,3,4,5a,6,10b,11,11a- 
octahydro-1H-pyrazino[1',2':1,5]pyrrolo[2,3-b] indol-10b-yl)-1H-indole-3- 
carboxylate (3.61). To a solution of diketopiperazine (3.59) (0.024 g, 0.046 mmol) in 
benzene (2.5 mL) was added lead tetraacetate (0.086 g, 0.18 mmol) at once. The mixture 
was refluxed for 2 h and then cooled to rt whereupon lead tetraacetate (0.180 g, 0.406 
mmol) was added and the mixture brought to reflux for 18 h. The mixture was then 
cooled to rt, quenched with sat. NaHCO3 (5 mL), diluted with EtOAc (10 mL) and the 
layers separated. The aqueous layer was extracted with EtOAc (3 x 5 mL), the organic 
extracts combined, washed with brine (10 mL), dried (Na2SO4), and concentrated. 
Preparatory TLC (50% EtOAc:hexanes) afforded 0.001 g (5%) of 3.61, 0.002 g (6%) of 
3.60, and 0.010 g (42%) of 3.59. 3.61: R/ 0.48 (50% EtOAc:hexanes); [a]D = +129.1° (c
= 0.604, CHCl3); 1H NMR (300 MHz, CDQ3) 8 8.29-8.25 (m, 1H), 8.21 (d, J  = 7.8 Hz, 
1H), 7.67 (dd, J  = 7.6, 0.8 Hz, 1H), 7.61-7.54 (m, 1H), 7.49-7.35 (m, 4H), 7.23 (s, 1H), 
6.81 (s, 1H), 5.91 (s, 1H), 4.98 (dd, J  = 8.9, 6.2 Hz, 1H), 3.82 (s, 3H), 3.67-3.61 (m, 2H), 
2.89 (s, 3H), 2.18 (s, 3H); 13C NMR (75 MHz, CDQ3) 8 169.4, 167.2, 164.6, 161.3,
156.2, 140.4, 134.2, 132.9, 132.3, 128.6, 128.4, 127.3, 126.7, 123.7, 123.2, 122.9, 119.4,
110.6, 108.3, 81.5, 79.0 (q, J  = 5.0 Hz), 71.7, 56.7, 51.1, 33.6, 32.3, 20.6; IR (neat) 2921, 
1751, 1670, 1541, 1484, 1457, 1436, 1395, 1349, 1312, 1257, 1207, 1157, 1043, 1013, 
990, 937 cm-1; LRMS (ESI) calcd for C28H28F3N4O7N  m/z (M+Na+) 607.2, found 607.1. 
3.60: Rf 0.22 (50% EtOAc:hexanes); [a]D = +71.2° (c = 0.098, CHCb); 1H NMR (500 
MHz, CDQ3) 8 8.27 (d, J  = 7.8 Hz, 1H), 8.23 (d, J  = 8.3 Hz, 1H), 7.77 (s, 1H), 7.56 (t, J  
= 8.3 Hz, 1H), 7.58 (d, J  = 7.3 Hz, 1H), 7.37 (t, J  = 7.8 Hz, 1H), 7.30 (t, J  = 7.3 Hz, 1H), 
7.28-7.24 (m, 1H), 7.23-7.18 (m, 1H), 6.67 (s, 1H), 4.27 (d, J  = 17.6 Hz, 1H), 3.94 (d, J  = 
15.6 Hz, 1H), 3.88 (s, 3H), 3.74 (d, J  = 17.6 Hz, 1H), 3.56 (d, J  = 15.6 Hz, 1H), 2.89 (s, 
3H), 2.22 (s, 3H); 13C NMR (125 MHz, CDCl3) 8 169.7, 165.0, 164.2, 162.1, 140.6,
135.7, 132.9, 132.2, 131.1, 128.3, 127.6, 125.8, 123.9, 123.0, 122.8, 119.1, 114.8, 111.3,
109.2, 89.6, 80.9, 71.4, 53.8, 51.4, 44.8, 34.1, 29.9, 21.3; IR (neat) 2921, 1751, 1670, 
1541, 1484, 1457, 1436, 1395, 1349, 1312, 1257, 1207, 1157, 1043, 1013, 990, 937 








Preparation of (5aK,10hK,11aK)-3-hydroxy-10b-(1#-indol-1-yl)-2-methyl-6-(2,2,2- 
trifluoroacetyl)-2,3,5a,6,11,11a-hexahydro-1#-pyrazino[r,2':1,5]pyrrolo[2,3- 
£]indole-1,4(10b#)-dione (3.65). To a solution of bis-amine (3.57) (1.200 g, 3.066 
mmol) in EtOAc (100 mL) and sat. NaHCO3 (20 mL) at 0 °C was added acid chloride 
3.62 (0.656 g, 3.37 mmol) in CH2Cl2 (4 mL) slowly dropwise. The mixture was allowed 
to stir until consumption of the starting material (TLC) and then the organic layer was 
separated. The aqueous layer was extracted with EtOAc (2 x 20 mL), the organic extracts 
combined, washed with brine (20 mL), dried (Na2SO4), and concentrated. The residue 
was diluted with MeOH (60 mL) and cooled to 0 °C followed by the addition of MeNH2 
(12 mL, 40 wt.% in water, 0.15 mol). The mixture was allowed to stir for 15 min. and 
then was diluted with EtOAc (100 mL) and water (60 mL). The aqueous layer was 
extracted with EtOAc (3 x 20 mL) and then the combined organics were washed with 
brine, dried (Na2SO4), and concentrated. The residue was then dissolved in CH2Cl2 (60 
mL) and cooled to 0 °C followed by addition of Et3N (0.85 mL, 6.1 mmol) and then 
TBSOTf (1.1 mL, 4.6 mmol). The mixture was allowed to stir for 5 min. and was then 
quenched with sat. NaHCO3 (20 mL) and the layers separated. The aqueous layer was 
extracted with CH2Cl2 (2 x 20 mL) and the combined organics were washed with 1M 
HCl (20 mL), brine (20 mL), dried (Na2SO4), and concentrated. The residue was then
dissolved in CH2Cl2 (60 mL) and cooled to 0 °C followed by the addition of Et3N (1.3 
mL, 9.2 mmol) and TFAA (0.88 mL, 6.1 mmol). The mixture was allowed to stir until 
completion (TLC) and then quenched with 1M HCl (20 mL)and the layers separated. The 
aqueous layer was extracted with CH2Cl2 (2 x 20 mL) and the combined organics were 
washed with sat. NaHCO3 (20 mL), brine (20 mL), dried (Na2SO4), and concentrated. 
The residue was then dissolved in THF (60 mL) and PPTS (0.912 g, 3.63 mmol) was 
added followed by TBAF (3.6 mL, 1M in THF, 3.6 mmol) at room temperature. The 
mixture was then concentrated at 40 °C and diluted with CH2Cl2 (100 mL) . The organic 
layer was washed with 1M HCl (20 mL), brine (20 mL), dried (Na2SO4), and 
concentrated. Flash chromatography (50-75% EtOAc: hexanes) afforded 1.059 g (64% 
over 5 steps) of 3.65 as a foam. 3.65: Rf 0.13 (50% EtOAc:hexanes); [a]D = +181.4° (c = 
1.446, CHCl3); 1H NMR (300 MHz, CDCl3) 8 8.28-8.21 (m, 1H), 8.18 (d, J  = 8.1 Hz, 
1H), 7.68 (d, J  = 7.6 Hz, 1H), 7.61-7.53 (m, 1H), 7.50-7.30 (m, 4H), 7.23 (s, 1H), 6.77 (s, 
1H), 5.43 (s, 1H), 5.06 (dd, J  = 9.2, 6.3 Hz, 1H), 4.94 (s, 1H), 3.82 (s, 3H), 3.65-3.56 (m, 
2H), 2.88 (s, 3H); 13C NMR (75 MHz, CDCl3) 8 167.2, 165.2, 165.0, 156.2, 140.3, 134.2,
133.0, 132.3, 129.1, 128.3, 127.5, 126.8 123.8, 123.1, 123.0, 119.2, 117.5, 110.6 108.2,
83.0, 79.2 (q, J  = 4.5 Hz), 71.7, 56.3, 51.2, 32.8, 32.4; IR (neat) 3391, 2951, 1693, 1602, 
1541, 1485, 1454, 1440, 1402, 1383, 1354, 1313, 1257, 1211, 1152, 1112, 1042, 962, 




(2:1) (exo acetate.endo acetate)
Preparation of methyl 1-((5a5',10bK)-11a-acetoxy-2-methyl-1,3,4-trioxo-6-(2,2,2- 
trifluoroacetyl)-2,3,4,5a,6,10b,11,11a-octahydro-1#-pyrazino[r,2':1,5]pyrrolo[2,3- 
£]indol-10b-yl)-1#-indole-3-carboxylate (3.70) and methyl 1-((5aK,10bK,11aK)-3- 
acetoxy-2-methyl-1,4-dioxo-6-(2,2,2-trifluoroacetyl)-2,3,4,5a,6,10b,11,11a- 
octahydro-1#-pyrazino [r,2':1,5]pyrrolo[2,3-£]indol-10b-yl)-1#-indole-3- 
carboxylate (3.61). To a solution of 3.65 (0.336 g, 0.618 mmol) in benzene (24 mL) was 
added Pb(OAc)4 (2.307 g, 4.942 mmol) at rt under N2. The mixture was immediately 
brought to reflux for 1.0 h followed by cooling to rt and was then diluted with EtOAc 
(100 mL) and quenched carefully with sat. NaHCO3 (100 mL) and separated. The 
aqueous layer was extracted with EtOAc (3 x 20 mL) and the combined organics were 
washed with brine (40 mL), dried (Na2SO4), and concentrated. Flash chromatography 
(33-50% EtOAc:hexanes) afforded 0.182 g (51%) of 3.70 (an analytical sample of 3.70- 
endo acetate and 3.70-exo acetate were obtained by flash chromatography (25% 
EtOAc:hexanes)) and 0.043 g (12%) of 3.61 as foams. 3.70-endo acetate: R/ 0.61 (50% 
EtOAc:hexanes); [a]o = -109.1° (c = 0.318, CHCl3); 1H NMR (500 MHz, CDCl3) 8 8.18 
(d, J  = 8.3 Hz, 1H), 8.13 (d, J  = 8.3 Hz, 1H), 7.89 (s, 1H), 7.59-7.54 (m, 1H), 7.48-7.38 
(m, 3H), 7.29 (t, J  = 7.3 Hz, 1H), 7.23-7.19 (m, 1H), 6.60 (d, J  = 8.3 Hz, 1H), 3.86 (s, 
3H), 3.84 (d, J  = 14.2 Hz, 1H), 3.45 (d, J  = 13.7, 1H), 3.24 (s, 3H), 1.54 (s, 3H); 13C
NMR (125 MHz, CDCb) 8 169.7, 164.9, 163.6, 155.6, 152.5, 140.8, 135.0, 132.0, 131.7,
130.6, 128.0, 127.5, 125.5, 124.3, 123.1, 122.9, 118.2, 110.4, 109.1, 89.1, 80.2 (q, J  = 3.8 
Hz), 71.4, 51.4, 47.0, 27.7, 20.1; IR (neat) 3057, 2953, 1739, 1697, 1609, 1542, 1484, 
1456, 1437, 1408, 1350, 1321, 1272, 1211, 1158, 1095, 1052, 1012, 929, 8 88 , 853, 767, 
740 cm-1; LRMS (ESI) calcd for C28H21F3N4O8N  (M+Na+) m/z 621.1, found 621.1. 
3.70-exo acetate: R/ 0.55 (50% EtOAc:hexanes); [a]D = +80.4° (c = 0.310, CHCl3); 1H 
NMR (500 MHz, CDCl3) 8 8.25 (d, J  = 7.8 Hz, 2H), 7.67 (s, 1H), 7.61 (t, J  = 7.3 Hz, 
1H), 7.55 (d, J  = 7.3 Hz, 1H), 7.42 (t, J  = 7.8 Hz, 1H), 7.33 (t, J  = 7.1 Hz, 1H), 7.29-7.21 
(m, 2H), 6.67 (s, 1H), 4.05 (d, J  = 15.6 Hz, 1H), 3.88 (s, 3H), 3.48 (d, J  = 16.1 Hz, 1H), 
3.20 (s, 3H), 2.72 (s, 3H); 13C NMR (125 MHz, CDCl3) 8 170.3, 164.6, 163.8, 155.1,
150.9, 135.3, 132.6, 132.5, 128.2, 127.8, 125.5, 123.9, 123.1, 122.9, 119.4, 116.7, 114.4,
110.7, 109.4, 8 8 .6 , 80.5 (q, J  = 4.6 Hz), 51.3, 45.2, 27.8, 21.0; IR (neat) 2952, 1754, 
1695, 1601, 1541, 1484, 1457, 1437, 1367, 1343, 1311, 1259, 1204, 1149, 1117, 1097, 
1040, 1008, 986, 922, 877, 861, 731 cm-1; LRMS (ESI) calcd for C28H21F3N4O8N  
(M+Na+) m/z 621.1, found 621.1.
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3.70-exo acetate 3.79 3.80
Preparation of methyl 1-((3^,5a5,10b^,11a^)-2,3-dimethyl-1,4-dioxo-6-(2,2,2- 
trifluoroacetyl)-1,2,3,4,5a,6,10b,11-octahydro-3,11a-
epidithiopyrazmo[r,2':1,5]pyrrolo[2,3-£]mdoM0b-yl)-1#-mdole-3-carboxylate 
(3.80). To a solution of 3.70-exo acetate (0.093 g, 0.16 mmol) in THF (4 mL) at -78 °C 
was added MeMgBr (0.10 mL, 0.31 mmol, 3.0 M solution in Et2O) slowly dropwise. The 
reaction mixture was immediately quenched with AcOH (0.5 mL) and diluted with 
EtOAc (30 mL) and H2O (10 mL). The aqueous layer was extracted with EtOAc (2 x 5 
mL) and the combined organics washed with sat. NaHCO3 (10 mL), brine (10 mL), dried 
(Na2SO4), and concentrated. The residue was dissolved in CH2Cl2 (3 mL) and cooled to 
-78 °C whereupon H2S gas was bubbled through the solution. Immediately after 
introduction of the gas, BF3 -OEt2 (0.2 mL, 1.6 mmol) was added dropwise and the H2S 
gas allowed to bubble through for 15 min. at -78 °C. The solution was warmed rt over 30 
min. while continuing to bubble H2S gas through the reaction mixture. After 2 h, the H2S 
gas balloon was replaced with a nitrogen balloon and the reaction mixture purged of H2S 
gas for 30 min. The reaction mixture was diluted with CH2Cl2 (30 mL) and washed with 
sat. NaHCO3 (10 mL), brine (10 mL), dried (Na2SO4), and concentrated. The residue was 
dissolved in MeOH:EtOAc (3 mL, 2:1) and O2 gas was bubbled through the solution for 
30 min. whereupon the flask was sealed and left to stir overnight. Concentration and flash 
chromatography (33%-50% EtOAc:hexanes) afforded 0.022 g (30% overall) of disulfide 
3.80 as a foam as a 3:1 mixture of diastereomers. 3.80: Rf = 0.27 (33% EtOAc:hexanes); 
1H NMR (500 MHz, CDQ 3) 8 8.30-8.24 (m, 1H), 8.18 (bs, 1H), 7.17 (d, J  = 7.8 Hz, 1H), 
7.66 (t, J  = 7.6 Hz, 1H), 7.58-7.50 (m, 2H), 7.40-7.32 (m, 2H), 7.28-7.22 (m, 1H), 7.11 
(s, 1H), 4.55 (d, J  = 15.6 Hz, 1H), 3.86 (s, 3H), 3.10 (s, 3H), 3.01 (d, J  = 15.6 Hz, 1H), 
1.98 (s, 3H); 13C NMR (125 MHz, CDCl3) 8 (selected peaks) 164.8, 164.7, 134.4, 132.6,
132.0, 128.4, 128.1, 127.6, 127.5, 126.0, 125.6, 124.3, 124.2, 123.2, 123.1, 122.4, 119.8,
174
119.5, 116.8, 114.5, 110.7, 108.8, 78.9, 73.2, 71.7, 51.2, 40.1, 27.7, 18.1; HRMS (ESI) 
calcd for C27H21F3N4O5S2Na m/z (M+Na+): 625.0803, found 625.0817.
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1H NMR, 300 MHz, CDCI3
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13C NMR, 125 MHz, CDCI3
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1H NMR, 300 MHz, CDCI3
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13C NMR, 125 MHz, CDCI3
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DEPT, 125 MHz, CDCI3
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Temp. 26*0 C / 299.1 K 
UNITY-500 "vxrSOOnmr"
STANDARD PROTON PARAM ETERS
Pulse 44.6 degrees 
Acq. time 11.637 sec 
Width 5499.8 Hz 
10 repetitions 
OBSERVE HI, 499.8136984 MHz 
DATA PROCESSING 
FT size 131072
Total time 3 hr, 19 min, 33 sec
1.176




13CNMR, 125 MHz , CDCI3
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1H NMR, 400 MHz, CDCI3
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1H NMR, 400 MHz, CDCI3
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1H NMR, 400 MHz, CDCI3
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13CNMR, 100 MHz , CDCI3
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1H NMR, 400 MHz, CDCI3
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1H NMR, 500 MHz, CDCI3
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13C NMR, 125 MHz, CDCI3
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(-)-desoxyeseroline (1.200) 
1H NMR, 500 MHz, CDCI3
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Desox;feseroline (1.200) - *H NMR (CDC13)
Synthetic (this work)
(500 MHz) 
ppm, multiplicity, J  (Hz)
Synthetic (Kulkami, 2009)
(300 MHz) 
ppm, multiplicity, J  (Hz)
Synthetic (Nakagawa, 2000)
(400 MHz) 
ppm, multiplicity, J  (Hz)
7.08, t, 7.8 
6.99, d, 7.3 
6.67, t, 7.3 







7.00, t, 7.6 
6.98, d, 7.8 
6.68, t, 7.4 







7.07, t, 7.6 
6.98, d, 7.8 
6.66, t, 7.4 







Desoxyeseroline (1.200) - 13C NMR (CDCI3)
Synthetic (this work) Synthetic (Kulkami, 2009) Synthetic (Nakagawa, 2000)
















NMR SPECTRA, HPLC AND MS/MS DATA CHAPTER 2
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C NMR, 125 MHz, CDCI3
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C NMR, 125 MHz, CDCI3
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1H NMR, 500 MHz, CD3OD
254
180 160 140 120







13C NMR, 125 MHz, CDCI3
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'H NMR, 300 MHz, CDCI3
13C OBSERVE
expl stdl3c
SAMPLE DEC. & VT
date Dec 6 2009 df rq 300.078
solvent CDCI3 an M l
file exp dpwxr 37
ACQUISITION dof 0
sfrq 75.462 dm yyy
tn C13 d m w
at 3.878 11200
np 128000 daeq
sw 16501-7 dr os 1.0
fto 9200 homo n
bs 1 PROCESSING
tpwr 55 lb 1*00
pw 5,0 wtfile
di 0 proc ft
tof G £n not used
nt 1024 math f
ct 33
a lock n werr
gain € woxp
180  160  140  1 2 0  100
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13C NMR, 75 MHz, CDCI3
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13C NMR, 125 MHz, CDCI3
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LC/MS Analysis of 2.71
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Te*tp, 26,D C / 299.1 K 
User: 1-14-87 
UNITY-500 "vKTSOOnaur"
Pula* 83.1 degrees 
Acq. tir&e 2,560 sec 
Width 25000,0 Hz 
12924 repetitions 
OBSERVE C13, 12S. 6787506 KHst 
DECOUPLE HI, 499.8161988 KHz 




Line broadening 0.5 Hz 
FT size 131072
Total time 14, tor, 16 min, 58 sec
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1H NMR, 500 MHz, CD3CN
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13C NMR, 125 MHz, CD3CN
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kapakahine E (2.4) 
nOe, 500 MHz, CD3CN 




HPLC Coinjection of Kapakahine E
LC-MS/MS (monitoring masses 996.4 and 804.0) 
UsingaWaters Sunfire dC18 (3.5 fxin, 2.1 x  ISO in in) eluting at 0.2 ml/inin 
with a gradient starting at 10% acetonitrile/water (0.1% formic acid) and 
concluding at 99% acetonitrile/water over 30 minutes.
0 9 R 1224_Q _1 1 Sm (Mn, 2x3)
1 6 .4 8
0 9R 1 2 2 4  Q  "I 0 Sm (Mn, 2x3)
1 6 .4 7
0 9 R1 224  Q  9 Sm  (Mn, 2x3)
1 6 .4 7
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KAPA E NATURAL 134 (6.279) Sb (2,10.00 ); Sm (SG, 2x0.50); Cm (15:196) Daughters of 996ES+
804.0 3.67e4
69.9 232.9 261.0 158.9
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KAPA E SYNTHETIC 25UM 60 (3.015) Sb (2,10.00 ); Sm (SG, 2x0.50); Cm (3:240) 
100 8 0 4 - °
69.9
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500 MHz, CD3CN: CD3OH:AcOH (200:100:1) 
Jlzir2Hi,J.Am.Chem.Soc. 2009,757,6360
Synthetic Kapakahine F
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Synthetic Kapakahine F
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Kapakahine F - ]H NMR (CD3CN:CD3OH:AcOH (200:100:1))
Synthetic (this work) Synthetic (Baran, 2009)
(500 MHz) (500 MHz)
ppm, multiplicity, J {Hz) ppm, multiplicity, J  (Hz)
8.26, d, 7.8 8.37, bs
8.04, d, 7.8 8.04, d, 7.5
7.60, bs 7.71, bs
7.59, d, 7.8 7.59, d, 8.0
7.57, d, 8.3 7.57, d, 9.0
7.34, t, 7.3 7.33, t, 8.0
7.24, d, 7.3 7.24, d 7.5
7 .15 ,s 7.14, s
7.12, t, 7.3 7.13, t, 7.5
7.04, t, 7.6 7.05, t, 7.5
7.04, t, 7.6 7.02, t, 7.5
6.98, t, 7.3 6.97, t, 7.5
6.86, d, 7.4 6.86, d, 7.5
6.82, t, 7.9 6.82, t, 8.0
6.28, d, 8.3 6.28, d, 8.5
5.55, s 5.56, s
4.98, t, 5.4 5.00, t, 5.5
4.67, dd, 12.8, 8.8 4.66, bdd, 12.0, 7.5
4.59, ddd, 15.2, 7.8, 7.8 4.61, bt, 7.0
4.30, dd, 3.2, 3.2 4.35, bs
4.18, dd, 13.3, 7.0 4.21, dd, 14.0, 7.0
3.42, d, 3.9 3.44, bs
3.22, dd, 14.2, 4.9 3.22, dd, 14.0, 5.0
3.12, dd, 14.5, 6.0 3.13, dd, 14.0, 5.5
2.96, d, 14.6 2.95, d, 14.5
2.57, dd, 14.6, 13.2 2.58, dd, 14.5, 13.0
1.70-1.60 m 1.70-1.61 m
1.42, d, 7.5 1.43, d, 7.0
0.96, d, 6.0 0.96, d, 6.0
0.92, d, 6.0 0.93, d, 5.5
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Kapakahine F - 13CNMR(CD3CN:CD3OH:AcOH (200:100:1))
Synthetic (this work) 
(125 MHz)









































NMR SPECTRA CHAPTER 3
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1H NMR, 300 MHz, CDCI3
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13C NMR, 75 MHz, CDCI3
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1H NMR, 500 MHz, CDCI3









13C NMR, 125 MHz, CDCI3
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13C NMR, 75 MHz, CDCI3
im
100 80 60 40 20 ppm 306

307
180 160 1 4 0 120 100
,Me
3.59








13C NMR, 75 MHz, CDCI3
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1H NMR, 500 MHz, CDCI3
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13C NMR, 125 MHz, CDCI3
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13C NMR, 75 MHz, CDCI3
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1H NMR, 500 MHz, CDCI3
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